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Abstract
Defining Cardiovascular Dysfunction in the Metabolic Syndrome:
therapeutic and nutritional approaches to treatment
Sara Brooks Fournier
Metabolic syndrome (MetS) is a complex disease state defined by the
manifestation of a cluster of cardiovascular (CV) risk factors including, abdominal
obesity, dyslipidemia, hypertension, and hyperglycemia. Individuals afflicted with
MetS have been demonstrated to assume the burden of a 3-fold increased risk of
cardiovascular disease (CVD) mortality, myocardioal infarction, stroke, type II
diabetes (T2DM) and all cause mortality. The national prevalence of
hyperglycemia and abdominal obesity paralleled by a surge in sedentary lifestyle
behavior underscore the importance of early identification and treatment of MetS.
Deleterious adaptations to both vascular and myocardial structure and function
have been demonstrated in MetS. Alterations in CV function associated with
accelerated arterial aging have been implicated in the association between MetS
and CVD. The underlying pathophysiology of MetS is not well understood and
CV dysfunction has not been comprehensively examined in a MetS population
free from confounding pathologies including T2DM and/or overt CVD.
Furthermore, the effects of therapeutic lifestyle interventions for targeting
subclinical CV dysfunction in MetS without T2DM and/or overt CVD require
investigation. Therefore, the directive of the studies included in this dissertation
was to perform a comprehensive assessment of CV function to validate the
presence of CV dysfunction in MetS and to evaluate practical therapeutic
strategies for improving cardiac and arterial dysfunction associated with MetS.
Results from these studies identified subclinical left ventricular (LV) diastolic
dysfunction at rest LV systolic dysfunction during exercise. Additionally, it was
discovered that deleterious adaptations to large artery structure and function
occur in individuals with MetS. Importantly, these alterations occurred in the
absence of chronic disease including T2DM and clinical CVD. These results
suggest for the first time that CV dysfunction does occur in individuals afflicted
with MetS without T2DM and/or CVD. The investigation of exercise training as a
therapeutic strategy for targeting arterial dysfunction revealed improvements in
central arterial stiffness, central systolic blood pressure and aerobic capacity
after 8 weeks of moderate/high intensity aerobic training. During peak exercise
we have demonstrated improvements in arterial-ventricular coupling, LV
contractility, peripheral vascular resistance, and aerobic capacity after 8 weeks of
aerobic training in MetS. Exercise training was unable, however, to improve
resting LV structure, LV diastolic function, or metabolic profile. Results from our
investigation using a nutritional therapeutic approach to CV dysfunction in MetS
demonstrate similar inconclusive findings. Single-dose supplementation with two
doses of trans-resveratrol demonstrated no conclusive therapeutic potential for
improving arterial stiffness or reducing central systolic blood pressure. These
results would suggest that a greater understanding of the underlying pathology of

MetS is required for identifying and optimizing therapeutic approaches to its
treatment. Taken together the results of these collective documents demonstrate
an understanding of the synergistic effects of co-occurring risk factors on CV
function in the absence of chronic clinical disease. Further, these results highlight
therapeutic and nutritional strategies for targeting CV dysfunction in MetS.

Acknowledgements
First, I would like to take the opportunity to acknowledge my advisor and
mentor, Dr. Paul Chantler. Thank you for taking a gamble on the pint-size ginger
and for introducing me to a realm of research that I didn’t even know that I would
learn to love. As a mentor you offer a unique blend of passion, expertise, and a
commitment to excellence in human subject research. Your drive continues to
challenge me to expand my ambitions, whether they be academic or otherwise.
Under your guidance (and with some tough love) I have made tremendous
strides in my personal confidence and I know that this confidence will continue to
guide me during my transition to the next level of my scientific training. Thank
you for the countless hours you have devoted to me over the last four years.
Cheers! I would also like to acknowledge my committee members, Dr. Taura
Barr, Dr. Gregory Dick, Dr. Jefferson Frisbee, and Dr. Mark Olfert. Thank you all
for your collective efforts in contributing to this dissertation and for your
unwavering encouragement during my graduate career.

Special thanks must be extended to the individual members of the everexpanding Chantler laboratory, both past and present. Evan DeVallance, thank
you for your friendship, your endless knowledge of clinical exercise and for
always offering an ear for my constant rambling. To Q, Corey, Kayla, Chris, and
Kent, thank you for your help and guidance over the past few years. I appreciate
you all more than you know and I am so grateful to be surrounded by such

iv

remarkable people every day. Finally, to the countless interns who have become
honorary Chantler lab members thank you for all of your hard work. While you
may not be permanent members of this laboratory you have all contributed in
some way to our success. To my friends and family at the HSC please know that
each of you have helped to make my graduate career so much more enjoyable.
For each of you I am extremely thankful.

I would like to acknowledge the West Virginia University Exercise
Physiology Graduate Education Department, especially Dr. Fred Minnear for
continued support during my graduate career. I would also like to extend special
thanks to Dr. Jamal Mustafa, Dr. Richard Dey, and the Cardiovascular and
Pulmonary T32 committee for selecting me for an appointment on this
distinguished training grant.

To the students and staff of the Human Performance Lab especially Dave,
Danny, and Diana, thank you for welcoming me to the world of clinical exercise
physiology and for your continued support, encouragement, and guidance over
the last 4 years. I will always carry a little guilt for all of those 5AM tests! You all
have helped to make the work presented in the following pages not only possible
but also enjoyable.

To my family, thank you all for your steadfast support, understanding, and
never-ending encouragement during my 6 year graduate career. I know that it

v

hasn’t been a joy ride to put up with me all of these years. You should know that I
value your love and encouragement more than I can articulate. To Ashley, for
constantly challenging me to become a better version of myself in all aspects, I
am so grateful.

vi

List of Abbreviations
AII

Angiotensin II

AGEs

Advanced Glycation End Products

AHA

American Heart Association

AS

Arterial Stiffness

AT

Aerobic Training

BH4

Tetrahydrobiopterin

BMI

Body Mass Index

cGMP

cyclic guanosine monosphosphate

CHD

Coronary Heart Disease

COX1

Cyclooxygenase 1

COX2

Cyclooxygenase 2

CRP

C-Reactive Protein

CVD

Cardiovascular Disease

DBP

Diastolic Blood Pressure

DT

Deceleration Time

Ea

Arterial Elastance

Ea/Ees

Arterial-Ventricular Coupling

ECs

Endothelial Cells

ED

Endothelial Dysfunction

EDV

End Diastolic Volume

Ees

End-Systolic Elastance

EF

Ejection Fraction

eNOS

Endothelial Nitric Oxide Synthase

ESP

End Systolic Pressure

ESPVR

End-Systolic Pressure-Volume Relation

ESV

End Systolic Volume

GLUT4

Glucose Transporter Type 4

GTP

guanosine-5’-triphosphate

HDL-C

High-Density Lipoprotein Cholesterol
vii

HOMA-IR

Homeostatic Model Assessment-Insulin Resistance

HR

Heart Rate

HTN

Hypertension

IVRT

Isovolumic Relaxation Time

LDL-C

Low-Density Lipoprotein Cholesterol

LVH

Left Ventricular Hypertrophy

MetS

Metabolic Syndrome

MMPs

Matrix Metalloproteinases

NCEP ATP III

National Cholesterol Education Program ATP III

NHANES

National Health and Nutrition Examination Survey

nNOS

Neuronal Nitric Oxide Synthase

NO

Nitric Oxide

PGH2

Prostaglandin H2

PGI2

Prostacyclin

PRSWi

Pre-load Recruitable Stroke Work

PVR

Peripheral Vascular Resistance

ROS

Reactive Oxygen Species

RT

Resistance Training

SBP

Systolic Blood Pressure

SEVR

Sub-Endocardial Viabilityhfh Ratio

SNS

Sympathetic Nervous System

SV

Stroke Volume

SW

Stroke Work

T2DM

Type II Diabetes Mellitus

TAC

Total Arterial Compliance

TG

Triglycerides

TIMPs

Tissue Inhibitor of Metalloproteinases

TxA2

Thromboxane A2

VSMC

Vascular Smooth Muscle Cell

WC

Waist Circumference

viii

TABLE OF CONTENTS
Abstract ............................................................................................................... ii
Acknowledgements ........................................................................................... iv
List of Abbreviations ........................................................................................ vii
Table of Contents............................................................................................... ix
List of Tables .................................................................................................... xiii
List of Figures .................................................................................................. xiv

Chapter 1. Background and Significance ......................................................... 1
1.1 The Metabolic Syndrome ..................................................................... 2
1.2 Macrovascular Adaptations .................................................................. 3
a. Conduit Remodeling ........................................................................ 4
b. Large Elastic Artery Stiffening ......................................................... 6
c. Endothelial Dysfunction ................................................................... 8
1.3 Cardiac Dysfunction ........................................................................... 10
a. LV Geometry ................................................................................ 11
b. LV Function at Rest ....................................................................... 12
c. LV Function during Aerobic Exercise ............................................. 14
1.4 Arterial-Ventricular Coupling .............................................................. 15
a. Left-Ventricular End-Systolic Elastance......................................... 15
b. Effective Arterial Elastance............................................................ 16
c. Arterial-Ventricular Coupling Ratio................................................. 17
d. Arterial-Ventricular Coupling during Exercise ................................ 18
e. Arterial-Ventricular Coupling in the Metabolic Syndrome .............. 19
1.5 Exercise Training ............................................................................... 21
a. Obesity .......................................................................................... 21
ix

b. Hypertension ................................................................................. 23
c. Dyslipidemia .................................................................................. 24
d. Glucose ......................................................................................... 26
e. Metabolic Syndrome ...................................................................... 27
1.6 Reference List .................................................................................... 30
1.7 Figure Legends .................................................................................. 48
1.8 Figures ............................................................................................... 49

Chapter 2. Exercise Reveals Impairments in Left Ventricular Systolic
Function in Patients with Metabolic Syndrome.............................................. 51

2.1 Abstract .............................................................................................. 52
2.2 Introduction ........................................................................................ 53
2.3 Methods ............................................................................................. 55
2.4 Results ............................................................................................... 63
2.5 Discussion .......................................................................................... 67
2.6 Acknowledgements ............................................................................ 75
2.7 Reference List .................................................................................... 76
2.8 Table Legends and Tables ................................................................. 84
2.9 Figure Legends and Figures .............................................................. 89

Chapter 3. Aerobic Exercise Training Reduces Arterial Stiffness in
Metabolic Syndrome ......................................................................................... 96

3.1 Abstract .............................................................................................. 97
3.2 Introduction ........................................................................................ 99
3.3 Methods ........................................................................................... 101
3.4 Results ............................................................................................. 109
3.5 Discussion ........................................................................................ 113
3.6 Sources of Funding .......................................................................... 122
3.7 Reference List .................................................................................. 123

x

3.8 Table Legends and Tables ............................................................... 130
3.9 Figure Legends and Figures ............................................................ 133

Chapter 4. Improved Arterial–Ventricular Coupling in Metabolic Syndrome
after Exercise Training ................................................................................... 137

4.1 Abstract ............................................................................................ 138
4.2 Introduction ...................................................................................... 140
4.3 Methods ........................................................................................... 142
4.4 Results ............................................................................................. 150
4.5 Discussion ........................................................................................ 153
4.6 Acknowledgements .......................................................................... 163
4.7 Reference List .................................................................................. 164
4.8 Table Legends and Tables ............................................................... 170
4.9 Figure Legends and Figures ............................................................ 174

Chapter 5. Acute Resveratrol Manuscript (In Preparation) ........................ 176

5.1 Abstract ............................................................................................ 177
5.2 Introduction ...................................................................................... 178
5.3 Methods ........................................................................................... 181
5.4 Results ............................................................................................. 188
5.5 Discussion ........................................................................................ 191
5.6 Sources of Funding .......................................................................... 195
5.7 Reference List .................................................................................. 196
5.8 Table Legends and Tables ............................................................... 202
5.9 Figure Legends and Figures ............................................................ 205

Chapter 6. General Discussion ...................................................................... 212

6.1 Reference List .................................................................................. 227

xi

Chapter 7. Future Directions .......................................................................... 235

7.1 Reference List .................................................................................. 239

Curriculum Vitae ............................................................................................. 241

xii

List of Tables
Chapter 2
2.1 Clinical characteristics of study cohort ............................................... 84
2.2 Measures of CV geometry at supine rest ........................................... 85
2.3 Measures of LV diastolic function at supine rest ................................ 86
2.4 Measures of CV function at seated rest ............................................. 87
2.5 Metabolic performance during exercise.............................................. 88

Chapter 3
3.1 Clinical characteristics of the subject cohorts ................................... 130
3.2 Arterial parameters pre and post intervention in MetS and controls . 131
3.3 Blood biomarkers pre and post intervention in MetS and controls ... 133

Chapter 4
4.1 Effects of exercise training on body composition and metabolic
biomarkers in MetS.......................................................................... 170
4.2 Effects of exercise training on supine LV geometry and diastolic
function in MetS ............................................................................... 171
4.3 Effects of exercise training on CV function in MetS.......................... 172
4.4 Effects of exercise training on aerobic capacity in MetS .................. 173

Chapter 5
5.1 Patient demographics and characteristics ........................................ 202
5.2 Baseline parameters in MetS and controls ....................................... 203
5.3 Multiple linear regression models ..................................................... 204

xiii

List of Figures
Chapter 1
1.1 Synthesis, activation, and signaling of NO ......................................... 49
1.2 Pressure-volume relationships ........................................................... 50

Chapter 2
2.1 LV diastolic function at rest and during exercise ................................ 91
2.2 Cardiac pump performance at rest and during upright exercise ......... 92
2.3 Cardiac contractility and arterial–ventricular coupling response
to exercise ......................................................................................... 93
2.4 Pressure and vascular resistance response during exercise ............. 94
2.5 Pressure and vascular resistance response during exercise. ........... 95

Chapter 3
3.1 Example of central pressure waveform ............................................ 134
3.2 Relationship between peak aerobic capacity (VO2 peak) and arterial
markers ........................................................................................... 135
3.3 Relationship between the change (post-pre values) in peak aerobic
capacity (VO2peak) and cfPWV ....................................................... 136

Chapter 4
4.1 Change in arterial-ventricular coupling (Ea/Ees), Ees, and Ea from rest
to peak exercise in Mets who underwent exercise training.............. 175

Chapter 5
5.1 Example of a central pressure waveform ......................................... 207
5.2 Plasma concentration of RSV and metabolites ................................ 208
5.3 Mean change in cSBP and cPP after supplementation with placebo
500mg and 1000mg of RSV ............................................................ 209
5.4 Mean change in AP and SEVR after supplementation with placebo
500mg and 1000mg of RSV ............................................................ 210

xiv

5.5 Mean change in AGI and AGI@HR75 after supplementation with
placebo 500mg and 1000mg of RSV ..................................................... 211

xv

Chapter 1
Literature Review

1

Metabolic Syndrome
In 1988 Gerald M. Reaven established “Syndrome X” to identify high-risk
patients with co-occurring metabolic risk factors predisposed to cardiovascular
disease (CVD) and type II diabetes (T2DM). Today we refer to the manifestation
of a cluster of co-morbidities as the metabolic syndrome (MetS). MetS as defined
by the guidelines set forth by the US National Cholesterol Education Program
Adult Treatment Panel III (NCEP) requires the manifestation of at least three of
the following five risk factors: abdominal obesity, dyslipidemia (e.g. increased
triglycerides, and decreased high density lipoprotein), hypertension, and
hyperglycemia. The prevalence of MetS among U.S. adults (≥ 20 years of age)
estimated from data collected using the National Health and Nutrition
Examination Survey (NHANES) from 1999 to 2010 indicates a decreasing trend
over the last decade from 25.5 percent to 22.9 percent [1]. The source of the
descending shift in MetS reflects individual decreases in the prevalence of
hypertriglyceridemia and in elevated blood pressure, both of which are correlated
with increases in the use of anti-hypertensive and lipid-modifying drugs.
Although this trend appears to reflect a favorable shift, the increasing trends in
the prevalence of hyperglycemia and elevated waist circumference (abdominal
obesity) and predictions based on the spread of the American obesity epidemic
estimate that the future incidence of MetS in the US will continue to rise [2]. The
American epidemic of obesity paralleled by a surge in sedentary lifestyle
behavior underscore the importance of early identification, treatment, and
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prevention of MetS. Compared to healthy individuals, those who present with
MetS assume the burden of a 3-fold increased risk of cardiovascular disease
(CVD) mortality, myocardial infarction, stroke, and all-cause mortality

[3-5]

and

T2DM. The pathophysiological mechanisms underlying these associations are
incompletely understood, however. Existing literature has reported evidence of
both vascular and myocardial abnormalities in MetS. Indeed our lab and others
have shown that MetS is associated with the acceleration of arterial aging.
Grouping of metabolic risk factors can also affect functional properties of the
arterial system, promoting vascular endothelial dysfunction. Given that large
elastic artery stiffness (AS) is a feature of MetS

[6-7]

and impaired endothelium-

dependent dilation of the brachial artery has been identified in the presence of
MetS, pathophysiological changes to the arterial vasculature may represent an
important link between MetS and increased CVD risk.

Macrovascular Adaptations
The large elastic arteries serve two important functions. First, they act as
conduits to deliver oxygen-rich blood pumped from the left ventricle (LV) to
peripheral arteries. Second, large distensible conduits (e.g. aorta) are
responsible for the Windkessel effect, which helps to maintain a relatively
constant arterial pressure despite the pulsatile nature of blood flow from the LV.
During systole the elastic aorta expands to store a portion of the blood ejected
from the LV. During diastole, potential energy created from the expansion and
subsequent passive elastic recoil of the aorta helps to maintain blood pressure
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and provide continuous steady blood flow to peripheral vessels. With aging and
under pathological conditions, the Windkessel effect is diminished as a result of
increases in AS and a loss of large elastic artery compliance [8].

Conduit Remodeling
The large elastic arteries are comprised of three distinct structural layers:
the tunica adventitia, the tunica media, and the tunica intima. Collagen and
elastin filaments responsible for the elastic properties of large arteries reside
within the tunic media, which is largely made up of smooth muscle cells and the
extracellular matrix. Biomechanical properties (stiffness and viscoelasticity) of the
aorta are determined primarily by the elastic matrix, which consists of elastic
fibers, collagens, proteoglycans, and glycoaminoglycans. Changes to conduit
artery structure can occur with normative aging as well as in the presence of
pathological stimuli in an effort to maintain arterial wall integrity. In individuals
with MetS, changes occur to the structure and function of the arterial system that
compromise the efficiency of the cardiovascular system and increase the risk for
the development of CVD. Two key contributors to arterial dysfunction associated
with MetS include arterial remodeling and large elastic artery stiffness (AS).
Arterial remodeling describes changes in vessel size; more specifically
this term refers to changes in the cross-sectional area within the elastic lamina
surrounding the vessel. Existing studies in healthy humans and nonhuman
primate and rodent models of aging provide evidence of luminal dilation in the
central elastic arteries with advancing age, leading to an increase in lumen size
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[9]. In healthy humans, outward remodeling of elastic arteries is a homeostatic
response to changes in blood flow in order to maintain optimal levels of shear
stress and circumferential wall tension [10].
MetS is regularly associated with thickening of the carotid wall, indexed as
carotid intimal medial thickness (cIMT). IMT refers to the measurement of the
thickness of the innermost layers of the arterial wall: the tunica intima and tunica
media. IMT is most commonly used in clinical trials and in observational studies
as an important endpoint for the evaluation of the progression or the regression
of atherosclerotic CVD [11]. Although IMT is strongly associated with the
identification of subclinical atherosclerosis, factors other than plaque formation
have an influence on IMT. Indeed, IMT has been shown to increase linearly as
much as 3-fold between the ages of 20 and 90 years in the absence of
atherosclerosis [12]. Further, studies using animal models not known to develop
atherosclerosis, including rodents and nonhuman primates, report thickening of
the intima media with aging [13-14]. In MetS cIMT has been shown to increase
between 0.08 mm and 0.11 mm vs. healthy controls [7, 15]. Specifically, when
considering impact of specific clusters of MetS components, the presence of low
HDL and abdominal obesity increases the probability of having an extreme
common carotid artery (CCA) IMT (i.e. values >2 SD from the mean of CCA IMT)
by 70 percent compared to those without reduced HDL or abdominal obesity [7].
A recent longitudinal study examining the temporal relationship between
structural arterial remodeling and arterial function provides evidence to support
the results from cross-sectional studies that suggest maladaptive arterial
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remodeling in MetS. Ferreira et al. [16] report that baseline values of
interadventitial diameter, lumen diameter (LD), circumferential wall tension
(CWT), circumferential wall strain (CWS) but not IMT were significantly elevated
in individuals with MetS vs. non-MetS. At follow-up MetS displayed significantly
steeper increases in IMT vs. non-MetS (0.011 vs. 0.005 mm/year, respectively),
and lumen diameter (0.055 vs. 0.023 mm/year, respectively). Importantly, despite
arterial remodeling, changes in CWS tended to decrease over time but remained
significantly elevated in MetS compared to non-MetS. These findings suggest
that arterial thickening in MetS occurs in advance of changes in CWS to restore
arterial wall integrity. Interestingly, those individuals who recovered from MetS at
the 6-year follow-up and non-MetS displayed similar arterial properties, pointing
to the reversible nature of an early pathological process.

Large Elastic Artery Stiffening
In addition to changes in arterial structure the large elastic arteries (i.e.
aorta and carotid) are subject to age-related stiffening [17]. Large elastic AS is a
strong independent predictor of CVD and mortality. AS has been shown to
increase with advancing age [18-19] and in the presence of MetS [15, 20].
Central AS can be assessed non-invasively from carotid-to-femoral pulse wave
velocity (PWV). Observational studies in healthy humans have demonstrated a
modest increase in central PWV that occurs in midlife [21]. In MetS, increases in
AS may have a detrimental impact on cardiac function; Increases in central
systolic pressure that accompany AS promote cardiac hypertrophy leading to
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decreases in diastolic pressure and impairment of coronary perfusion [22]. For
individuals with MetS, the CVD risk associated with increased AS is of particular
importance as a 1.0 m/sec increase in AS corresponds to a 15 percent increased
risk of CV mortality after adjustment for age, sex and risk factors [23]. Evidence
f rom existing lite rature indicates that changes in the expression and/or
bioactivity of structural proteins in the arterial wall (and heart) lead to AS. AS is
influenced by the composition of the extracellular matrix (elastin-collagen
network) and by vascular smooth muscle cell function (VSMC) [24-25]. Further,
increased collagen production and smooth muscle cell proliferation, as a
consequence of endothelial dysfunction, can alter the structure and composition
of the arterial wall and increase AS [26-30]. MMPs and TIMPs are key regulators
of arterial and cardiac [26-27, 29-30] remodeling. In animal models, increased
MMP9 activity, responsible for the degradation of elastin and collagen [31], was
directly linked with AS [32] and cardiac stiffness [33]. In hypertensive patients,
plasma MMP9 and TIMP1 were elevated vs. controls, and implicated in AS and
an increased risk of CV events [34-36]. Notably, TIMP1 inhibits MMP1 activity
that increases type 1 collagen (high tensile strength and rigidity) formation. While
structural changes that contribute to AS take several months to develop, AS
can also be altered acutely by changes in VSMC tone, which is regulated by
endothelial cell function and sympathetic nervous system activity [37].
Sympathetic stimulation can alter AS through an indirect change in arterial
pressure or through a direct increase in vascular tone, causing vasoconstriction
and decreased arterial diameter [38-40]. Moreover, impaired endothelial
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dysfunction, as a result of low-grade inflammation [28], enhances vasoconstrictor
activity, altering large artery smooth muscle tone [41-43] which may contribute
to acute changes in AS.

Large Artery Endothelial Dysfunction
Endothelial dysfunction (ED) is regarded as an early event in the initiation
and progression of atherosclerosis, and as a trademark of vascular disease [4445]. Impaired endothelial function refers to an imbalance in the production of
endothelial-derived mediators that regulate vascular permeability, coagulation,
platelet aggregation, and vascular tone. Among the specialized functions of the
endothelial monolayer in the regulation of vascular homeostasis, its role in
controlling vascular tone is considered the most extensively studied and thus, the
term ED refers to an imbalance in the relative contribution of endothelium-derived
relaxing factors and contracting factors. Under normal physiological conditions,
the vascular endothelium produces mediators of vascular hemodynamics in
response to physical and chemical stimuli. ECs contribute to the regulation of
blood pressure and blood flow through the production and release of vasodilators
including nitric oxide (NO) [46] and prostacyclin (PGI2), as well as
vasoconstrictors including endothelin-1, thromboxane A2 (TxA2), and angiotensin
II (ANG II). The balance between endothelial-derived relaxing factors and
contracting factors represents a major determinant of basal vascular smooth
muscle tone [47].
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In a clinical setting, ED is quantified by an impaired endotheliumdependent relaxation of the vascular smooth muscle in response to a chemical or
physical stimulus. Impaired relaxation of the smooth muscle is associated with
diminished production or availability of vasodilator substances, particularly NO,
due to a decline in the production of NO by the endothelium, inactivation of NO
by reactive oxygen species (ROS), or a decline in the availability of co-factors
required for the synthesis of NO. In the presence of cardiovascular risk factors
(e.g. hypertension, T2DM, hyperglycemia, etc.) the normal production of NO by
eNOS (Figure 1) is altered such that eNOS favors the generation of ROS
including superoxide, and hydrogen peroxide. This shift in eNOS function is
termed “eNOS uncoupling” [48]. EC activation and ED initiate a change in the
anti-proliferative, quiescent state of the healthy endothelium to one that promotes
increased production of endothelial-derived constricting factors, increased EC
permeability, increased expression of adhesion molecules, increased secretion of
chemokines, VSMC proliferation, and platelet activation and thrombosis.
Endothelial-dysfunction in conduit arteries is most often quantified by the
recording of endothelial-dependent dilation following pharmacological (e.g.
nitroglycerin or sodium nitro-prusside) or physiological stimulation of endothelialmediated NO synthesis [49]. Clinical assessment and identification of ED has
been shown to be an independent predictor of cardiovascular events [45].
Impaired endothelium-dependent dilation of the brachial artery has been
identified in the presence of MetS, a finding that is expected, as each component
of MetS is associated with ED [50-55]. Such findings suggest that ED may
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mediate, in part, the mechanisms responsible for the increased CVD risk in
MetS. The exact mechanism by which MetS causes ED remains unclear and it is
likely that multiple pathways are involved; however, oxidative stress appears to
be a primary mechanism contributing to loss of vascular homeostasis in MetS.
MetS is associated with a chronic state of low-grade inflammation [56].
The presence of inflammation and other co-morbidities of MetS including,
hyperglycemia and insulin resistance leads to a decreased generation of NO and
an increased production of ROS through eNOS uncoupling [48]. Elevated levels
of ROS stimulate the continued production of ROS in a positive feedback loop,
leading to chronic elevations in oxidative stress and a decrease in NO
production,

reduced

EC

sensitivity

to

NO,

and

an

increase

in

NO

inactivation/degradation [57]. Further, inflammation promotes the release of cell
growth factors that contribute to adverse vascular remodeling observed in MetS
through stimulation of VSMC proliferation and collagen formation [58].

Cardiac Dysfunction
Existing studies have documented the adverse effects of individual MetS
components including hypertension, T2DM, and obesity on cardiac structure and
function. In individuals with the MetS, groupings of interrelated risk factors act
synergistically to increase the risk of adverse cardiovascular events, such that
MetS is associated with a 3-fold increased risk of mortality resulting from CVD,
coronary heart disease, and all causes compared to those without MetS [59].
Recent literature has reported evidence of preclinical myocardial abnormalities in
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MetS. While it is unsurprising that each component of MetS is known to
independently and adversely affect cardiac structure and function, the
combination of risk factors has been shown to convey additional risk [60-61].
Consequently, the greater CVD burden associated with MetS may be mediated,
in part, by asymptomatic abnormalities in left ventricular (LV) systolic function,
which has been noted at rest in some studies [62-65], but not all [66-67].

Left Ventricular Geometry
General agreement exists in regards to adaptations of cardiac structure in
the presence of MetS. The impact of MetS on changes in LV mass have been
shown to be greater than the contributions of the individual components of MetS
(e.g. blood pressure and body size) [68], emphasizing the importance of the
synergistic effects of the component of MetS. Indeed, increases in LV mass and
relative wall thickness have been reported in hypertensive subjects with MetS
compared to hypertensive subjects without MetS [69] indicating an association of
MetS with increased LV mass independent of hypertension. Studies comparing
LV structure and function between individuals without MetS, pre-MetS, and MetS
indicate progressive LV dysfunction and remodeling with an increasing burden of
MetS [67]. Similarly, Aijaz et al. [70] identified an increase in LV mass index (91.7
vs. 87.9 g/m2; P=0.04) and LV diastolic dysfunction in women (n=1058) with
isolated MetS (i.e. excluding individuals with MetS and established hypertension
and/or T2DM) compared to those without MetS. LV hypertrophy (LVH) promotes
a decrease in coronary flow reserve (decreased capillary density per unit of
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myocardium and increased resistance to flow [71]) and is often a precursor of
diastolic dysfunction, however, impaired LV relaxation has been identified in
MetS patients independent of LV mass [67]. The presence of LVH is a risk factor
for CV morbidity and mortality, including the development of systolic and diastolic
function and further progression to heart failure [72-73]. Thus, together with
impairments in cardiac function, LVH may provide a modest explanation for the
increased CV risk in individuals with MetS.

Left Ventricular Function at Rest
Although the LV structural differences in MetS are fairly well agreed upon,
consensus is lacking with regard to changes in LV function. The prevalence of
diastolic myocardial dysfunction in individuals aged 65 years and older is
estimated to be 35 percent in individuals with MetS [74]. In MetS and in T2DM,
diastolic dysfunction results from abnormal myocardial active relaxation and an
increase in LV passive stiffness due to metabolic derangements and structural
remodeling [74]. Previously, Chinali et al. [66] have shown alterations of LV
diastolic dysfunction as characterized by early LV relaxation in American Indians.
In agreement with this finding, echocardiographic evaluation of parameters
related to LV diastolic function including E/A ratio, deceleration time (DT), and
isovolumic relaxation time (IVRT) by Turhan et al. [75] provides evidence of early
diastolic dysfunction in MetS vs. healthy control subjects. Using cardiac magnetic
resonance imaging technology, Nyman et al. assessed cardiac fat compartments
and LV function in men with MetS. These authors found that Mets was

12

associated with LV diastolic dysfunction and LV concentric remodeling.
Furthermore, epicardial and pericardial fat correlated with the degree of LV
diastolic dysfunction implicating a role for visceral obesity in the development of
MetS-associated LV diastolic dysfunction [76].
Some studies [62-64, 66-67, 77], but not all [66-67] have suggested that
individuals with MetS present with LV systolic dysfunction at rest. It has been
suggested that the elevated risk for CVD in MetS is mediated, in part, by
impaired resting LV systolic function; however, conclusions regarding systolic
dysfunction in MetS remain controversial with some studies reporting
impairments in LV contractile function assessed using a doppler-derived index of
myocardial performance [75]. Wong et al. [78] have identified LV systolic
dysfunction in patients with Mets using global strain rate, strain, and regional
systolic velocity and diastolic velocity. In an effort to explain the broad contrasting
results from several human studies it is important to emphasize that many
investigators rely on load-dependent measures to assess LV contractility
including ejection fraction (EF). Despite its traditional application, EF is a poor
prognostic measure of systolic function because it may be potentially influenced
by common observations in MetS including loading conditions and chamber
remodeling. Other common load-dependent indices used in the literature to
evaluate myocardial contractility include fractional shortening, systolic time
intervals and strain and strain rate deformation parameters. Using myocardial
strain and strain rate imaging to assess intrinsic LV myocardial contractility, Gong
et al. reported impaired global systolic strain and strain rate in the septum,
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lateral, posterior, anterior, and inferior walls of the LV in patients with MetS.
Importantly, subclinical abnormalities in LV systolic and diastolic function were
observed in the presence of normal LV EF [79].

Left Ventricular Function during Aerobic Exercise
Exercise testing is a well-established procedure for physiological stress
that can be used to elicit cardiovascular abnormalities not present at rest.
Pathophysiologic irregularities may emerge when cardiac demands are
increased during aerobic exercise. MetS patients often report a reduced quality
of life as a consequence of exertional dyspnoea and reduced exercise capacity
[74]. The deterioration of exercise capacity in MetS has been suggested to be a
consequence of early diastolic myocardial dysfunction [74].
While the assessment of cardiac function in MetS has been documented
within the literature, this manuscript will attempt to add to the current
understanding of cardiac dysfunction in MetS by addressing some important
limitations of existing investigations. A general shortcoming observed in many
studies includes the use of load-dependent measures of myocardial contractility.
In individuals with MetS, loading conditions including resting heart rate (HR), and
chamber geometry are often altered and therefore, may influence loaddependent assessments. Further, the MetS populations considered in the
existing literature often include individuals with T2DM and/or overt CVD [67, 78,
80]. With the inclusion of individuals with symptomatic or clinical CVD,
observations of CV structure and function may reflect a synergistic consequence
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of the presence of MetS and other confounding pathologies rather than MetS
alone. Notably, many studies examining CV structure and function in MetS are
limited to resting situations when the CV system is attempting to optimize
chamber pumping efficiency [81]. During aerobic exercise the CV system
prioritizes cardiac efficacy over energetic efficiency to meet the body’s increasing
demands [82]. Accordingly, maximal graded exercise testing may expose
subclinical LV abnormalities undetectable at rest that may predispose this
population to CVD.

Arterial-Ventricular Coupling
A comprehensive understanding of

cardiac function requires an

examination of the interactions between the left ventricle (LV) and the arterial
system (arterial-ventricular coupling). Arterial-ventricular coupling (Ea/Ees) is a
key determinant of cardiovascular function and is most often assessed in the
pressure-volume plane as the ratio of effective arterial elastance (Ea; a lumped
parameter of the net arterial impedance to stroke flow [83-84]) to left ventricular
end-systolic elastance (Ees; a load-independent index of the contractility and
systolic stiffness of the LV [85-86]).

Left Ventricular End-Systolic Elastance
Early work by Suga and Sagawa [87-90] was the first to conceptualized
and conceive a role for LV end-systolic elastance (Ees) in LV pump function and
myocardial energetics. The end-systolic pressure-volume relation (ESPVR) can
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be obtained using an excised canine heart preparation to generate a series of
pressure-volume loops during acute alterations in preload or afterload at a
constant contractile state. Ees is quantified as the slope of the ESPVR and is
generally assumed to be linear (Figure 1). Ees represents an index of LV
contractility and may be influenced by LV geometric remodeling and the
biophysical properties of the myocardium [85-86]. Accordingly, caution must be
applied when interpreting the significance of changes in Ees in the absence of
abnormalities in other measures of LV systolic function [91].

Ees can be

approximated as [(end-systolic pressure (ESP) / end-systolic volume (ESV)) –
V0], where V0 represents the volume-axis intercept of the ESPVR obtained when
the ESPVR is extrapolated to zero pressure, assuming a linear relationship.
When calculating Ees some assumptions to consider are: 1) that the slope of the
ESPVR is linear and is independent of loading conditions; 2) V0 represents a
common intercept with the volume-axis for joining instantaneous pressurevolume points at similar times during the cardiac cycle; 3) Ees is a function of
time only, and is independent of instantaneous and past pressure and volume
[87-90].

Effective Arterial Elastance
Effective arterial elastance (Ea) is approximated as the ratio of LV endsystolic pressure (ESP) and stroke volume (SV), and is often considered to be a
lumped parameter of the net arterial load imposed on the LV [92-93]. Specifically,
Ea is an index which integrates elements of arterial load including peripheral
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vascular resistance (PVR), total arterial compliance (TAC), characteristic
impedance, and systolic and diastolic time intervals [83]. Notably, a significant
limitation of Ea is that while it provides information on the steady and pulsatile
components of the arterial load, it is unable to provide information on their
relative contribution [93]. Ea is determined from pressure-volume loops as the
negative slope of the line joining the end-diastolic volume (EDV) and end-systolic
pressure (ESP) points (Figure 1). Later work by Kelly et al. [94] showed
agreement between Ea measured invasively as ESP/SV from pressure-volume
data and Ea calculated from arterial impedance data in normal and hypertensive
humans.

Arterial-Ventricular Coupling Ratio
Original efforts by Sunagawa et al. led the way for the conception of
innovative methods to compare arterial load and LV performance as traditionally
measured in the frequency domain and the time domain respectively [83].
Quantification of effective arterial elastance and LV end-systolic elastance using
the same units (mm/mL) provided the first platform for the study of arterial and
ventricular interactions. The ratio of Ea/Ees is a measure of the interaction
between the LV and the arterial system [83]. Early experimental studies
discovered that the heart is able to transfer maximal stroke work (SW;
mechanical energy) when Ea/Ees = 1.0 while energetic efficiency (ratio of SW to
pressure-volume area) is maximized at lower values of Ea/Ees [95]. In healthy
men and women, in the resting state, mean ± SD values of EA/ELV, EA, and
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ELV measured invasively are ≈1.0 ± 0.36, 2.2 ± 0.8 mmHg/ml, and 2.3 ± 1.0
mmHg/ml, respectively [96]. Examination of Ea/Ees and its components using
non-invasive

methods

offers

the

potential

for

a

more

comprehensive

understanding of arterial and LV interactions under normal physiologic conditions
and in various disease states.

Arterial-Ventricular Coupling and Its Components During Exercise
At rest, the LV and the arterial system are optimally coupled to produce
SW. During exercise, small changes to HR, LV contractility, preload, and
afterload ensure that the cardiovascular system adapts to meet the increased
metabolic demands of the body. Using adult dogs, Little and Cheng [97] showed
that submaximal exercise produced a left-shift in the LV pressure-volume relation
with an increased slope (Ees) which caused a decrease in the ratio of Ea to Ees
from rest to submaximal exercise. Notably, despite the decrease in Ea/Ees the
coupling of the arterial system and the LV remained in the range to produce
nearly optimal SW during steady state exercise. Studies in healthy human
subjects show agreement with work performed using animal models. For
example, Chantler et al. [92] examined Ea/Ees at rest and at peak exercise in
normotensive and hypertensive subjects and found that Ea/Ees decreased in
both men and women due to a disproportionate increase in Ees vs. Ea during
exercise. During exercise the increase in Ea parallels the observed increase in
AS despite reduced peripheral vascular resistance [98].
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Arterial-Ventricular Coupling in the Metabolic Syndrome
The following section will review the influence of some of the individual
components of MetS on arterial-ventricular coupling and its components.

Aging
Normative aging is known to be associated with alterations in LV structure
and function in both men and women. Notably, advancing age is accompanied by
increases in LV wall thickness and collagen deposition [86]. Consequently, aging
is also associated with an increase in resting Ees [96, 99-100]. A comparison of
resting Ea/Ees in old (70 ± 8 yr, n = 15) and young (30 ± 5 yr, n = 17) subjects
showed no significant differences due to comparable increase in both Ea and
Ees (11 percent and 15 percent, respectively) in older subjects [101].

Hypertension
Hypertension is diagnosed when systolic blood pressure and diastolic
blood pressure reach and exceed values of 140 mmHg and 80 mmHg
respectively. If left untreated, over time hypertension can have deleterious effects
on arterial and LV structure and function. For example, patients with
hypertension have been shown to have greater carotid wall thickness, central
arterial stiffness and greater wave reflection compared to normotensive patients
[102]. In addition, increased wall tension and wall tensile stress elicit pathological
changes in LV structure [103]. General agreement exists in the literature
regarding the impact of hypertension on arterial-ventricular coupling with
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hypertensive subjects displaying significant increases in Ea and Ees compared to
normotensive subjects [104-105]. Notably, these same studies report no
differences in the ratio of Ea/Ees indicating matched increases in Ea and Ees in
hypertensive subjects.

Obesity
Deleterious changes that occur with obesity have been well documented
within the literature including reduced arterial distensibility [106] and increased
AS [106-107]. Further, obesity in the absence of CVD has been shown to cause
changes in cardiac geometry including increased LV mass and LV volumes
[108]. In terms of how changes in arterial and cardiac structure and function due
to obesity affect arterial-ventricular coupling and its components, recent evidence
has shown that when Ea and Ees are scaled ratiometrically or allometrically to
body surface area, there is a significant increase in Ea and Ees in obese vs. nonobese controls [109]. The same study reported no change in the ratio of Ea/Ees
between obese and non-obese controls, irrespective of body size [109].
Arterial-ventricular

coupling

and

its

components

are

essential

determinants of the interactions between the heart and arteries. However, to
date, very few studies in humans have examined the impact of MetS, free from
T2DM and/or overt CVD, on cardiac energetics at rest or during exercise. This
manuscript will set out to examine how the presence of MetS will impact arterialventricular coupling and its components at rest and during exercise.
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Metabolic Syndrome and Exercise Training
Recommendations from the American Heart Association (AHA) for the
management of MetS encourage therapeutic lifestyle changes to target the
negative effects of atherogenic diet, weight gain, and sedentary lifestyle
behavior. Exercise training has been reported to prevent and/or partly reverse
MetS, however the most optimal exercise (i.e. type, duration, frequency, and
intensity) for the treatment of MetS remains unresolved [110]. The following
section will focus on the role of exercise training in the prevention and treatment
of MetS and its individual components.

Obesity
Significant excess body weight (BMI ≥ 30 kg/m2) may occur as a result of
a long-term imbalance between energy intake and energy utilization. In the US
the cholesterol-rich western diet and declining rates in physical activity in
combination with long-term caloric excess have created an obesity epidemic.
Evidence from scientific literature encourages the use of regular exercise to
manage weight and decrease the long-term risk of obesity-related diseases
including MetS and type II diabetes. Central adiposity or abdominal obesity,
expressed as waist circumference (WC), is a key feature of MetS and is strongly
associated with the risk of incident CVD events [111]. In a randomized, controlled
study comparing diet-induced weight loss and exercise-induced weight loss,
Ross et al. enrolled obese (BMI ≥27kg/m2 and WC >100cm), sedentary men
(n=101) and reported a greater significant reduction in total body fat following 12
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weeks of exercise-induced weight loss [112]. Further, exercise-without-weightloss showed a reduction in abdominal and visceral fat, which is closely related to
WC and BMI [112]. Similarly, the authors of Studies of a Targeted Risk
Reduction Intervention through Defined Exercise (STRRIDE-AT/RT) [113], a
large randomized clinical trial of obese and overweight adults, found that WC
was significantly reduced after combined aerobic/resistance exercise training vs.
resistance training alone; Aerobic training alone produced a trend toward a
significant decrease in WC. In a second publication from the STRRIDE study
[114],

all

three

amount/vigorous

eight-month
intensity,

low

aerobic

exercise-training

amount/vigorous

groups

intensity,

and

(high
low

amount/moderate intensity) displayed significant reductions in weight loss, fat
loss, and waist and hip circumference measurements despite no significant
changes in dietary intake for any group. These authors concluded that in nondieting, mildly obese individuals a modest amount of moderate-intensity exercise
(e.g. 30 minutes per day) is necessary to reverse a positive caloric imbalance
and maintain body weight. In a small pilot study [115], 32 patients with MetS
were recruited to address the efficacy of two modes of exercise to reverse
features of MetS. Participants were randomized to equal volumes of either
continuous moderate exercise or aerobic interval training for 16 weeks. Following
16 weeks of exercise training investigators reported exercise-induced reductions
in WC and total body weight. Together with reported improvements in lipogenesis
(the process by which simple sugars are converted to fatty acids) and increased
circulating levels of adiponectin, these data suggest reductions in intraabdominal
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visceral obesity and improvements in fat metabolism following 16 weeks of high
intensity aerobic exercise training.

Hypertension
Long-term hypertension (HTN) (SBP ≥140mmHg and DBP ≥90mmHg) is
recognized as a strong independent predictor of CVD [116]. It has been
estimated that 40 percent of prehypertensive (SBP levels of 120 to 139 mmHg
and/or DBP levels of 80 to 89 mm Hg) US adults will progress to HTN [117].
Studies based on the evaluation of physical activity using survey results support
the idea that physical fitness may play a role in the attenuation of the progression
to HTN [118-119]. Results from a recent study that followed 13,953 men (20-90
yrs.) free from hypertension, CVD and cancer, over a 36-year period support the
notion that cardiorespiratory fitness can delay the age-associted increase of BP
over an adult lifespan [120]. These results underscore the potential for delaying
age-associated changes in BP by improving physical fitness levels with regular
exercise and are in agreement with national guidelines for the primary and
secondary prevention of HTN [116]. Specifically, the American College of Sports
Medicine and the AHA recommends at least 150 minutes of moderate intensity,
75 minutes of high intensity exercise, or a combination of the two each week
supplemented with at least 30 minutes of aerobic activity per day per week [121].
Importantly, the use of different exercise modalities as well as the parameters of
frequency, duration, and intensity may have varying effects on BP. Historically
regular endurance training has been the preferred physical activity for producing
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favorable changes in BP [122-125]. Recent evidence from a meta-analysis of
randomized controlled trials to compare the effects of various exercise modalities
on the magnitude of changes in SBP and DBP in healthy adults found that
endurance training, dynamic resistance training, and isometric resistance training
significantly reduce BP and DBP [126]. Further, this analysis demonstrated that
no significant differences in effect size were observed between endurance
training and dynamic resistance training, however, the authors report that in
hypertensive individuals, the greatest reductions in BP occurred after dynamic
endurance training compared to other exercise modalities. A subgroup analysis
of endurance training revealed that exercise-training programs of less than six
months resulted in larger reductions in BP compared to programs of a longer
duration. In terms of training intensity, low-intensity endurance training produced
smaller BP reductions than those observed following moderate- or high-intensity
endurance exercise [126].

Dyslipidemia
Dyslipidemia describes a disorder of lipoprotein metabolism. In MetS,
dyslipidemia manifests as elevated total cholesterol, increased low-density
lipoprotein cholesterol (LDL-C), decreased high-density lipoprotein (HDL-C), and
elevations in plasma triglyceride (TG) concentrations. Studies focused on
identifying the effects of exercise training and blood lipid profiles report dosedependent relationships between exercise training volume and favorable
changes in blood lipids [127]. Specifically, data from cross-sectional studies have
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identified increases (2-3 mg/dL) in HDL-C and decreases in TG (8-20 mg/dL)
following exercise training designed to elicit between 1200 to 2200 kcal/week
[127]. Moderate intensity walking or jogging approximately 15-20 miles per week
would be an appropriate stimulus to meet weekly caloric expenditures required to
elicit favorable change in blood lipids [127]. Data from a meta-analysis of
randomized controlled trials examining the effects of aerobic exercise on lipid
and lipoproteins in overweight and obese adults is less convincing with trending,
but statistically nonsignificant beneficial increases (3%) in HDL-C [128]. In
contrast, evidence from the same meta-analysis suggests that aerobic exercise
training produces a statistically significant (11%, p < 0.05) reduction in TG which
remained significant even after removal of studies in which changes in diet,
smoking status, and use of drugs could produce changes in the blood lipid profile
[128]. In contrast to these reports, data from the Health, Risk Factors, Exercise
Training and Genetics (HERITAGE) Family Study [129], reveal a beneficial effect
(+4.9%, p<0.005) of 20 weeks of aerobic exercise training on men with high
TG/low HDL-C and visceral adipose tissue. In men with isolated low HDL-C and
normolipidemia 20 weeks of aerobic exercise training was unable to produce a
significant increase in HDL-C (+0.4%, P=NS) [129]. While the lack of an effect in
men with isolated HDL-C may seem discouraging, the “HDL-raising” effect
observed in men with unfavorable blood lipids and abdominal obesity highlight
the potential for exercise training to produce favorable changes in individuals with
two or more cardiovascular risk factors as is seen in MetS.
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Impaired Fasting Plasma Glucose
Under normal physiological conditions, the body responds to elevations in
blood glucose concentrations by signaling the production and release of insulin
by the pancreas. After binding to cell-surface receptors in skeletal muscle, fat,
and liver, insulin initiates the uptake and storage of glucose, thereby playing a
key role in the regulation of glucose homeostasis. In MetS, insulin resistance can
result in chronically elevated blood sugar and if left untreated, the development of
T2DM. Exercise is often employed as a lifestyle-related intervention to reverse
and/or control elevations in blood glucose through improvements in insulin
sensitivity. Data from human studies suggest significant improvements in fasting
plasma glucose and insulin sensitivity in individuals with impaired glucose
tolerance following aerobic exercise training. A recent investigation examined
adaptations in insulin sensitivity (HOMA) in response to continuous moderate
exercise or high intensity aerobic interval training in individuals with MetS [115].
When compared to continuous moderate exercise, high intensity aerobic
exercise training 3x/week for 16 weeks was shown to be superior at improving
insulin sensitivity (HOMA) in MetS [115]. The observed benefits of high intensity
exercise training above and beyond moderate intensity exercise training
highlights the importance of exercise intensity for targeting improvements in
insulin action and glucose homeostasis. Several human studies have
demonstrated similar findings and suggest an important role for substrate
utilization. For example, high intensity exercise contributes to the use of
intramuscular glycogen as a reserve source of available glucose for fuel. The
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post-exercise actions of insulin include stimulation of glucose uptake by the liver
and muscle cells and subsequent glycogen synthesis to replenish depleted
intramuscular glycogen. Evidence from animals studies using a rat model of
MetS demonstrates that treadmill training for 1 hour/day, 5 days/week for 10
weeks reduced blood pressure, improved insulin sensitivity, and increased
glucose transporter Type 4 (GLUT4) content in the heart, white adipose tissue,
and gastrocnemius muscle relative to untrained animals [130]. Exercise traininginduced improvements in insulin sensitivity are believed to be mediated from
increases in GLUT4 gene expression [131] as well as from improved
translocation of GLUT4 from the cytoplasm to the cell membrane [132-133].

Metabolic Syndrome
When considering the efficacy of a therapeutic lifestyle change for the
management of MetS, it is important to take into account not only the effects of
exercise training on each individual risk factor but to focus on reversing multiple
risk factors for the prevention and improvement of MetS. Evidence from the
STRRIDE study examining the effects of different volumes of exercise training on
multiple components of MetS reveal that both shorter duration/moderate intensity
and longer duration/vigorous intensity had significantly reductions in ATP III and
MS z scores compared to inactive controls [134]. Compared to moderateintensity exercise, vigorous-intensity exercise produced a greater number of
improved components of MetS [134] however, a modest amount of moderateintensity

exercise

was

adequate

to
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obtain

metabolic

health

benefits.

Comparatively, a second publication from the STRRIDE study addressed the
comparison of cardiometabolic benefits of aerobic training, resistance training,
and combined training in MetS [113]. Investigators reported significant
improvements in the MS z score following combined exercise training and a trend
toward improvement following aerobic training, while resistance training failed to
have any effect on MS z score [113]. Despite the reported benefits of combined
exercise training in MetS, the authors concluded that aerobic exercise training
represented the most efficient mode of exercise training to address the
cardiometabolic risk factors associated with MetS citing that the argument for
combined exercise training was weak when considering the time commitment vs.
cardiometabolic health benefits [113]. Similarly, findings from the HERITAGE
Family Study to determine the efficacy of aerobic exercise training for treating
MetS, provide evidence of the efficacy of physical activity in treating individuals
with multiple cardiovascular risk factors [135]. The HERITAGE STUDY recruited
288 men and 333 women who were evaluated for MetS to participate in a 20week ramp-style aerobic exercise-training program. Interestingly the overall
prevalence of MetS decreased from 16.9 percent to 11.8 percent following
exercise training. Of the total number of participants with MetS at the start of the
study, 30.5 percent were no longer classified as meeting the NCEP diagnostic
criteria for MetS following training. Even more encouraging is the fact that this
study did not include individuals with overt cardiovascular disease or
hypertension and thus, the observed benefits of aerobic exercise in the treatment
of MetS may play an important role in the prevention of the progression of
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subclinical metabolic disease to overt chronic disease [135]. The results of the
HERITAGE Family Study and others strongly support the NCEP ATP III
recommendations for the use of therapeutic lifestyle modifications (aerobic
exercise training) for the treatment of individuals with MetS.
While the benefits of exercise training on reversing and preventing the
progression of MetS to overt CVD are well agreed upon, the mechanisms
underlying exercise training-induced adaptations in MetS are unclear. Aerobic
exercise training has been established as an effective intervention for improving
arterial stiffness, increasing aerobic capacity, and improving peak LV
performance and LV contractility in healthy persons as well as in older persons
with overt CVD, including T2DM and coronary artery disease. However it is
unknown whether aerobic exercise training can improve arterial stiffening and
peak LV-arterial coupling and CV function in MetS, which would likely reflect a
reduction in CVD risk. In this document we will demonstrate the benefits of
aerobic exercise training on arterial stiffness and arterial-ventricular coupling and
its components in MetS free from T2DM and/or overt CVD.
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Figure Legends
Figure 1. Synthesis, activation, and signaling of NO for smooth muscle cell
relaxation.

Figure 2. This figure was modified from Chantler et al. [136]. Pressure-volume
relationships illustrating the slope of the end-systolic pressure volume
relationship (Ees), and the slope of the line joining end-systolic pressure and
end-diastolic volume points (Ea) in healthy controls.

48

Figure 1.

Figure 2.

49

50

Chapter 2
EXERCISE REVEALS IMPAIRMENTS IN LEFT VENTRICULAR SYSTOLIC
FUNCTION IN PATIENTS WITH METABOLIC SYNDROME

Sara B. Fournier1,2, Brian L. Reger1, David A. Donley1, Daniel E. Bonner1,
Bradford E. Warden2,3, Wissam Gharib2,3, Conrad F. Failinger2, Melissa D.Olfert4,
Jefferson C Frisbee,2,5, I. Mark Olfert1,2, and Paul D. Chantler1,2

1Division
2Center

of Exercise Physiology, School of Medicine, West Virginia University;

for Cardiovascular and Respiratory Sciences, School of Medicine, West

Virginia University; 3Division of Cardiology, School of Medicine, West Virginia
University. 4Human Nutrition and Foods, Davis College of Agriculture, West
Virginia University. 5Department of Physiology and Pharmacology, School of
Medicine, West Virginia University.

Running Head: Exercise Reveals LV Systolic Dysfunction in MetS

This research was originally published in Experimental Physiology. “Fournier,
S.B., et al., Exercise reveals impairments in left ventricular systolic function in
patients with metabolic syndrome. Exp Physiol, 2013.”
51

Abstract
Metabolic syndrome (MetS) is the manifestation of a cluster of
cardiovascular (CV) risk factors and is associated with a three-fold increase risk
of CV morbidity and mortality, which is suggested to be mediated, in part, by
resting left ventricular (LV) systolic dysfunction. However, to what extent resting
LV systolic function is impaired in MetS is controversial, and there are no data
indicating whether LV systolic function is impaired during exercise. Accordingly,
the objective of this study was to comprehensively examine LV and arterial
responses to exercise in MetS individuals without diabetes and/or overt CVD
compared to a healthy control population. CV function was characterized using
Doppler echocardiography and gas exchange in MetS (n=27) vs. healthy controls
(n=20) at rest and during peak exercise. At rest, MetS individuals displayed
normal LV systolic function but reduced LV diastolic function vs. healthy controls.
During peak exercise, individuals with MetS had impaired contractility; pump
performance, and vasodilator reserve capacity vs. controls. A blunted contractile
reserve response resulted in diminished arterial-ventricular coupling reserve and
limited aerobic capacity in MetS vs. controls. These findings possess clinical
importance as they provide insight to the pathophysiological changes in MetS
that may predispose this population of individuals to an increased risk of CV
morbidity and mortality.
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Introduction
Individuals with the metabolic syndrome (MetS) are at a three-fold
increased risk of cardiovascular disease (CVD) mortality than non-MetS
individuals [1]. Alarmingly, the prevalence of MetS in US adults is 34 percent and
is on the rise due, in part, to rising rates of obesity [2], which will likely lead to a
further increase in CVD incidence. This increased CVD mortality in MetS may be
mediated, in part, by impaired LV systolic function that has been noted at rest in
some studies [3-6] but not all [7, 8]. However, many of the studies used loaddependent measures of systolic function (endocardial or midwall fractional
shortening) or ejection fraction, which is more representative of the interaction
between the LV and arterial system [9], as measures of LV systolic function
(Azevedo et al., 2007; Aijaz et al., 2008; Mahmud et al., 2009; de las Fuentes et
al., 2007). Further, the populations examined in these studies were confounded
by including MetS patients with diabetes and/or overt CVD [7, 10, 11], and/or
comparing MetS individuals to a control group that contained individuals with
CVD [3-7, 11]. Such confounding factors do not allow interpretations as to
whether the severity of the changes in cardiovascular (CV) function is
representative of MetS or other pathologies.
Importantly, existing evidence of LV dysfunction in MetS is limited to
resting situations, where the CV system is attempting to optimize chamber
pumping efficiency [12]. In contrast, during exercise the CV system is set to
prioritize the output of the heart over energetic efficiency by coordinating
changes in LV function, arterial tone, endothelial function, venous return, and
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autonomic signaling. Thus, it could be expected that LV abnormalities,
undetectable at rest, may appear with exertion to limit exercise capacity in MetS
and contribute to an impaired quality of life [13]. However, to date, the
pathophysiological alterations in LV function, and the degree to which these
changes influence the interaction of the heart with the arterial system during
exercise in MetS is unknown. Thus, examining the LV functional changes during
exercise may further provide pathophysiological insights into the CVD risk in
MetS patients. Accordingly, the aim of this study was to determine the severity of
LV and arterial dysfunction during exercise in MetS individuals without diabetes
and/or overt CVD compared to a healthy control population. Further, we will also
examine resting LV systolic and diastolic function between MetS and healthy
controls. We hypothesize that MetS individuals will have an impaired LV
contractile response (peak end-systolic elastance and pre-load recruitable stroke
work) to maximal exercise, leading to a blunted arterial-ventricular coupling
response during exercise compared to healthy age-sex matched controls.
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Methods
Study Population
Twenty-seven subjects with MetS were recruited into the study. MetS was
defined according to the updated National Cholesterol Education Program: Adult
Treatment Panel III [14] comprised of three out of the following five components:
1) obesity (waist men >102 cm, women >88 cm); 2) low HDL cholesterol
(men<40 mg/dL; women<50 mg/dL); 3) hypertriglyceridemia (≥150 mg/dL); 4)
elevated glucose (≥100 mg/dL), and; 5) elevated BP (130/85 mmHg or use of
hypertensive medications). The MetS population was compared to twenty healthy
controls free from CVD, as determined by a detailed history, physical
examination, and a normal resting and exercise electrocardiogram. Exclusion
criteria for MetS and healthy controls included abnormal resting and/or exercise
electrocardiogram, diabetes mellitus (HbA1c ≥6.5 % or use of diabetic
medications), pulmonary disease, angina, atrial fibrillation, aortic stenosis (or
other types of valve disease), anemia, myocardial infarction, stroke, or coronary
revascularization as assessed by a detailed medical history, and physical
examination. No evidence of wall motion abnormalities was identified during the
maximal exercise test. Subjects who participated in regular exercise, defined as
greater than 30 minutes, three times/week were excluded to ensure similar
physical activity levels between groups. All subjects provided written informed
consent to participate that was approved by WVU Institutional Review Board.
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Study Design
Physiological assessments were performed between 7:00-10:00 AM, in a
quiet, temperature-controlled room, after a 12-hour fast and abstinence from
alcohol, caffeine, and vitamins. CV medications were withheld 24 hours prior to
assessments. After a minimum 15 minutes of quiet rest subjects underwent
supine, resting, non-invasive assessments of arterial and cardiac structure and
function. Once supine assessments were completed, subjects moved to a
modified monarch bike (Figure 1) where upright rest and exercise measures of
CV function were obtained.

Exercise Performance
Subjects underwent upright cycle maximal exercise testing. To optimize
acquisition of the echo images, the back support of the cycle was set at
approximately 130 degrees. Pedal speed was maintained at 50 rpm, and
workloads increased by 25 W every 3 minutes until exhaustion. Oxygen
consumed (VO2), carbon dioxide produced (VCO2), and the respiratory exchange
ratio (RER=VCO2/VO2) were measured (ParvoMedics) throughout exercise.
Subjective symptoms of fatigue (BORG score 6 to 20) [15], and BP’s (sphygmomanometry) were recorded at the end of each workload. Registered
diagnostic cardiac sonographers acquired transthoracic echo-Doppler/tissue
Doppler images during the final 1.5 minutes of each 3-minute exercise workload
(GE Vivid i, GE Healthcare, Chalfont St. Giles, United Kingdom).
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Cardiovascular Measurements
Arterial Geometry and stiffness: In the supine position, ultrasound (GE
Vivid i) 2-D images of the right common carotid artery were obtained 1-2 cm
proximal to the carotid bifurcation to measure maximal lumen diameter, and
intima-medial thickness (cIMT) following standard procedures [16]. Crosssectional area of the carotid artery was calculated as [(maximal lumen
diameter/2)2 x π]-(maximal lumen diameter/2-cIMT)2 x π). Carotid circumferential
stress was calculated as systolic BP x (carotid diameter in diastole/2). Carotid to
femoral pulse wave velocity (cfPWV; central arterial stiffness) was measured by
applanation tonometry (AtCor Medical, Sydney, Australia) [17]. ECG-gated
waveforms were sequentially recorded. Aortic distance (D) was calculated as the
difference in the distances from the carotid to the suprasternal notch and from
the suprasternal notch to the femoral artery. Time delay was calculated using a
foot-of-the-wave method.

Left Ventricular Geometry and Remodeling: In the supine position, LV
dimensions, wall thickness, and chamber volumes were determined in triplicate
from 2-D, M-mode, and Doppler spectra echocardiography using standard
methods [18]. Sex-specific LV hypertrophy (LVH) and geometry patterns based
on LV mass index and relative wall thickness (RWT) was defined as LV mass
index >95 g/m2 for women or >115 g/m2 for men, and LV geometry was classified
as normal, concentric remodeling, concentric LVH, or eccentric LVH [18].
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Resting Diastolic Function: In the supine position, the medial mitral annular
early diastolic velocity (e’) was determined by spectral tissue Doppler imaging
(GE Vivid i) using standard methods. The e’ velocity is inversely related to the
time constant of isovolumic relaxation (τ), derived from τ =(14.70-100e’)/0.15
[19]. Early (E) and late (A) transmitral flow velocities, the isovolumetric relaxation
time (IVRT), and the deceleration time of early filling velocity (Dec T) were
measured by pulsed-wave Doppler (GE Vivid i). End-diastolic pressure was
estimated as EDP =11.96+0.596 x E/e’ [19].

Left Ventricular Volumes and Contractility: In the upright seated rest position
and during exercise, LV end diastolic (EDV), and end-systolic (ESV) volumes,
along with ejection fraction (EF) were determined from Simpson’s biplane
method; the recommended method for measurement of volumes [18]. Cardiac
index (Ci) was determined from the product of heart rate (HR) and stroke volume
index. Load-independent measures of chamber contractility were examined as:
1) pre-load recruitable stroke work (PRSW [calculated from product of peak
volumetric ejection rate from LV outflow Doppler and systolic BP, divided by
EDV]), determined from the validated single-beat technique [20] and; 2) LV endsystolic elastance (Ees [calculated from BP, stroke volume, EF, and pre-ejection
and systolic ejection time intervals from LV outflow Doppler]), determined by the
validated single-beat technique [21]. The orientation of the LV outflow Doppler
velocity was positioned 5 mm proximal to the aortic valve in the apical five
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chamber view. The change in each parameter from upright seated rest to peak
exercise was used to characterize contractile reserve.

Arterial Function: Effective arterial elastance (Ea), a measure of the net arterial
load, was calculated as end-systolic pressure (ESP)/stroke volume (SV), where
ESP is approximated as 0.9 × systolic blood pressure (SBP) [9]. Systemic
vascular resistance index (SVRi) was calculated as mean arterial pressure
(MAP) x 80/Ci. The change in each parameter from upright seated rest to peak
exercise was used to characterize global arterial reserve.

Arterial-Ventricular Coupling: The LV and the central arteries have
bidirectional interactions. These interactions were examined the depiction of the
function of the LV and arterial system in terms of elastance i.e., LV chamber
elastance (Ees) and arterial Elastance (Ea), and examining their ratio (arterialventricular coupling ratio: Ea/Ees) [9].

Scaling for Body Size
Adequate scaling of physiological measures for body size is essential for
correct interpretation, and often the relationship between body size and
physiological function may not be linear, a major assumption for the ratiometric
scaling approach [22]. The allometric scaling approach accounts for this potential
nonlinear relationship by normalizing physiological measures using exponential
powers that linearize the relationship. In our data set, the relationship between
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body surface area (BSA) and cardiac volumes, cardiac output, and PRSW were
adequately scaled for using the ratiometric scaling approach. No relationships
were presented between BSA and Ees, or Ea. To account for differences in
chamber size, Ees was normalized to end-diastolic volume (EDV). However,
EDV was allometrically related to Ees and thus EDV to the power of 0.45 was
used to scale Ees. Also, LVM was allometrically scaled to height to the power of
2.7. The relationship between BSA and the CV parameters were examined using
Pearson’s

correlation.

Initally,

significant

correlations

were

adjusted

ratiometrically, y= a+bx+ ε, where b represents the slope of the line of best
fit, a the intercept on the y-axis, and ε the additive residual error term. If
significant correlations remained between the ratiometrically adjusted CV
variable and BSA, then these data were adjusted allometrically, y=axbε,
where y represents the CV variable, x represents BSA,

a represents the

proportionality coefficient or constant multiplier, b is the power function exponent,
and ε represents the multiplicative residual error term, as described in detail
previously [22].

Sample Size and Statistical Analysis
Measurements of CV function were performed offline, by a single
investigator who was blinded to group allocation. The intra-class correlation
coefficient (ICC) for all echocardiographic variables was derived in a subset of
subjects (n=8). At rest, the ICC for all variables, collected on two separate days,
was >0.80. Similar results were obtained for echocardographic variables
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evaluated during peak exercise with all variables having an ICC>0.80 with the
exception of the arterial-ventricular coupling ratio (ICC=0.63).
Based on previous data identifying differences in peak exercise Ees (≈4
mmHg/ml/m2) and the Ea/Ees ratio (≈0.10) between young and older healthy
individuals [23-25] sample size was calculated as follows using G*Power 3.1:
Assuming independence among subjects and a SD estimate of 6.5 mmHg/ml/m2
for peak Ees and 0.11 for the Ea/Ees ratio at peak exercise, eighteen subjects
per group would provide us with an 80 percent power (2-sided α=0.05), to detect
a difference of 4 mmHg/ml/m2 for peak Ees and 0.10 for peak Ea/Ees between
any two groups.
All analyses were performed using SPSS version 20 (SPSS Inc, Chicago,
Illinois). A two-tailed p≤0.05 was required for significance. Data are reported as
mean ± SEM unless otherwise stated. Normality was evaluated by the
Kolmogorov-Smirnov test. Categorical variables were compared by the chisquare test. Continuous variables were log transformed as necessary and
compared between groups through ANCOVA adjusting for sex. The changes
from rest to peak exercise in CV parameters were examined by: a) calculating
their delta and comparing this variable between groups using ANCOVA adjusting
for sex, and; b) by examining a time (seated rest to peak exercise) by group
(MetS vs. healthy controls) interaction evaluated using a two-way repeatedmeasures ANOVA. Further, to account for structural differences (LV Mass,
cfPWV, cIMT) between groups we: c) examined the time by group interaction
adjusting for LV Mass, cfPWV, and cIMT as covariates in the repeated-measures
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ANCOVA; d) in a subset of the population, individuals (MetS vs. controls) were
matched by age, LV Mass, cfPWV, cIMT, peak HR, and respiratory exchange
ratio, and analyzed using a repeated-measures ANCOVA (time by group
interaction) (see supplemental data).
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Results
Subject Characteristics
As expected, baseline CVD risk factors were significantly different
between MetS and controls but not for age or sex as summarized in Table 1.

Cardiovascular Differences at Rest
Arterial Structure and Function
In MetS subjects, carotid diameter, carotid CSA and cIMT were larger
(p<0.05) compared to controls. As such, carotid circumferential stress was larger
in MetS (Table 2). Although net arterial load (Ea) and vascular resistance (SVRi)
did not significantly differ between groups (Table 3), cfPWV was moderately
increased (23%, p<0.01) in MetS vs. controls and remained significant after
adjusting for MAP between groups (p=0.01), indicating an increase in arterial
stiffness in MetS.

Left Ventricular Structure and Function
LVmass was 37 percent larger in MetS, but RWT was similar compared to
controls. Thus, LVH was 18 percent greater in MetS than controls, with 33
percent of MetS presenting with concentric remodeling and 7 percent presenting
with concentric and eccentric LVH (Table 2). In addition to these remodeling
differences between groups; the MetS group tended to present with reduced
supine LV diastolic function evident by a greater impaired LV relaxation (lower e’
and longer τ), a higher A-wave (thus the E/A ratio was reversed p<0.01), and a
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higher E/e’ (a predictor of elevated LV filling pressure), and EDP vs. controls
(Table 3).
Comparisons of EDV, ESV, and SV were significantly elevated in MetS
however, after adjusting to BSA, cardiac volume no longer differed between
groups (Table 4). Cardiac index (Ci) and HR were also similar between groups.
LV load-independent contractility as assessed by Ees, EesEDV0.45, and PRSW
did not differ between MetS and controls at rest. The similarity between groups in
Ees and Ea guaranteed that Ea/Ees (a measure of net cardiovascular
performance) was also comparable between groups.

Cardiovascular Responses to Upright Exercise
Exercise Performance and Cardiac Function
Aerobic capacity adjusted to body weight (ml/min/kg) at peak exercise and
at the ventilatory threshold were (p<0.001) lower in MetS than healthy controls,
this was despite both MetS and controls achieving similar rates of perceived
exercise exhaustion, exercise duration and peak workload (Table 5).
During exercise, there was no significant time by group interactions for
components of LV diastolic function, namely, IVRT, E-wave, A-wave, and Dec T
(Figure 2). The change from rest to peak exercise in EDVi (p>0.9) and SVi
(p=0.3) did not significantly differ between MetS and controls. However, there
was a significant time by group interaction for the reduction in ESVi during
exercise with MetS individuals having a blunted decrease vs. healthy controls
(Figure 3). MetS individuals also demonstrated a blunted increase in EF (6%,
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p=0.02), and Ci (-24%, p<0.05) compared to controls, which were evident at
submaximal workloads (Figure 3); whereas peak HR was lower at peak exercise
in MetS. Importantly, LV contractility reserve (change from rest to peak exercise)
was impaired in MetS compared to controls, evident by a blunted increase in Ees
(-35%, p=0.01), and PRSWi (-26%, p=0.013) in MetS (Figure 4). Once again
these differences were manifested at submaximal exercise workloads. Further,
even after adjusting statistically the above parameters individually for either peak
HR, LV Mass, cIMT, or cfPWV the results above did not differ significantly.
Further, in a subcohort of this population matched for resting LV Mass, cIMT,
cfPWV, peak exercise HR and respiratory exchange ratio, the results above did
not differ significantly (see supplemental data).

Arterial Function and AVC Reserve
During exercise the change in Ea did not differ between groups (p>0.2)
(Figure 4B). The combination of an impaired contractile reserve in MetS, but a
similar change in Ea between groups during exercise considerably limited the
Ea/Ees response in MetS (25% impaired decrease, p<0.05) compared to controls
(Figure 4A). Submaximal and peak SBP and DBP were higher in MetS than
controls (Figure 5A), and a significant time by group interaction was noted for the
change in SVRi during exercise. We further examined these data by statistically
adjusting the above CV variables for LV Mass, cIMT, or cfPWV, and with the
exception of SVRi (p=0.1 time by group interaction), the results above did not
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differ significantly. Similarly, the results above did not differ significantly from the
subcohort analysis (see supplemental data).
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Discussion
The present study provides the first comparison of LV and arterial
structure and function responses to exercise in non-diabetic MetS individuals
without overt CVD. This finding is of significant clinical interest, and a growing
public health concern. Our study provides evidence of LV systolic dysfunction
during exercise including limitations in peripheral vasodilation accumulating in a
blunted arterial-ventricular coupling reserve and impaired peak aerobic capacity
in MetS. These data demonstrate that pathophysiological CV alterations occur in
the earliest stages of MetS development, prior to any evidence of chronic
disease such as diabetes and/or overt CVD, and that impaired LV systolic
function during exercise occurs prior to evidence of LV systolic dysfunction at
rest.

Resting LV and Arterial Structure and Function
Previous studies examining CV alterations in MetS patients (with or
without diabetes) have been limited to characterizing differences in LV and
arterial structure and function at rest. MetS patients are traditionally
characterized as having increased cIMT (range 9-16%), and PWV (range 1332%) [26, 27]. The results of the present study are similar to previous findings
with MetS individuals presenting with a 21 percent higher PWV, and an 18
percent higher cIMT. They also confirm the presence of increased LV Mass in
MetS (in the absence of CVD and/or diabetes) reported by existing studies [7,
27].
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Although the LV structural differences in MetS are fairly well agreed upon,
consensus is lacking with regard to changes in LV function. Some studies [3-8],
but not all [7, 8], have suggested that MetS individuals have LV systolic
dysfunction at rest [3-6]. However, many of these studies used EF as a measure
of systolic function, which despite its conventional clinical application, is a rather
poor prognostic measure of systolic function as it is potently influenced by
loading conditions and chamber remodeling [28]. Further, the populations
examined in these studies were confounded by the inclusion of MetS patients
with diabetes [4, 7, 11] and moderate stenosis [5], conditions that would
exacerbate symptoms of LV dysfunction. In addition, control subjects included
people with hypertension [4-6], obesity [7], diabetes [3, 4, 11], and many were
taking CV medications [5, 11]. Such confounding factors do not allow
interpretation as to whether the changes in LV function are representative of
MetS or of other existing pathologies. Using load-independent measures of
contractility (Ees, or Ees•EDV, and PRSWi) we found no evidence of LV
dysfunction in MetS. The present findings cannot exclude the possibility of
cellular abnormalities in the cardiomyocytes of MetS individuals. However, we did
identify differences in resting diastolic function in MetS versus healthy controls
(Table 4), which has been previously reported in some [6, 8] but not all [29, 30]
studies. It has been postulated that LV diastolic dysfunction is a pre-cursor of LV
systolic dysfunction and heart failure with a preserved EF (HFpEF) [31-33]. In
addition, abnormalities of LV relaxation, i.e. grade 1 diastolic dysfunction, confer
a two-fold increase in all-cause and cardiac mortality [32]. This statistic highlights
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the clinical importance of recognizing the early, and/or subclinical, changes in
diastolic function at rest in individuals with MetS.

Aerobic Capacity and Cardiovascular Reserve Function
Exercise provides a powerful tool to examine the response of the LV and
arterial systems to stress and to assess functional reserve. If LV function is
impaired in MetS individuals it would likely be revealed during exercise, and to
promote intolerance to exercise.
Widely regarded as a load-independent measure of LV chamber
performance, the change from rest to peak exercise in Ees is blunted with
advancing age and may be limited further in the presence of disease [34].
Although at rest Ees is determined by geometric and biochemical properties that
regulate LV end-systolic stiffness (i.e. structural changes from LV hypertrophy or
fibrosis) [35], acute changes in Ees, such as those observed during exercise
reflect inherent changes in LV contractile function [9]. Using load-independent
measures of LV contractility, we identified a blunted Ees, and PRSWi reserve
capacity in MetS that manifested at submaximal workloads (Figure 4). Ha et al.
[36] noted a blunted increase in s’ in MetS during exercise; however the extent of
the LV function impairment was limited by the load dependence of s’ and the lack
of a healthy control for comparison. In the present study, impaired LV contractility
was accompanied by altered cardiac pump performance, and an impaired
vasodilator reserve capacity in MetS. Importantly, impaired contractile function
and vasodilator capacity resulted in a blunted arterial-ventricular coupling
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response to exercise. Ea/Ees is a key determinant of CV performance, cardiac
energetics and exercise capacity [9]. At rest in healthy individuals, Ea/Ees varies
from 0.5-1.0 to ensure maximal cardiac power and chamber efficiency [12].
During exercise, Ea/Ees decreases due to an acute mismatch between Ees and
Ea to optimize cardiac performance [9]. While resting Ea/Ees did not differ
between our groups, the Ea/Ees response to exercise was considerably blunted,
which in part contributed to reduced peak aerobic capacity in MetS. Similar
impairments in Ea/Ees have been reported during acute maximal exercise with
advancing age and have been suggested to explain, in part, diminished CV
functional capacity in the elderly [34].
Mechanisms limiting CV reserve in MetS individuals remain speculative.
But, it is likely that multiple factors are involved, including sympathetic nervous
system activity, activation of the renin-angiotensin-aldosterone system, and
cardiac metabolism during exercise [37-39]. Importantly, the blunted CV
response is unlikely to be attributed to differences in exercise effort exercise
duration, maximal workload, and peak BORG were similar between groups
(Table 5). Further, the blunted CV responses in MetS remained evident even
after: a) adjusting statistically for peak HR and the respiratory exchange ratio
(which were higher in MetS vs. controls); and b) in the subgroup analyses in
which subjects were matched for peak HR and the respiratory exchange ratio.
Impairments in contractile reserve observed in the present study may be
mediated in part by altered calcium handling, as the influx of calcium is a primary
determinant of cardiac performance. Specifically, contractile dysfunction as a
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result of alterations in sarcoplasmic reticulum calcium handling has been
implicated in aging and type 2 diabetes [40, 41]. Although there was no sign of
wall motion abnormalities during exercise in MetS, the use of upright
echocardiography may have missed subtle wall motion abnormalities [42]. Thus
this blunted systolic function in MetS could, in part, be a manifestation of early
myocardial ischemia even in the presence of normal wall motion during exercise.
An additional potential mechanism for the impaired CV response to
exercise in MetS may be depressed systemic peripheral vasodilation in the
resistance vessels. An impaired SVRi response to exercise is evident in HFpEF
and is known to contribute to limited exercise capacity in systolic heart failure,
and is thought to be a result of a reduction in NO generation [43, 44]. In
accordance with these findings, we observed a blunted reduction in SVRi during
exercise in MetS vs. controls. Indeed, endothelial dysfunction is a common
denominator linking MetS, type 2 diabetes, and CVD [45] suggesting that therapy
targeted to promoting the bioavailability and/or stimulating the generation of NO
may effectively improve systemic vasodilatation during exercise in MetS.
The MetS is characterized by structural changes to the heart (increase LV
Mass and remodeling) and conduit arteries (increased cIMT and cfPWV) [27, 46].
These structural changes are not only predictors of CV events (myocardial or
cerebral infarction) [47, 48] and mortality [49, 50] but they are also predictors of
poor aerobic capacity [51-54]. It is plausible that the LV and arterial structural
differences noted between MetS and healthy controls could contribute to the
blunted CV response during exercise. However, after adjusting for LV mass,
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cIMT, or cfPWV in the statistical models, the blunted Ees, PRSWi, Ci and EF
response from rest to peak exercise in MetS remained. We further examined
these relationships by matching healthy controls and MetS by LV mass, cIMT,
and cfPWV. Once again, MetS individuals demonstrated a blunted CV response
to exercise compared to healthy controls in this subcohort. These results suggest
that the structural CV differences between MetS and healthy controls do not fully
account for the impaired exercise CV response in MetS.
Previous literature has suggested a link between LV diastolic dysfunction
and exercise intolerance [7, 55]. Although the focus of this study was to examine
the extent of LV systolic dysfunction during exercise (and thus echocardiographic
views were optimized to examine systolic function), we were able to compare
some components of LV diastolic function during exercise between MetS and
controls. No differences in IVRT, and Dec T were evident between groups.
Further, the early (E) and late (A) mitral inflow filling velocities, during
submaximal workloads, did not differ between groups. At moderate exercise
workloads there is a high incidence of fusion of the E and A-wave, thus from 50
W onwards the A-wave dominated and no differences were noted between
groups at peak exercise (Figure 2). Unfortunately the acquisition of LV diastolic
parameters during exercise is cumbersome, limiting our ability to fully
characterize the extent of exercise diastolic function. Therefore we cannot
eliminate the possibility that diastolic abnormalities during exercise may have
contributed to the CV reserve deficits.
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Limitations
Due to the small sample size and cross-sectional nature of our study, we
cannot infer causality between MetS and CV abnormalities. Although pressure
and flow were not directly measured, but rather estimated from non-invasive
surrogates, these have been previously validated against invasive hemodynamic
measurements performed at rest [20, 21]. However, the non-invasive
measurement of end-systolic elastance and pre-load recruitable stroke work
have been validated during exercise. Further, our peak cardiac data may be
underestimated due to the challenge of acquiring echocardiograhic images
during exercise, but this technique has been successfully used by others [56, 57],
to which we observe similar values and responses in our subjects, suggesting
fidelity in our data. Although, it is possible that the lower peak HR and respiratory
exchange ratio in MetS may have contributed to their blunted CV response to
exercise, this impaired CV response remained evident in a subcohort of
individuals matched for peak HR and the respiratory exchange. The overall
significance and strength of our study is that our MetS patient population did not
have the disease-related confounders and/or medications seen in most of the
existing studies, which allows to report a comprehensive examination of resting
and exercise arterial and LV measures in MetS individuals prior to the
development of chronic disease.

Conclusion
This study demonstrates that individuals with MetS display evidence of
impaired systolic contractile function, vasodilator, and cardiac pump function
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reserve capacity during exercise. These deficits contribute to abnormal arterialventricular coupling and exercise intolerance in individuals with MetS without
diabetes and/or overt CVD. Whether the development of MetS and associated
CV changes, and the progression to MetS together with diabetes is along the
same pathophysiological pathway to heart failure warrants further investigation.
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Table 1. Clinical Characteristics

Age, years
Sex, female %

Controls

MetS

(n=20)

(n=27)

45 ± 2.5

49

65

±

1.9

63

p Value
0.24
0.57

Height, cm

169 ± 2

169

±

2

0.92

Weight, kg

71 ± 2

103

±

4

<0.001

Waist circumference, cm

85 ± 5

119

±

5

<0.001

Body Fat, %

25 ± 2

39

±

2

<0.001

BSA, m2

1.80 ± 0.03

2.11

±

0.04

<0.001

BMI, kg/m2

25.0 ± 0.8

36.0

±

1.0

<0.001

SBP, mmHg*

115 ± 2

134

±

3

<0.001

DBP, mmHg*

75 ± 1

83

±

1

<0.001

Ejection Fraction, %

61 ± 1

58

±

1

0.06

Triglycerides, mg/dL

94 ± 10

170

±

29

0.036

HDL, mg/dL

55 ± 3

43

±

2

<0.001

Glucose, mg/dL

93 ± 2

99

±

1

0.018

5.60

±

0.07

0.03

12.1

±

1

<0.001

2.98

±

0.37

<0.001

HbA1c, %
Insulin, µIU/mL
HOMA-IR

5.35 ± 0.09
6.1 ± 1
1.32 ± 0.23

Hypertensive %

0

56 %

<0.01

Diabetes Mellitus %

0

0

Hypertension

0

56%

<0.05

Cholesterol

0

7%

<0.05

Medications

Values are mean ± 1 SEM; BSA: body surface area; BMI: body mass index;
SBP: systolic blood pressure; DBP: diastolic blood pressure; HDL: highdensity lipoprotein; HbA1c: hemoglobin A1c; HOMA-IR: homeostatic model
assessment of insulin resistance. *SBP and DBP taken during screening visit
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Table 2: Measures of Cardiovascular Geometry at Supine Rest
Controls
(n=20)
Arterial Geometry
cIMT, mm
Diastolic diameter, mm
Carotid CSA, mm2/m2
Cardiac Geometry
LV Mass, g
LV Mass Index, g/m2
LV Mass/height2.7, g/m2.7
Relative Wall Thickness

MetS
(n=27)

p Value

0.61
5.78
10.3

±
±
±

0.02
0.12
0.32

0.72
6.17
12.7

±
±
±

0.04
0.13
0.68

0.02
0.04
<0.01

136
75
33
0.39

±
±
±
±

7
3
1

186
88
46
0.41

±
±
±
±

11
5
3

<0.01
0.046
<0.01
0.41

0.02

0.02

LV Hypertrophy %

1

19

0.18

Concentric Remodeling, %

25

33

0.14

Concentric Hypertrophy, %

1
0

7
7

0.14
0.14

Eccentric Hypertrophy, %
Values are mean ± 1 SEM, p-values adjusted for sex; cIMT: carotid intima-medial thickness;
CSA: cross-sectional area.
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Table 3: Measures of Left Ventricular Diastolic Function at Supine Rest
Controls
(n=20)
LV Diastolic Function
E, m/s
0.81

MetS
(n=27)

p Value

± 0.04
± 0.03

0.82

±

0.03

0.65

0.73

±

0.03

<0.01

1.19

±

0.07

<0.01

74

±

3

0.54

203

±

7

0.10

A, m/s

0.57

E/A ratio

1.47

IVRT, m/s

71

± 0.08
± 3

Dec T, m/s

220

±

e’, m/s

0.13

0.11

±

0.01

0.03

τ, ms

28

± 0.01
± 3

41

±

3

<0.01

E/e’

6.46

± 0.40
± 0.24

8.19

±

0.59

0.02

16.9

±

7

0.02
0.36
Values are mean ± 1 SEM, p-values adjusted for sex; E: peak
velocity of the early diastolic mitral flow; A: peak velocity of the late
diastolic mitral flow; E/A: E divided by A; IVRT: isovolumetric
relaxation time; Dec T: mitral flow deceleration time of early filling
velocity; e’: mitral annular early diastolic velocity; τ: time constant of
isovolumetric relaxation; E/e’: E divided by e’; LV EDP: left ventricular
end-diastolic pressure
LV EDP, mmHg

15.9
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Table 4: Measures of Cardiovascular Function at Seated Rest
Controls
(n=20)

MetS
(n=27)

p Value

LV Performance
EDV, ml
EDVi, ml/m2
ESV, ml
ESVi, ml/m2
SV, ml
SVi, ml/m2
LV Contractility
Ees, mmHg/ml
Ees·EDV0.45
PRSW, g/cm2
PRSWi, g/cm2/m2
Integrated indexes

87
48
36
20
51
28

±
±
±
±
±
±

6
3
3
1
3
2

103
48
49
21
59
28

±
±
±
±
±
±

5
2
2
1
3
1

0.02
0.92
<0.01
0.52
0.09
0.76

3.21
85
90
52

±
±
±
±

0.33
6
4
2

2.91
91
94
51

±
±
±
±

0.18
25
3
2

0.45
0.48
0.93
0.66

Heart rate, bpm
68 ± 2
66 ± 2
0.46
Ea/Ees ratio
0.91 ± 0.06
0.93 ± 0.07
0.93
3.85 ± 0.20
0.18
Cardiac Output
3.43 ± 0.22
2
Cardiac Index, L/m ·min
2.03 ± 0.12
2.16 ± 0.08
0.33
Arterial Function
SBP, mmHg
116 ± 3
127 ± 3
<0.01
MAP, mmHg
90 ± 2
99 ± 2
<0.01
2.58 ± 0.15
0.58
Ea, mmHg/ml
2.71 ± 0.17
SVRi, dyne·m2/s·cm-5
1261 ± 78
1063 ± 75
0.08
cf-PWV, m/s
6.6 ± 0.2
8.0 ± 0.2
<0.01≠
Carotid Circum Stress,
18.8 ± 0.8
23.4 ± 1.4
0.01
mmHg
Values are mean ± 1 SEM, p-values adjusted for sex; ≠ adjusted for
differences in mean arterial pressure; EDV: end-diastolic volume (i=index); SV:
stroke volume; Ees: end-systolic elastance; PRSWi: preload recruitable stroke
work index; Ea/Ees: arterial-ventricular coupling ratio; Ea: arterial elastance;
SVRi: systemic vascular resistance index; cf-PWV: carotid to femoral pulse
wave velocity.
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Table 5: Metabolic Performance during Exercise
Controls

MetS

(n=20)

(n=27)

869 ± 65
1.15 ± 0.02

946 ± 49
1.09 ± 0.02

0.34

113 ± 9
166 ± 4

123 ± 5
154 ± 3

0.29

177 ± 8
68 ± 4

191 ± 4
77 ± 4

0.01

19 ± 0.3
24.6 ± 1.4

19 ± 0.3
17.1 ± 0.9

0.56

16.8 ± 1.1
638 ± 72

11.8 ± 0.8
628 ± 57

<0.01

65 ± 2
91 ± 5

67 ± 2
69 ± 2

0.58

29 ± 1
38 ± 1

0.70

VE/VO2 at max

29 ± 1
41 ± 1

VE/VCO2 at max

35 ± 1

35 ± 1

0.75

Exercise duration, s
Peak respiratory exchange ratio
Peak work load, W
Peak Heart rate, bpm
Peak SBP, mmHg
Peak DBP, mmHg
Subjective effort score (6-20)
VO2peak, ml/kg/min
VO2 at ventilatory threshold, ml/kg/min
Time to ventilatory threshold, s
Ratio VO2 at ventilatory threshold to VO2peak, %
Ratio of observed to predicted VO2peak, %
VE/VO2 at VT, %

Values are mean ± 1 SEM, p-values adjusted for sex
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p Value

0.01

0.01

0.09

<0.01

0.91

<0.01

0.10

Figure Legends
Figure 1. Schematic illustration of the experimental set-up for the graded
exercise test. Subjects performed maximal upright cycle ergometry with the back
support angled at approximately 130°.

Figure 2. LV Diastolic function at rest and during exercise. The change from rest
to max exercise in (A) isovolumetric relaxation time (IVRT), (B) early (E) and late
(A) mitral inflow velocities, and (C) the deceleration time of early filling velocity
(Dec T) in MetS and controls. No significant time by group interactions for IVRT
or Dec T were evident between MetS and controls during max exercise. Further
at peak exercise no differences were observed between groups for the early (E)
and late (A) mitral inflow filling velocities, however, at moderate workloads the Eand A-waves become superimposed at extreme workloads the A-wave
dominates over the E-wave. *p<0.05 MetS vs. controls; # p<0.05 time by group
interaction. Data presented as means ± SEM.

Figure 3. Cardiac pump performance at rest and during upright exercise. The
change from rest to max exercise in (A) cardiac volumes, (B) ejection fraction
(EF), (C) cardiac index (Ci), and (D) heart rate (HR) in MetS and controls. During
exercise the change from rest to max exercise in EDVi and SVi was similar
between MetS and healthy controls. A significant time by group interaction was
identified for the reduction of ESVi during exercise with MetS displaying a blunted
decrease vs. controls. Compared to controls MetS also demonstrated a blunted
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increase in EF and Ci at max exercise, which was evident at submaximal
workloads. Peak HR was significantly lower in MetS vs. controls. *p<0.05 MetS
vs. controls; #p<0.05 time by group interaction. Data presented as means ±
SEM.

Figure 4. Cardiac contractility and arterial-ventricular coupling response to
exercise. The change from rest to max exercise in (A) pre-load recruitable stroke
work index (PRSWi), (B) end-systolic elastance (Ees) and effective arterialelastance (Ea), (C) and the arterial-ventricular coupling ratio (Ea/Ees) in MetS
and controls. Compared to controls, MetS displayed a blunted increase in Ees
and PRSWi at max exercise. During exercise the combination of a blunted
increase in Ees and a comparable change in Ea between groups resulted in a
blunted Ea/Ees ratio in MetS compared to controls. *p<0.05 MetS vs. controls;
#p<0.05 time by group interaction. Data presented as means ± SEM.

Figure 5. Pressure and vascular resistance response during exercise. The
change from rest to max exercise in (A) systolic (SBP) and diastolic (DBP) blood
pressure, and (B) systemic vascular resistance index (SVRi) in MetS and
controls. Systolic BP and diastolic BP were higher in MetS vs. controls at
submaximal and maximal workloads. +p=0.08 vs. controls; *p<0.05 MetS vs.
controls; #p<0.05 time by group interaction. Data presented as means ± SEM.
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Abstract
The metabolic syndrome (MetS) is associated with a 3-fold increase risk of
cardiovascular disease (CVD) mortality partly due to increased arterial stiffening.
We

compared

the

effects

of

aerobic

exercise

training

on

arterial

stiffening/mechanics in MetS without overt CVD or Type 2 Diabetes. MetS and
healthy controls (Con) underwent 8 weeks of exercise training (ExT; 11 MetS and
11 Con) or remained inactive (NonT; 11 MetS and 10 Con). The following
measures were performed pre and post intervention: radial pulse wave analysis
(applanation tonometry) was used to measure augmentation pressure and index,
central pressures, and an estimate of myocardial efficiency; arterial stiffness was
assessed from carotid-femoral pulse wave velocity (cfPWV, applanation
tonometry); carotid thickness was assessed from B-mode ultrasound; and peak
aerobic capacity (gas exchange) was performed in the seated position. Plasma
matrix metalloproteinases (MMP), and CVD risk (Framingham risk score) were
also assessed. cfPWV was reduced (p<0.05) in MetS-ExT (7.9+0.6 to 7.2+0.4
m/s) and Con-ExT (6.6+1.8 to 5.6+1.6 m/s). Exercise training reduced (p<0.05)
central systolic pressure (116+5 to 110+4, mmHg), augmentation pressure (9+1
to 7+1, mmHg), augmentation index (19+3 to 15+4%), and improved myocardial
efficiency (155+8 to 168+9) but only in the MetS group. Aerobic capacity
increased (p<0.05) in MetS-ExT (16.6±1.0 to 19.9±1.0) and Con-ExT (23.8±1.6
to 26.3±1.6). MMP-1 and 7 were correlated with cfPWV and both MMP-1 and 7
were reduced post-exercise training in MetS. These findings suggest that some
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of the pathophysiological changes associated with MetS can be improved after
aerobic exercise training thereby lowering their CV risk.

Keywords: metabolic syndrome, arterial stiffness, exercise training

98

Introduction
The metabolic syndrome (MetS) is associated with a 3-fold increase risk of
cardiovascular disease (CVD) mortality than individuals without MetS [1]. Current
predictions are that by the year 2020, as much as 40% of the population will have
MetS. Part of this increased CVD risk in MetS is attributed to the
pathophysiological changes to the arterial system, namely increased arterial
stiffness, carotid thickening, and higher central arterial pressures [2, 3]. A 1 m/s
increase in central pulse wave velocity (PWV: a measure of arterial stiffness)
corresponds to an age-, sex-, and risk factor–adjusted risk increase of 15% in
cardiovascular and all-cause mortality [4]. Further, a 0.1 mm increase in carotid
artery intima media thickness (cIMT) is associated with a 18% and 15%
increased risk for a stroke and myocardial infarction, respectively [5]. Therefore,
it is critically important that effective interventions aimed at improving arterial
health are identified.
Aerobic exercise training has been shown to be an effective intervention to
improve arterial compliance/stiffness in healthy young and middle/older persons
[6, 7]. However, with metabolic disease, previous studies have examined
exercise interventions in populations with a single metabolic risk factor (obesity,
hypertension, hypercholesterolemia) [8-10], or in MetS with type 2 diabetes
(T2DM) [11, 12]. Because the development of MetS occurs prior to the
development of T2DM and overt CVD, it is important to know if exercise training
can reverse the arterial stiffening and produce improvements in the CVD risk
profile of MetS individuals prior to overt T2DM or CVD. Understanding the

99

mechanisms mediating favorable changes in arterial function prior to the
progression to T2DM are important. It is possible that the changes in the arterial
expression, architecture, and/or bioactivity of structural proteins that play a major
role with CVD, are either reversed or ameliorated through exercise. Favorable
effects of exercise on improving the balance with pro-and anti-inflammatory and
oxidative stress markers could improve nitric oxide bioavailability, and alter
matrix metalloproteinases (MMPs), and/or tissue inhibitors of MMP (TIMPs)
activity. MMP are regulators of tissue remodelling and its activity is greatly
affected by mechanical stretch. Chronic exercise training, which acts as a
mechanical stressor to the arteries, could exert its effects by altering MMP/TIMP
activity directly and/or indirectly via the anti-inflammatory and oxidative stress
responses of exercise.
We examined whether aerobic exercise training can reverse arterial
stiffness and improve arterial mechanics including central pressures in
individuals with MetS without overt CVD or T2DM. Further, we examined the
potential mechanisms (inflammation, and MMP/TIMP activity) through which
aerobic exercise may improve arterial health. We hypothesized that exercise
training in MetS would reduce central arterial stiffness compared to the nontrained MetS control group.
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Methods
Study Population
21 healthy controls (41+ 2 years; 71% female) and 22 MetS (45 + 2 years;
60% female) subjects participated in the study. The healthy controls were free
from CVD, as determined by a detailed history, physical examination, and a
normal resting and exercise electrocardiogram. MetS subjects were free from
overt CVD and diabetes. Further, none of the participants were current or former
smokers or were being treated for peripheral artery disease. MetS was defined
according to the updated National Cholesterol Education Program: Adult
Treatment Panel III [13] comprised of 3 out of the following 5 components: 1)
obesity (waist men >102 cm, women >88 cm); 2) low HDL cholesterol (men<40
mg/dL; women<50 mg/dL); 3) hypertriglyceridemia (≥150 mg/dL); 4) elevated
glucose (≥100 mg/dL & <126 mg/dL), and; 5) elevated BP (130/85 mmHg or use
of hypertensive medications).
Exclusion criteria included T2DM (HbA1c ≥6.5 % or use of diabetic
medications), pulmonary disease, angina, atrial fibrillation, aortic stenosis,
anemia, myocardial infarction, stroke, or coronary revascularization as assessed
by a detailed medical history physical examination, and a resting and exercise
electrocardiogram. Subjects who participated in regular exercise, defined as >30
minutes, 3 times/week were excluded. All subjects provided written informed
consent to participate that was submitted to and approved by WVU Institutional
Review Board.
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Study Design.
Assessments were performed between 7:00-10:00 AM, in a quiet,
temperature-controlled room, after a 12 hour fast, and abstinence from alcohol,
caffeine, and vitamins. Cardiovascular medications were withheld 24 hours prior
to assessments. Upon completion of the anthropometric assessments and after a
minimum 15 minutes of quiet supine rest, subjects underwent supine measures
of arterial structure/function followed by a blood draw.

Body Anthropometry
Height, and weight, along with waist and hips circumference were
measured using standard laboratory procedures. Fat distribution was assessed
by measuring the waist circumference at the site of the smallest circumference
between the rib cage and the ileac crest with the subjects in standing position.
Hip circumference was measured at the site of the largest circumference
between waist and thighs. Body composition was calculated from body volume of
the BodPod® (Life measurement, Concord, CA, USA). Subjects wore tightly
fitting bathing suits and a swim cap during the volume-measurements in the
BodPod®. Body mass index (BMI) was calculated as weight (kg)/height (m)2.

Arterial Geometry
Ultrasound (GE Vivid i) 2-D images of the right common carotid artery
were obtained 1-2 cm proximal to the carotid bifurcation to measure maximal
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lumen diameter, and intima-medial thickness (cIMT). Cross-sectional area of the
carotid artery was calculated as [(maximal lumen diameter/2)2 x π]-(maximal
lumen diameter/2-cIMT)2 x π). The wall to lumen ratio of the right common
carotid artery (CCA W/L) was calculated as 2 x cIMT/lumen diameter in diastole
[2].

Arterial Function
Brachial systolic (SBP) and diastolic (DBP) blood pressure was measured
with an automated, oscillometric, sphygmomanometer (Critikon Dinamap
Compact BP monitor, GE Medical, Tampa, Fla , USA) and pulse pressure (PP)
was

calculated

from

SBP-DBP.

Pulse

wave

analysis

was

performed

noninvasively on the radial artery (SphygmoCor system, AtCor Medical, Sydney,
Australia). All measurements were made in triplicate, and the mean values used
for subsequent analysis. The SphygmoCor system synthesizes a central
(ascending aortic) pressure waveform from the radial pressure waveform that
does not differ from that of an intra-arterially recorded wave [14] using a validated
generalized transfer function [15] that has good reproducibility under major
hemodynamic changes [16]. These waveforms were calibrated against brachial
mean arterial and diastolic pressure to estimate aortic pressures.
The characteristics of the aortic pulse wave (Figure 1) were determined as
follows using established guidelines [17]. Forward wave pressure was defined as
the difference between pressure at the waveform foot and the pressure at the
inflection point and used as an index of peak left ventricular ejection velocity (P1,
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Figure 1). Left ventricular (LV) systolic ejection duration was taken as the time
from the foot of the pressure wave upstroke to the incisura of the dicrotic notch.
Augmented pressure (AP), a measure of the contribution of wave reflections to
SBP, was defined as the difference between aortic SBP and the pressure at the
forward wave peak. Augmentation index (AGI) provides a measure of the
contribution of wave reflection pressure (i.e. AP) to SBP relative to total PP. AGI
was calculated as the ratio of amplitude of the pressure wave above its systolic
shoulder (i.e. the difference between the early and late systolic peaks of the
arterial waveform), to the total PP expressed as a percentage (P2−P1/PP*100)
[14]. Since AGI varies with heart rate, AGI is commonly adjusted to a ‘standard
heart rate’ of 75 beats per minute (AGI@75). Travel time of the forward pressure
wave from the aorta to the peripheral reflection site and back (Tr) was
determined from the time from the initial upstroke of the pressure wave to the
foot of the reflection wave and used as a proxy of aortic pulse wave velocity.
Systolic-to-diastolic pressure shifts were assessed by the systolic (red shaded
area, Figure 1) and diastolic (blue shaded area, Figure 1) pressure-time
integrals. The Buckberg sub-endocardial viability ratio (SEVR) index, which
correlates with LV sub-endocardial:sub-epicardial flow ratio (an apparent marker
of sub-endocardial ischemia) [18], was calculated as the percentage ratio of the
diastolic (diastolic time index, DTI):systolic (tension time index, TTI) pressuretime integral.
Carotid to femoral pulse wave velocity (cfPWV; central arterial stiffness)
and carotid to radial pulse wave velocity (crPWV: peripheral arterial stiffness)
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were measured by applanation tonometry (AtCor Medical, Sydney, Australia).
ECG-gated waveforms were sequentially recorded. Aortic distance (D) was
calculated as the difference in the distances from the carotid to the suprasternal
notch and from the suprasternal notch to the femoral artery or radial artery. Time
delay was calculated using a foot-of-the-wave method.
Using B-mode ultrasound (GE Vivid i) the right CCA strain was calculated
as (ΔDc)/D x 100, where ΔDc is the difference between systolic and diastolic
carotid diameter, D is the diastolic diameter. CCA circumferential wall stress =
Mean BP x CCA W/L. Peak CCA circumferential wall tension was calculated as
aortic SBP x (Dc in systole/2)

Blood Analysis
Venous blood sampling was obtained in the morning after a 12-hour
overnight fast. Post training blood samples were collected at least 48 hours after
the last exercise session. Serum and plasma was obtained from blood samples
collected in either serum separation tubes with polymer gel/silica activator (BD
Vacutainers®) or plasma separation tubes (BD Vacutainers®). Using standard
procedures

total

cholesterol,

high-density

lipoprotein

(HDL)

cholesterol,

triglycerides, glucose and insulin were processed at West Virginia University
Hospital’s central laboratory in Morgantown, West Virginia. Homeostasis model
assessment of insulin resistance (HOMA-IR) was estimated with the following
formula: insulin resistance = fasting plasma insulin (in microunits per ml μU/mL) ×
fasting plasma glucose (FPG, in millimoles per litre)/22.5. HOMA β-cell function
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was also assessed from 360* fasting insulin/(fasting glucose-63). Plasma MMP
(1, 2, 7, 9, and 10) and TIMP (1 and 2) activity, serum adhesion molecules
(Serum Endothelial Leukocyte Adhesion Molecule-1, soluble cell adhesion
molecules-1, vascular cell adhesion molecule-1, and tissue plasminogen
activator inhibitor-1), and serum inflammatory markers (IL-6, IL-8, and TNFα)
were run on a Luminex® 100™ Bioanalyzer (Luminex Corp., Austin, TX, USA)
according to the kit manufacturer's (Milliplex ELISA kits, Millipore Corporation,
MA, USA) instructions.

The reader is referred to the online supplement for

further details on blood processing.

CVD Risk
The Framingham Risk Score (FRS) was calculated based on sex, age,
brachial SBP, treatment for hypertension, smoking and diabetes status, HDL,
and total cholesterol to establish an individual’s general 10 year CVD risk, along
with their estimated Framingham vascular age [19]. Further, we also estimated
vascular age based on published sex-specific algorithms for cfPWV (PWVage)
[20].

Intervention
Individuals were assigned into either an 8-week aerobic exercise
intervention group (ExT) or an 8 week non-exercise control (Non-ExT) group.
Initially, 11 controls were assigned to the Non-ExT group however, one dropped
out for personal reasons. Data were only analyzed on subjects who completed
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the study. The Non-ExT exercise training groups (Controls: n=10, 80% female;
MetS: n=11; 55% female) were instructured to maintain their normal lifestyle
activities. The ExT groups (Controls: n=11, 64% female; MetS: n=11; 73%
female) performed 8 weeks of supervised aerobic exercise, 3 days/week for 60
min/day at a fixed exercise intensity performed in the Human Performance Lab at
West Virginia University. The intensity of prescribed exercise was based on
individual results of maximal upright bicycle cardiopulmonary exercise tests with
the resistance to peddling increasing by 25 watts every 3 minutes until subjects
reached exhaustion. Subjects were required to pedal at 50 revolutions/minute.
We deployed a ramp exercise protocol, whereby the exercise intensity started at
60% of heart rate reserve (heart rate range determined during exercise stress
test) and increased every 2 weeks by 10%; from weeks 6-8 heart rate reserve
was set at 85%. Adherence to the exercise prescription was documented through
the use of Portable heart rate monitors (E600, Polar Electro OY, Oulu, Finland)
and physical activity logs. Approved modalities included treadmills, elliptical
machines, and cycle ergometers. The participants were instructed to maintain
current eating behaviors for the duration of the 8-week intervention. All posttraining measurements were performed at least 48 hours after the last exercise
session to avoid the immediate effects of a single bout of exercise. In addition,
measurements before and after intervention periods were obtained at the same
time of day for each subject.
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Statistical Analysis
Our sample size calculation for our primary outcome measures (cfPWV)
assumed a power of 90% and an alpha error probability of 0.05. We found that
we required a sample size of at least 11 subjects to detect a clinically significant
effect of exercise training on arterial stiffness such as a difference in cfPWV of
1±1 (SD) m/s. Normality was evaluated by the Kolmogorov-Smirnov test.
Categorical variables were compared by the chi-square test. Continuous
variables were log transformed as necessary and pre-exercise variables were
compared between groups with a One-way ANOVA with a Tukey’s post hoc test.
To evaluate the effects of exercise training paired t-tests and two-way repeatedmeasures ANOVA were used. All analyses were performed with the statistical
package SPSS version 21 (SPSS, Chicago, IL). Values shown in the tables
represent means ± SEM unless otherwise stated. P <0.05 was defined as
significant.
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Results
Age, anthropometric and metabolic characteristics of the healthy controls
and MetS groups are shown in Table 1. MetS and controls groups did not differ
by age or sex; however, by study design the MetS groups had significantly higher
anthropometric and metabolic characteristics.

Additionally, pre-exercise peak

VO2 was lower (p<0.05) in MetS NonT (18 ± 2 ml/min/kg) and MetS ExT (16 + 1
ml/min/kg) groups vs. healthy NonT (25 + 2 ml/min/kg) and healthy ExT (24 ± 2
ml/min/kg) controls. However, within each group (i.e., MetS Non-ExT vs. ExT,
and controls Non-ExT vs. ExT) individuals were well matched with no significant
differences in age, baseline metabolic and arterial parameters.

Arterial Parameters
It is well known that MetS patients have higher central and brachial
pressures, an increased arterial stiffness, and arterial remodeling compared to
healthy controls. Similar differences were evident in our population (Table 2). In
healthy controls, 8 weeks of exercise training significantly reduced cfPWV and
AGI, and there was a significant time (Pre vs. Post) by group (Non-ExT vs. ExT)
group interaction for cfPWV. However, no other significant differences in arterial
structure/function were found pre-and post-exercise training in healthy controls.
Importantly, 8 weeks of exercise training in MetS patients reduced brachial and
central SBP, although only a significant reduction was identified in the central
SBP (p<0.05). Further, AP was significantly reduced (20%, p<0.05) in the MetSExT group. Although AGI was not affected by exercise training, a reduction (21%,
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p=0.06) in AGI@75HR was identified. Indeed, resting HR was reduced (6%,
p<0.05) in MetS-ExT group. Due to the reduction in central SBP the systolic
region of the pressure wave was reduced (9%, p<0.05) along with an
improvement in SEVR (8%, p<0.05) in the MetS-ExT group, and there was a
significant time (Pre vs. Post) by group (Non-ExT vs. ExT) interaction for SEVR.
Importantly, aerobic training lowered cfPWV in MetS individuals by 9% (p<0.05),
which remained significant after adjusting for differences in MAP. Further, there
was a significant time (Pre vs. Post) by group (Non-ExT vs. ExT) group
interaction for cfPWV. In contrast, 8 weeks of exercise training had no effect on
improving crPWV, cIMT, carotid cross-sectional area, carotid lumen to wall ratio,
carotid wall stress or tension in MetS-ExT.
In the Non-ExT controls and MetS, no differences in arterial structure and
function were found 8 weeks post-intervention compared to baseline values
(Table 2).

Blood Biomarkers
We also examined the effects of exercise training on improving metabolic
markers, inflammation, and vascular proteins circulating in the blood. No
differences in metabolic markers, adhesion or the inflammation markers were
evident in either the healthy controls or MetS group after the intervention (Table
3). However, a reduction in MMP-1 (p<0.05), and to a lesser extent MMP-7
(p=0.06), was evident after exercise training in the MetS group, but not in the
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healthy control group. A significant time (pre and post intervention) by group
(MetS NonT vs. MetS ExT) interaction was identified for MMP-7.

Aerobic Capacity and CVD risk
Aerobic capacity was increased (p<0.05) in MetS (16.6±1.0 to 19.9±1.0)
and healthy controls (23.8±1.6 to 26.3±1.6) after exercise training, whereas no
changes were found in MetS (18.5±1.6 vs. 18.2±1.2) and healthy controls
(25.6±2.8 vs. 25.8±2.5) who remained inactive. As expected the FRS and the
vascular age calculated from the Framingham Risk algorithm were higher
(p<0.05) in both MetS groups compared to healthy controls (Table 1). Exercise
training did not affect the FRS in MetS (8±4% vs. 6±3) or healthy controls (2±1%
vs. 2±1). However, in MetS exercise training significantly reduced vascular age
calculated from the Framingham Risk algorithm (from 47±8 to 44±7 years,
p=0.02), and from cfPWV (from 55±5 to 50±4 years, p=0.04). Adding PWVage to
the FRS tended to reduce the calculated CVD risk (10±5 vs, 6±3%), but
statistical significance was not reached (p=0.15). In contrast, neither vascular
age calculated from the FRS (34±4 vs. 33±4 years, p=0.6) or from cfPWV (40±3
vs. 37±4 years, p=0.1) was altered in the healthy controls ExT group. Similarly,
adding PWV to the FRS did not alter their calculated CVD risk (3±1% vs. 2±1%).

Relationship between Aerobic Capacity, and Arterial Health.
An inverse relationship (p<0.05) was identified between VO2peak, and
cfPWV (Figure 2A), cIMT (Figure 2B), AP (Figure 2C), and both central and
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brachial SBP (Figure 2D). We also calculated the change (post-pre values) in
cfPWV, cIMT, AP, AGI, AGI@HR75, and both brachial and central SBP, and
compared that to the change in VO2peak. A significant and inverse relationship
was found only between VO2peak and cfPWV (Figure 3).
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Discussion
Our laboratory [2] and others [3] have shown that the MetS is associated
with arterial dysfunction, reflected by an increase in arterial stiffness, cIMT,
carotid cross-sectional area, carotid wall stress and tension. Part of this arterial
dysfunction reflects the sedentary lifestyle of individuals with MetS, and physical
inactivity is independently associated with cardiovascular and all-cause mortality
[21]. The present study is novel in that we examined whether aerobic exercise
training would be an effective non-pharmacological therapy to lower arterial
stiffness and improve other markers of arterial health in MetS patients who had
yet to transition to more adverse stages of the cardiometabolic disease such as
the co-occurrence of T2DM, or the presence of overt CVD (angina, heart attack,
stroke etc). Of particular importance, cfPWV, which is increased in MetS (even
without overt CVD) compared to age-matched healthy controls, is significantly
reduced after 8 weeks of aerobic exercise in MetS by almost 1 m/s. Given the
clinical significance of increased arterial stiffness, this reduction in cfPWV after a
short period of exercise training likely reflects a reduction in CV risk.
In the present study, the reduced cfPWV in MetS after exercise training
occurred in the absence of significant improvements in weight, BMI, and
metabolic profile, suggests the effects of aerobic training on the arterial stiffness
may be independent of these other well-established benefits of exercise. The
reduction in cfPWV coincided with a reduction in central SBP, AP, AGI, and an
improvement in sub-endocardial variability. The average reduction in SBP with
aerobic exercise training is 3.9 mmHg and is independent of body weight and
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race [22]. We found that 8 weeks of exercise training reduced brachial and
central SBP between 5-6 mmHg in MetS. As central SBP predicts cardiovascular
outcomes more closely than brachial BP [23], the reduction in cSBP is clinically
relevant. Given that arterial stiffness and augmentation pressure play key roles in
determining central SBP, the reduction in central SBP can be attributed in part to
a reduction in arterial stiffness, and a reduction AP. Central AP represents the
amount of pressure added to the systolic pressure peak based on the reflected
wave. A decrease in arterial stiffness can result in a corresponding decrease in
the transmission velocity of the forward and reflected waves causing the reflected
wave to arrive later in the central aorta and augment pressure in late systole or
early diastole. Thus, once AGI (an indirect measure of systemic arterial stiffness),
was adjusted to a standard HR (AGI@HR75) a reduction in the reflected
pressure wave was evident. Adjusting for HR in our study was important given
that exercise training in MetS was associated with a 4 bpm reduction in HR.
Effectively, a decrease in HR will extend the duration of the cardiac cycle, shifting
the reflected wave into systole and increasing AP. In addition to the effects of
HR, wave reflection is also dependent on arterial stiffness [24], which decreased
to a greater extent than HR in exercised trained MetS. The improvements in
central pressure dynamics corresponded to an increase in SEVR, an indirect
marker of subendocardial perfusion [18], which may suggest an improvements in
cardiac function.
Aerobic exercise training did not alter cIMT, carotid cross-sectional area,
or wall to lumen ratios, or carotid dynamics (CCS strain, wall stress or wall
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tension) in MetS. This lack of change in cIMT is similar to that reported
elsewhere in middle-aged and older healthy men [25, 26] suggesting that regular
exercise training typically does not alter the large conduit vessels.
Our data might suggest that exercise training exerted greater benefits to
MetS than healthy controls as evident by the larger exercise-induced decreases
in cSBP, AP, TTI and increase in SEVR in MetS compared to healthy controls.
Likewise, MetS patients also exhibited a tendency to have greater reduction in
cfPWV (0.7 vs. 0.3 m/s) and VO2peak (3.3 vs. 2.5 ml/min/kg) than controls.
However it must be emphasized no significant ANOVA interaction effects were
observed between MetS and healthy controls with these pre-post training
responses, and that our study was also not originally powered to test this
question. Nevertheless, it is tempting to speculate that potential for greater
improvement in these parameters for MetS patients may be due to their elevated
baseline compared to controls and therefore could provide a greater range for
the exercise stimulus to act on. This is an important question that will require
additional research/subjects before a clear understanding is gained.
Recent evidence suggests that any initial benefit with exercise training on
arterial stiffness in persons with established MetS and T2DM is attenuated over
the long term [11, 27]. Whereby, at 3 months of aerobic exercise training a 1423% reduction in cfPWV has been reported [11, 28], yet after 6 months of
exercise training the reduction in cfPWV was not maintained [11]. These data
suggest that the prescription of aerobic exercise on improving arterial stiffness
may be more beneficial prior to the occurrence of T2DM in those with MetS, than
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starting once the patient is already at a high cardiometabolic risk. To what extent
this initial reduction in arterial stiffness through short-term exercise training in
MetS without T2DM is maintained for an extended period of time, and whether
exercise training helps to delay or prevent the transition from MetS to T2DM
warrants further investigation.

Potential mechanism behind improved arterial stiffness
The stiffness of the arterial system is dependent on the dynamic
(autonomic tone, smooth muscle cell contractility, endothelial function) and
material properties (elastin content and integrity, collagen content, fibrosis,
elastin and collagen cross-linking, calcification) of the artery [29]. Sympathetic
activation of the vascular smooth muscle cells causes vasoconstriction,
decreasing lumen diameter, and increasing arterial stiffness. Although we did not
measure sympathetic activity, exercise training has been shown to improve
sympathetic -and parasympathetic nervous activities in obese individuals [30,
31]. Thus, it is possible that the improvement in arterial stiffness in the current
study may be in part due to improved autonomic function.
Arterial stiffness is also in part modulated by endothelial dysfunction.
Exercise training in both obese/MetS patients has been shown to improve
endothelial function [32, 33], which may improve arterial function via intermittent
increases in shear stress, which stimulates nitric oxide bioavailability, and upregulating endothelial NO synthase protein expression and phosphorylation [34].
Changes in distending pressure affect arterial stiffness, where at higher
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pressures the force on the arterial wall is transferred to the stiffer collagen limiting
distention. In our study, MAP did not change, and the decrease in cfPWV in the
training groups remained significant after adjusting for MAP. Thus, it is unlikely
that a reduction in distending pressure contributed to the improved arterial
compliance.
In terms of the material properties that effect arterial stiffness, the main
contributors to increased arterial stiffness are increased collagen concentration,
non-enzymatic glycation resulting in the formation of collagen crosslink, and
vascular smooth muscle hypertrophy [29]. Hyperglycemic conditions, and
oxidative stress, accelerate the generation of advanced glycation end-products
precursors contributing to variable pathologies such as T2DM, MetS and obesity.
In our study, we did not measure the amount of advanced glycation end-product
deposition; however we did measure plasma markers of tissue remodelling
(MMP and TIMP) and found that exercise training lowered circulating MMP-1 and
7. Interestingly, both MMP-1 and 7 were positively associated with cfPWV. More
evidence is required to identify to what extent MMPs play a role in arterial
remodeling through exercise training.
Chronic low grade inflammation, specifically IL-6, IL-8, and TNFα have
been postulated to be involved in the pathogenesis of MetS [35] and arterial
stiffness [36], and in the present these markers tended to be elevated in MetS vs.
controls. However, we found that exercise training did not alter inflammatory
markers in MetS. In contrast, improvements in TNFα, and IL-18 have been found
after 12 weeks and 1 year of exercise training in MetS with or without T2DM [37,
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38]. Thus, the lack of change in inflammatory state in our MetS group after
exercise training maybe due to the shorter duration of exercise we used.

Clinical implications

A strong relationship exists between arterial stiffness and CVD mortality
[4] and in our study the decrease in cfPWV by almost 1 m/s may reflect a
lowering of CVD events and mortality by approximately 14% [4]. The reduction in
cfPWV coincided with a reduction in central SBP, which is important given that a
reduction SBP by 2 mmHg is associated with a 10% and 7% decrease in
mortality from cerebral vascular and CVD events [39]. Arterial stiffness
contributes substantially to cardiac workload and energetics, and is inversely
correlated with VO2peak [40, 41]. We have confirmed this relationship and shown
that the change in VO2peak and cfPWV with exercise training are inversely related.
These data suggest that individuals with more compliant arteries may have more
optimal coupling between the heart and arterial system allowing for greater peak
CV performance. Indeed, arterial-ventricular coupling is a critical determinant of
net CV performance [42]. It has been reported that MetS with a high aerobic
fitness have a lower risk of mortality than unfit MetS [43], which may in part be
explained by the lower degree of arterial stiffening [41].

Increasing arterial stiffness is regarded as a measure of premature
vascular aging [44]. According to normative reference values of arterial stiffness
[45], the baseline biologic vascular age of our MetS group may be estimated to
be 6 years older than it would be in healthy individuals of a similar age. The
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reduction in cfPWV observed in the MetS ExT group may translate into a reversal
of age-related arterial stiffening of 5 years [46]. Adding vascular age calculated
from cfPWV to the FRS lowered the calculated CVD risk by 4%.

Future directions
The mechanisms responsible for improving arterial function and aerobic
capacity in MetS patients after exercise training likely reflect multiple CV
adaptations some of which we have pointed out. However, the specific roles of
the sympathetic nervous system, the structure and function of resistance vessels,
and oxidative stress require further examination in both human and animal
models. Given the lack of change in metabolic profile of our MetS population it
would be important to identify whether exercise training of longer durations (6
months plus), or exercise training plus diet control would exert greater benefits
on both arterial function and metabolic profile of MetS patients. It would also be
important to identify whether the beneficial effects of short term exercise training
on lowering arterial stiffness is maintained over a longer period of time or indeed
is it lost as evident in T2DM patients. Further, it will also be important to conduct
longitudinal studies to identify whether persistent exercise training in MetS can
delay or prevent the transition to MetS with overt CVD/diabetes.”

Limitations
There are several limitations. There may be sex differences in the effects
of exercise training on arterial stiffness that could not be detected given the small
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number of male vs. female subjects. Second, more direct measures of autonomic
function should be used to assess whether changes in sympathetic activity
contributed to a reduction in cfPWV. Another limitation is the circulating levels of
MMP’s do not necessary reflect what is going on at the arterial sites. However,
because the changes on the cellular level are reflected in body fluids,
determination of MMPs in blood have been recommended as noninvasive tools
in the diagnosis and monitoring of several diseases [47]. Although we reviewed
each participant medical history and performed a physical examination we
cannot completely rule out that participants may have had some degree of
peripheral artery disease. Despite this exercise training in MetS (with or without
peripheral artery disease) significantly improved arterial health. Four of our MetS
patients had a BMI >40 kg/m2 indicating they were severely obese. However,
being severely obese did not limit their ability to improve arterial function, as we
repeated the statistical analyses excluding these individuals and found that the
main story of the paper did not change. Lastly, a potential limitation is the
measurement of plasma lipids obtained from lithium heparin coated collection
tubes, given that heparin precipitates some lipoproteins. This may explain, in
part, the lack of change in blood lipids post-exercise training the short duration of
exercise training.
In conclusion, the present study indicates that aerobic exercise training is
an effective approach to reduce arterial stiffening and improve CVD risk profiles
in individuals with the MetS (without T2DM and overt CVD). Whether long-term
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aerobic exercise training maintains the beneficial effects on arterial stiffness in
MetS and delays the transition to T2DM requires further study.
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Table 1: Clinical Characteristics of the subject cohorts
Controls NonT
Controls ExT
MetS NonT
MetS ExT
Age, years
40 ±
4
41 ±
4
44 ±
3
46 ±
4
Sex, female %
80%
64%
64%
73%
Height, cm
165 ±
3
168 ±
2
171 ±
3
168 ±
3
Weight, kg
68 ±
4
69 ±
4
102 ±
7*^
106 ±
5*
Body Fat, %
25 ±
4
24 ±
2
36 ±
2*^
45 ±
2*
BSA, m2
1.75 ±
0.06
1.78 ±
0.06
2.13 ±
0.08*^
2.13 ±
0.06*
BMI, kg/m2
25 ±
1
24 ±
1
34 ±
2*^
38 ±
2*
Waist circumference, cm
83 ±
3
86 ±
6
107 ±
3*^
124 ±
9*
Total Cholesterol, mg/dL
191 ±
11
177 ±
12
189 ±
12
191 ±
12
Triglycerides, mg/dL
93 ±
14
81 ±
14
161 ±
23*^
115 ±
16
HDL, mg/dL
56 ±
5
57 ±
4
40 ±
4*^
50 ±
5
Glucose, mg/dL
93 ±
3
92 ±
3
97 ±
1
98 ±
2
HbA1c, %
4.9 ±
0.3
5.4 ±
0.1
5.7 ±
0.1*
5.6 ±
0.1*
Insulin, µIU/mL
5 ±
1
5 ±
1
11 ±
2*^
10 ±
1*^
Beta Cell function
62 ±
10
79 ±
37
111 ±
20*^
105 ±
16*^
HOMA IR
1.3 ±
0.2
1.0 ±
0.3
2.7 ±
0.5*^
2.4 ±
0.3*^
Framingham Risk Score, %
2 ±
1
2 ±
1
8 ±
2*^
8 ±
4*^
Framingham Vascular Age, years
36 ±
3
34 ±
4
54 ±
4*^
47 ±
7*^
Hypertensive %
0
0
73
82
Hypertension category
Normal, %
40
64
18
18
Pre-hypertension, %
10
18
0
0
Stage 1, %
0
0
82
73
Stage 2, %
0
0
0
1
Diabetes Mellitus %
0
0
0
0
Smokers, %
0
0
0
0
Medications
Diuretics, %
0
0
10
18
Β-blockers, %
0
0
0
18
ACEI/ARB, %
0
0
36
18
0
0
0
0
CA2+ blockers, %
Statins, %
0
0
0
18
Values are mean ± 1 SEM; BSA: body surface area; BMI: body mass index; HDL: high density lipoprotein; HbA1c: hemoglobin A1c; HOMA-IR: homeostatic model
assessment of insulin resistance.
*p<0.05 compared to healthy control NonT group; ^ p<0.05 compared to healthy control ExT group;
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Table 2: Differences in arterial parameters pre and post intervention in MetS and controls

Controls NonT (n=10)
Pre

Post

Controls ExT
(n=11)
Pre

MetS NonT
(n=11)
Post

Pre

Post

MetS ExT
(n=11)
Pre

Post

bSBP (mmHg)

117±3

115±4

111±3

110±3

128±4^

126±4

125±5^

120±4

bDBP (mmHg)

74±2

75±3

73±2

71±2

84±3*

81±2

80±2*

78±2

bPP (mmHg)

42±3

41±2

38±2

39±2

43±3

45±3

46±5

42±3

bMAP (mmHg)

91±3

88±3

87±2

85±2

100±3*

97±2

96±2*^

93±3

cSBP (mmHg)

107±3

104±4

103±3

101±2

117±4^

114±3

116±5^

110±4†

cPP (mmHg)

31±2

30±2

29±2

28±2

32±2*^

33±2

36±5

32±3

P1 H (mmHg)

24±2

23±1

22±2

23±1

25±2

26±2

27±3

25±2

AP (mmHg)

7.2±1.7

6.5±1.8

6.6±1.8

5.6±1.6

6.9±1.4

6.7±1.3

8.9±1.4

7.1±1.4†

AGI (%)

22±5

20±5

21±5

18±5†

21±4

20±3

24±2

23±4

AGI@75HR (%)

18±4

16±5

14±5

11±4

17±4

16±3

19±3

15±4†

HR (bpm)

67±3

67±4

61±2

61±2

68±2

66±2

65±2

61±3†

SEVR (%)

153±7

156±8

170±6

169±6

149±6

150±7

155±8

168±8†#

TTI (mmHg.sec/min)

2137±91

2090±87

1945±71

1904±78

2430±84^

2345±93

2297±112^

2098±93†

DTI (mmHg.sec/min)

3278±114

3179±136

3267±84

3183±103

3581±122

3457±97

3460±88

3465±116

AoTr (msec)

141±4

146±5

151±6

152±4

143±4

148±3

148±3

155±5

cfPWV (m/s)

6.59±0.35

6.86±0.45

6.34±0.25

6.06±0.27†#

7.45±0.44*^

7.44±0.36

7.93±0.58*^

7.24±0.44†#

crPWV (m/s)

8.29±0.32

7.97±0.37

8.33±0.32

7.65±0.39

7.76±0.22

7.64±0.24

7.93±0.40

7.98±0.36

cIMT (mm)

0.61±0.03

0.63±0.03

0.58±0.02

0.58±0.02

0.69±0.06^

0.67±0.04

0.70±0.04^*

0.67±0.04

Dc (mm)

5.70±0.16

5.85±0.15

5.83±0.18

5.86±0.19

5.93±0.14

5.88±0.20

6.18±0.14

6.09±0.17

cCSA (mm2)
CCA W/L ratio

10±1
0.21±0.02
8.0±
0.9
20±1

11±1
0.21±0.02
7.9±
0.7
19±1

10±1
0.20±0.01
7.2±
0.9
17±1

10±1
0.20±0.01
7.5±
0.6
17±1

12±1*^
0.23±0.02
6.7±
0.5
24±3^

12±1
0.23±0.02
7.0±
0.5
23±2

12±1*^
0.22±0.01
7.3±
0.6
22±2^

12±1
0.22±0.01
7.9±
0.8
21±2

CCA Strain (%)
CCA WS (mmHg)

CCA WT (kPa)
33±1
33±1
32±1
32±1
37±1^
37±1
39±2^
37±2
b=brachial; c = central; SBP, systolic pressure; DBP, diastolic pressure; PP, pulse pressure; P1 H, aortic incident pressure wave; AP, aortic augmentation pressure; AGI, aortic augmentation index;
AGI@75HR, aortic augmentation adjusted for heart rate; HR, heart rate; SEVR Subendocardial viability ratio; TTI, Tension time index; DTI, Diastolic time index. AoTr, return of aortic reflective wave;
cfPWV, carotid-femoral pulse wave velocity; crPWV, carotid-redial pulse wave velocity; Dc, carotid diameter in diastole; CCA W/L, common carotid artery wall to lumen ratio; CCA Strain, common carotid
artery strain; CCA WS, common carotid artery circumferential wall stress, CCA WT, common carotid artery circumferential wall tension. FRS; Framingham Risk Score. Data presented as Mean ± SEM
*p<0.05 compared to healthy control NonT group; ^ p<0.05 compared to healthy control ExT group;
†p<0.05 compared to Pre-values within a group (Controls NonT, Controls ExT, MetS NonT, MetS-ExT)
≠significant (p<0.05) group (e.g., MetS-NonT vs. MetS-ExT) by time (pre to post) interaction
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Table 3: Differences in blood biomarkers pre and post intervention in MetS and controls

Controls NonT
Controls ExT
MetS NonT
Pre
Post
Pre
Post
Pre
Post
Total cholesterol, mg/dL
191±11
178±13
177±12
173±11
189±12
194±15
Triglycerides, mg/dL
93±14
86±10
81±17
90±17
161±23*^
173±18
HDL, mg/dL
56±5
52±5
57±4
53±4
40±4*^
38±3
Glucose, mg/dL
94±3
89±3
92±3
94±2
97±1
96±2
Insulin, µIU/mL
5.2±1.0
5.3±1.0
4.5±1.4
4.4±1.1
11.1±2.3*
11.8±2.3
1.25±0.27
1.21±0.24
1.02±0.33
1.00±0.24
2.71±0.61*^
2.83±0.58
HOMA_IR
0.78±0.09
0.75±0.07
0.57±0.06
0.56±0.02
0.91±0.10
0.87±0.09
sE-Selectin, ng/ml
7.7±1.8
8.6±1.9
6.4±1.4
5.5±1.2
7.3±1.4
7.2±1.3
sVCAM-1, ng/ml
3.5±0.9
3.4±0.8
4.4±0.7
4.2±0.7
4.0±0.6
3.8±0.6
sICAM-1, ng/ml
1.2±0.1
1.1±0.1
1.2±0.3
1.0±0.2
1.4±0.2
1.4±0.2
tPAI-1, ng/ml
IL-6, pg/ml
1.3±0.4
1.4±0.4
1.3±0.4
1.0±0.3
4.3±1.9
2.3±0.3
IL-8, pg/ml
3.2±1.0
3.7±1.0
2.8±0.6
2.4±0.5
5.1±0.8
4.8±1.2
TNFα, pg/ml
5.3±1.1
5.5±1.5
3.2±0.4
2.8±0.3
5.3±0.9
5.0±0.9
MMP-1, pg/ml
21±3
32±10
23±3
24±5
24±3
24±4
MMP-2, pg/ml
3452±429
3484±508
3962±202
3962±442
4263±427
4260±326
MMP-7, pg/ml
648±61
629±60
705±139
674±138
543±48
571±64
MMP-9, pg/ml
849±145
656±111
751±77
635±100
853±121
741±55
MMP-10, pg/ml
20±2
30±8
25±3
24±1
25±3
24±2
TIMP-1, pg/ml
1459±711
1173±456
1533±544
1569±555
1245±205
1323±222
TIMP-2, pg/ml
1585±836
1314±607
1794±655
1781±694
1290±233
1305±239
*p<0.05 compared to healthy control NonT group; ^ p<0.05 compared to healthy control ExT group;
†p<0.05 compared to Pre-values within a group (Controls NonT, Controls ExT, MetS NonT, MetS-ExT)
≠
significant (p<0.05) group (e.g., MetS-NonT vs. MetS-ExT) by time (pre to post) interaction
Sample size for examining the effects of exercise training on blood biomarkers is noted below:
Adhesion molecules: Con NonT n=6; Con ExT, n=9; MetS NonT n=9; MetS ExT, n=9
Inflammatory markers: Con NonT n=6; Con ExT, n=10; MetS NonT n=9; MetS ExT, n=9
MMP: Con NonT n=7; Con ExT, n=10; MetS NonT n=8; MetS ExT, n=10
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MetS ExT
Pre
Post
191±12
183±9
115±16
130±17
50±5
47±4
98±2
96±3
9.8±1.4^
11.5±2.5
2.37±0.34^
2.68±0.57
0.95±0.01
0.83±0.01
6.0±1.5
5.5±1.3
5.0±0.7
5.1±0.9
1.2±0.2
1.3±0.2
3.1±1.1
3.0±0.8
4.1±0.9
4.0±0.6
5.5±0.6
6.0±0.8
27±5
22±5†
4383±405
3793±143
893±215
789±202#
858±95
879±141
27±4
27±5
2273±581
2302±664
1824±470
1888±575

Figure Legends
Figure 1. Example of central pressure waveform. The systolic and diastolic
pressures are the peak and trough of the pressure waveform. Augmentation
pressure (AP) is the pressure added to the forward wave by the reflected wave
(P1-P2), whereas augmentation index is the ratio between AP and central pulse
pressure (PP = systolic - diastolic pressure). The dicrotic notch represents
closure of the aortic valve and is used to calculate ejection duration (ED). Time to
wave reflection is calculated at the point of rise in the initial ejection wave to the
onset of the reflected wave. Travel time (Tr) represents the time taken for the
forward pressure wave from the aorta to the reflection site and back. Systolic-todiastolic pressure shifts were assessed by the systolic (red shaded area) and
diastolic (blue shaded area) pressure-time integrals.

Figure 2. Relationship between peak aerobic capacity (VO2 peak) and arterial
markers, namely carotid femoral pulse wave velocity (A), carotid intima medial
thickness (B), augmentation pressure (C), and brachial (bSBP) and central
(cSBP) systolic pressure (D).

Figure 3. Relationship between the change (post- pre values) in peak aerobic
capacity (VO2 peak) and carotid femoral pulse wave velocity.
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Abstract
Purpose: The metabolic syndrome (MetS) is associated with a three-fold
increase risk of cardiovascular (CV) morbidity and mortality, which is in part, due to a
blunted CV reserve capacity, reflected by a reduced peak exercise left ventricular
contractility and aerobic capacity, and a blunted peak arterial-ventricular coupling. To
date, no study has examined whether aerobic exercise training in MetS can reverse the
peak exercise CV dysfunction. Further, examining how exercise training alters CV
function in a group of individuals with Mets prior to the development of diabetes and/or
overt CVD, can provide insights into whether some of the pathophysiological changes to
the CV can be delayed/reversed, lowering their CV risk. The objective of this study was
to examine the effects of 8 weeks of aerobic exercise training in individuals with MetS
on resting and peak exercise CV function.
Methods: Twenty MetS underwent either 8 weeks of aerobic exercise training
(MetS-ExT; n=10) or remained sedentary (MetS-NonT; n=10) during this time period.
Resting

and

peak

exercise

CV

function

was

characterized

using

Doppler

echocardiography and gas exchange.
Results: Exercise training did not alter resting left ventricular diastolic or systolic
function and arterial-ventricular coupling in MetS. In contrast, at peak exercise an
increase in LV contractility (40%, p<0.01), cardiac output (28%, p<0.05) and aerobic
capacity (20%, p<0.01), while a reduction in vascular resistance (30%, p<0.05) and
arterial-ventricular coupling (27%, p<0.01), were noted in the MetS-ExT but not the
MetS-NonT group. Further, an improvement in Lifetime Risk Score was also noted in
the MetS-ExT group.
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Conclusions: These findings have clinical importance as they provide insight that
some of the pathophysiological changes associated with MetS can be improved and
lower the risk of CVD.

Key Words: cardiovascular disease, cardiac function, arterial function, and obesity.
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Introduction
The metabolic syndrome (MetS) is a cluster of metabolic risk factors
(abdominal obesity, elevated blood pressure and glucose, and dyslipidemia) that exerts
a three-fold increased risk of cardiovascular disease (CVD) mortality compared to nonMetS individuals [1]. Alarmingly, the prevalence of MetS in US adults is 34% and is on
the rise due, in part, to rising rates of obesity [2]. MetS has become a leading health
concern because of its strong association with future myocardial/cerebral vascular
events and CVD mortality [1].
The MetS-associated pathophysiological changes to the CV system contribute to
the increased CVD risk. Such changes include an increase in arterial dysfunction
(increased arterial stiffness, and endothelial dysfunction), left ventricular (LV)
hypertrophy, and impaired CV reserve capacity [3-5]. In particular, individuals with MetS
demonstrate an impaired coupling between the heart and arterial system [5]. This
interaction, termed arterial-ventricular coupling (Ea/Ees), is an important determinant of
net CV performance [6] and cardiac energetics [7]. Ea/Ees is indexed by the ratio of
effective arterial elastance (Ea; a measure of the net arterial load imposed on the left
ventricle) to left ventricular end-systolic elastance (Ees; measure of LV chamber
performance) [6]. Impaired Ea/Ees is most readily evident when the CV system is under
stress and/or with increasing age [8]. For example, in MetS, the ability to reduce the
Ea/Ees ratio is blunted during aerobic exercise [5]. Further, this impaired coupling
response coincides with a reduced peak aerobic capacity in MetS [5], which has been
proposed to be an independent predictor of mortality relative to other risk factors [9].
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In healthy older individuals, exercise training has been shown to increase aerobic
capacity, improve peak LV performance (smaller end-systolic volume and increased
stroke volume), and increase LV contractility [10, 11]. In patients with coronary artery
disease, Ea/Ees during handgrip isometric exercise was improved after exercise
training. It is unknown whether exercise training in people with MetS (prior to the
development of diabetes or overt CVD) can improve peak exercise LV-arterial coupling
and CV function. An improvement in Ea/Ees and CV function in MetS would likely reflect
a lower CVD risk. Thus, the objective of this study was to examine the effects of 8
weeks of exercise training on peak exercise arterial-ventricular coupling in clinically
defined MetS patients without diabetes or clinical indications of CVD. We hypothesized
that aerobic exercise training would improve peak Ea/Ees in MetS due to an
improvement in peak exercise LV contractility.
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Methods
Study Population
Twenty MetS subjects free from overt CVD and diabetes as determined by a
detailed medical history, physical examination, and a normal resting and exercise
electrocardiogram participated in this study. MetS was defined according to the updated
National Cholesterol Education Program: Adult Treatment Panel III comprised of three
out of the following five components: 1) obesity (waist men >102 cm, women >88 cm);
2) low HDL cholesterol (men<40 mg/dL; women<50 mg/dL); 3) hypertriglyceridemia
(≥150 mg/dL); 4) elevated glucose (≥100 mg/dL & <126 mg/dL), and; 5) elevated BP
(130/85 mmHg or use of hypertensive medications).
Exclusion criteria included diabetes mellitus (HbA1c ≥6.5 % or use of diabetic
medications), pulmonary disease, angina, atrial fibrillation, aortic stenosis, anemia,
myocardial infarction, stroke, or coronary revascularization as assessed by a detailed
medical history physical examination and a resting and exercise electrocardiogram.
Subjects who participated in regular exercise, defined as >30 minutes, 3 times/week
were excluded. All subjects provided written informed consent to participate that was
approved by WVU Institutional Review Board.

Study Design
Physiological assessments were performed between 7:00-10:00 AM, in a quiet,
temperature-controlled room, after a 12 hour fast and abstinence from alcohol, caffeine,
and vitamins. CV medications were withheld 24 hours prior to assessments. After a
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minimum 15 minutes of quiet rest subjects underwent resting non-invasive assessments
of arterial and cardiac structure and function.

Exercise Performance
Following assessment of resting CV measurement, subjects exercised to
exhaustion on a modified cycle ergometer (Monarch 827, Sweden) equipped with a car
seat to allow semi-recumbent exercise in seated upright position at approximately 130
degrees. This upright position is necessary and important to allow acquisition of optimal
echocardiographic images during exercise. Throughout exercise the echo images were
acquired approximately 60-90 seconds into each 3-minute exercise workload. If all
images were not acquired within the time frame the duration of the exercise stage was
extended to acquire those images. Pedal speed was maintained at 50 rpm, and
workloads increased by 25 W every 3 minutes until exhaustion. Oxygen consumed
(VO2), carbon dioxide produced (VCO2), respiratory exchange ratio (RER=VCO2/VO2),
ventilation (Ve), ventilatory threshold (VT), and the ventilatory equivalent for CO2
(Ve/VCO2) were measured throughout exercise using a metabolic cart (TureOne 2400,
ParvoMedics, Sandy, UT). Subjective symptoms of fatigue (BORG score 6 to 20), and
blood pressure (sphygomomanometry) were recorded at the end of each workload.

Rest and Exercise Echocardiography
Echocardiograms were obtained using a GE Vivid i (GE Healthcare, Chalfont St.
Giles, United Kingdom), portable ultrasound imaging system with a 5S-RS (2.0-5.0
MHz) Wideband Phased Array transducer. All echocardiograms were performed by
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experienced registered diagnostic cardiac sonographers. At rest, standard 2dimensional images were obtained in the following acoustic views; parasternal long
axis, and apical 4 chamber view. Pulsed wave Doppler tracings of the mitral valve inflow
velocity (recorded at the leaflet’s tips) were recorded in the apical 4 chamber view.
Continuous/pulse wave Doppler tracings of the LV outflow track velocity were obtained
in the apical 5 chamber view positioned 5 mm proximal to the aortic valve. Spectral
tissue Doppler imaging was performed in the apical 4 chamber view with the gate
sample positioned in the lateral corner and septal side of the mitral annulus. During
exercise, the sonographer quickly acquired a 2-dimensional image of the parasternal
long axis view to obtain the size of the LV outflow tract diameter (base of the aortic
leaflets). The sonographer then focused on capturing: 4-chamber views to obtain
cardiac volumes and mitral flow velocities; and 5-chamber views to obtain pulse-and
continuous-wave Doppler-flow from the LV outflow track.

Left Ventricular Geometry and Remodeling
In the supine position, LV dimensions, wall thickness, and chamber volumes
were determined in triplicate from 2-dimensional, M-mode, and Doppler spectra
echocardiography using standard methods [12]. Sex-specific LV hypertrophy (LVH) and
geometry patterns, based on LV mass index and relative wall thickness were defined as
LV mass index >95 g/m2 for women or >115 g/m2 for men, and LV geometry was
classified as normal, concentric remodeling, concentric LVH, or eccentric LVH [12].

Arterial-Ventricular Measurements
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In the upright, seated rest position and during exercise, LV end diastolic (EDV)
and end-systolic (ESV) volumes, along with ejection fraction (EF) were determined from
Simpson’s biplane method [12]. Cardiac volumes were normalized to body surface area
(BSA). Cardiac index (Ci) was determined from the product of heart rate (HR) and
stroke volume index. Peak arteriovenous oxygen extraction was calculated from the
Fick equation (VO2peak/cardiac output). Systemic vascular resistance index (SVRi) was
calculated as mean arterial pressure (MAP) × 80/Ci. The indexes of arterial and
ventricular elastance were calculated as; 1) arterial elastance (Ea) a measure of the net
arterial load, was calculated as end-systolic pressure (ESP)/stroke volume (SV), where
ESP is approximated as 0.9 × systolic blood pressure (SBP)[6]. Of note, ESP calculated
as 0.9 × SBP has previously been shown to closely approximate central ESP [13]; 2) LV
end-systolic elastance (Ees [calculated from BP, stroke volume, EF, and pre-ejection
and systolic ejection time intervals from LV outflow Doppler]), was determined by the
validated single-beat technique [14]; and 3) Arterial ventricular coupling ratio was
determined from Ea/Ees [6]. Of note, Ea/Ees is mathematically related to EF via the
formula Ea/Ees = (1/EF)-1. Reserve was defined as the difference in these variables
between seated rest and peak exercise.

Diastolic Function
In the supine position, the medial mitral annular early diastolic velocity (e’) was
determined by spectral tissue Doppler imaging (GE Vivid i) using standard methods.
Early (E-wave) and late (A-wave) transmitral flow velocities, the isovolumetric relaxation
time (IVRT), and the deceleration time of early filling velocity (Dec T) were measured by
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pulsed-wave Doppler (GE Vivid i). End-diastolic pressure was estimated as EDP =
11.96 + 0.596 × E/e’ [15]. Because of the high incidence of fusion of the E- and A-wave
during moderate/high intensity exercise, with the A-wave dominating, we are not able to
measure Dec T- or E-wave. Therefore we were limited to measuring peak exercise
IVRT and A-wave.

Body Anthropometry
Height, weight, and waist and hip circumference were measured using standard
laboratory procedures. Fat distribution was assessed by measuring the waist
circumference at the site of the smallest circumference between the rib cage and the
iliac crest with subjects in a standing position. Hip circumference was measured at the
site of the largest circumference between waist and thighs. Lean body mass and fat
mass were measured using air displacement plethysmography (BodPod, COSMED Inc.,
USA). During assessment of body composition subjects wore close-fitting bathing suits
and a swim cap. Body mass index (BMI) was calculated as weight (kg) divided by height
(m) squared.

Blood Analyses
Venous blood sampling was obtained in the morning after a 12-hour overnight
fast. Post training venous samples were collected at least 48 hours after the last
exercise session. Plasma obtained from blood sampling was analyzed at West Virginia
University Hospital’s central laboratory in Morgantown, West Virginia. Total cholesterol,
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high-density lipoprotein (HDL) cholesterol, triglycerides, and glucose were determined in
plasma (lithium heparin, Becton Dickenson Plasma Separator Tubes) using BeckmanCoulter (CA, USA) DxC automated chemistry analyzers. Total cholesterol was
measured using a cholesterol esterase/cholesterol oxidase/peroxidase-driven, timedendpoint method (Coefficients of Variation <7%). HDL cholesterol was measured using
a cholesterol esterase/cholesterol oxidase/peroxidase-driven, timed endpoint assay with
automated initial homogeneous solubilization step (Coefficients of Variation <7%).
Triglycerides

were

measured

oxidase/horseradish
Variation

5-7%).

using

peroxidase-driven,

Glucose

was

a

lipase/glycerol

timed-endpoint

measured

kinase/glycerophosphate
method

electrochemically

(Coefficients
using

a

of

glucose

oxidase/catalase/molybdate-driven oxygen rate method (Coefficients of Variation <5%).
Glycated hemoglobin (A1c fraction) was measured in whole blood (K2-EDTA, Becton
Dickenson) using a BioRad (Hercules, CA, USA) Variant II Turbo High Performance
Liquid Chromatography (HPLC) system (Coefficients of Variation <2%). Insulin was
measured in serum (untreated/red-top tube, Becton Dickenson) on an Immulite 2000
immunochemistry

system

(Siemens,

USA;

Coefficients

of

Variation

<10%).

Homeostasis model assessment of insulin resistance (HOMA-IR) was estimated with
the following formula: insulin resistance = fasting plasma insulin (in microunits per
millileter, μU/mL) × fasting plasma glucose (FPG, in millimoles per liter, mmol/L) / 22.5.

Training Intervention
MetS were assigned into either an 8 week aerobic exercise intervention group
(MetS-ExT) or an 8 week non-exercise control (MetS-NonT) group. Group assignments
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were made using a pseudo-random balance approach to ensure equal numbers
enrolled in each group. The MetS-NonT exercise group (n=10; 50% female) were asked
to maintain their normal sedentary lifestyle. The MetS-ExT group (n=10; 70% female)
performed 8 weeks of supervised aerobic exercise in the Human Performance Lab at
West Virginia University School of Medicine, 3 times per week for 60 minutes at a fixed
exercise intensity. The intensity of prescribed exercise was based on individual results
of maximal cardiopulmonary exercise tests. We used a ramp exercise protocol, whereby
exercise training intensity started at 60% of heart rate reserve (heart rate range
determined during exercise stress test) and increased every 2 weeks by 10%; from
weeks 6-8 heart rate reserve was set at 85%. Adherence to the exercise prescription
was documented through the use of wrist watch-style heart rate monitors (E600, Polar
Electro OY, Oulu, Finland) and physical activity logs. Approved modalities included
treadmills, elliptical machines, and cycle ergometers. All participants were instructed to
maintain current eating behaviors for the duration of the 8-week intervention. All posttraining measurements were performed 24-48 hours after the last exercise training
session to avoid the immediate effects of a single bout of exercise. Measurements
made before and after exercise training were obtained at the same time of day for each
subject.

Lifetime Risk Score for CVD
The Lifetime Risk Score is a strong predictive capacity for future CV mortality and
is based on an algorithm that incorporates sex (male/female), age (years), SBP
(mmHg), diabetes mellitus (yes/no), total cholesterol (mg/dL), smoking (yes/no), BMI
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(kg/m2), and physical fitness (Metabolic equivalent; 1 MET = 3.5 ml/kg/min) [16, 17].
Calculation of the score is available using a web-based interface (www.lifetimerisk.org).

Statistical Analysis
Measurements of CV function were performed offline by a single investigator who
was blinded to group allocation. The intra-class correlation coefficient (ICC) and
coefficient of variations for all echocardiographic variables were derived in a subset of
subjects (n=8). At rest, the ICC and the coefficient of variation for all variables, collected
on two separate days, was >0.80 or between 7-12%, respectively. Similar results were
obtained for echocardographic variables evaluated during peak exercise with all
variables having an ICC>0.80 and coefficient of variation between 7-12% with the
exception of the arterial-ventricular coupling ratio (ICC=0.63).
Normality was evaluated by the Kolmogorov-Smirnov test. Continuous variables
were log transformed as necessary. To evaluate the effects of exercise training, paired
t-tests and two-way repeated-measures ANOVA were used. We also ran a mixed
effects models with a time-varying covariate to examine whether the change (pre vs
post training intervention) in CV parameters where due to changes other CV
parameters. All analyses were performed with the statistical package SPSS version 21
(SPSS, Chicago, IL). Values shown in the tables represent means ± SEM unless
otherwise stated. A p <0.05 was defined as significant.
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Results
Age, anthropometric, and metabolic characteristics of MetS individuals are
shown in Table 1. The breakdown of metabolic components were: 100% had a waist
circumference >102 cm (men) or >88 cm (women); 75% had elevated BP
(130/85 mmHg or use of hypertensive medications); 70% had a low HDL cholesterol
(men<40 mg/dL; women<50 mg/dL); 30% had hyper-triglyceridemia (≥150 mg/dL); and
50% had elevated glucose (≥100 mg/dL). In terms of LV remodeling, 15% had normal
LV geometry and concentric remodeling, 50% had eccentric LV hypertrophy, and 20%
had concentric LV hypertrophy.

Effects of Exercise Training on Metabolic Profile, Body Composition, and LV Geometry
Eight weeks of exercise training did not alter basal fasting HbA1C, glucose,
insulin, HDL, triglycerides, or HOMA-IR (Table 1). Further, exercise training was
insufficient to significantly alter body composition (weight, lean mass or percent body
fat), LV mass (in absolute terms and relative to BSA), the internal LV dimensions
(internal diameter, septal and posterior wall thickness), and relative wall thickness in
MetS (Table 2).

Effects of Exercise Training on LV Diastolic Function
Resting LV diastolic function (i.e., E-wave, A-wave, E/A ratio, IVRT, Dec T, E/e'
and EDP) was not affected by 8 weeks of exercise training in MetS (Table 2). During
exercise we were limited to examining changes in components of LV diastolic function
namely IVRT, and A-wave. No significant differences in peak IVRT (MetS-ExT; 16±1 vs.
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16±2; Non-T; 15±1 vs. 15±2), and A-wave (MetS-ExT; 1.38±0.06 vs. 1.28±0.11; Non-T;
1.48±0.08 vs. 1.53±0.06) were found in either MetS-ExT or Non-T pre and post
intervention.

Effects of Exercise Training on Arterial Ventricular Coupling
Exercise training in MetS did not alter resting Ea/Ees, Ea, or Ees (Figure 1).
Further, with the exception of resting SVRi which was lower in the MetS-NonT, no
differences in resting CV function were evident in either MetS group (Table 3). There
were no significant time (pre and post) by group (MetS-ExT vs. NonT) interactions at
rest for any CV parameter.
At peak exercise, aerobic training in MetS lowered peak Ea/Ees (-27%, p<0.01)
by increasing peak Ees (+40%, p<0.01) and no change in peak Ea in MetS-ExT (Figure
1). In contrast, peak Ea/Ees, Ea, and Ees did not significantly differ between pre and
post visits in MetS-NonT. Similarly, peak EF, and Ci were significantly (p<0.05)
increased, and peak ESVi and SVRi were reduced (p<0.05) after exercise training in
MetS-ExT, whereas no differences were found in MetS-NonT (Table 4). Furthermore,
significant time (pre and post) by group (MetS-ExT vs. NonT) interactions for peak
Ea/Ees, Ees, EF, and SVRi were evident.
Exercise capacity, in both absolute (L/min) and relative (ml/min/kg of body mass
or lean mass) terms was improved in MetS after 8 weeks of exercise training as
reflected by a 19-20% increase (p<0.01) in VO2peak and a 4% increase (p<0.05) in
Ve/VCO2 (Table 4). Of note, a time (pre and post) by group (MetS-ExT vs. NonT)
interaction for VO2peak was identified despite no differences in the respiratory exchange
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ratio, or perceived rate of exertion, in either MetS group. Further, no differences in peak
arteriovenous oxygen difference were evident pre or post intervention in MetS (Table 4).
Taking all individuals into consideration, an initial relationship between pre-intervention
values for Ea/Ees delta (max-rest) and VO2peak (r=-0.58, p<0.01) was found. We then
examined whether the difference in Ea/Ees delta from visit 1 and visit 2 was correlated
with the change from visit 1 and 2 in VO2peak, however this relationship did not reach
statistical significance (r=-0.40, p=0.09). In a stepwise mixed model approach with
repeated measures and a time-varying covariate, we found that Ea/Ees delta
contributed towards 16% of the variance on the effects of exercise training on peak
VO2.

Lifetime Risk Score
In the MetS-ExT group, the Lifetime Risk Score was significantly reduced
(20±7% to 16±6%, p=0.01) after training, whereas in the MetS-NonT group no
difference was found (13±2% vs. 13±2%, p=0.8). Further, we identified a significant
inverse correlation between the Lifetime Risk Score and peak VO2 (r=-0.53, p=0.02).
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Discussion
This is the first study to examine the effects of aerobic exercise training on peak
arterial-ventricular coupling in patients with the MetS. We report that following 8 weeks
of aerobic exercise training, peak arterial-ventricular coupling, peak LV contractility and
aerobic capacity were significantly improved and similar to levels noted in healthy
untrained controls [5]. Our unique patient population afforded the opportunity to assess
whether exercise training can reverse impaired CV function reported in MetS patients
prior to a diagnosis of CVD and/or diabetes. Since MetS is believed to be a harbinger in
the pathogenesis of diabetes and CVD, these data provide evidence that exercise
based interventions at this critical (preclinical disease) time point may help to reverse
the pathophysiological progress of CVD, and/or delay the progression to overt CVD
and/or diabetes.
The MetS is associated with pathophysiological changes to the CV system
associated with an increased CVD mortality risk. Recently we reported that resting LV
systolic function was well preserved in MetS patients who clearly manifested the
symptoms of the metabolic disorder (including hypertension, insulin resistance, and
hyperlipidemia) but who are free from overt CVD and/or diabetes [5]. Conversely, in this
same population we observed LV remodeling, LV hypertrophy and reduced LV diastolic
function at rest [5]. The progression from MetS to T2DM is characterized by additional
LV enlargement and LV diastolic dysfunction, with evidence of LV systolic dysfunction
and related sympathetic alterations [18]. In our MetS population, exercise training was
unable to reverse the LV structural changes or impairments in LV diastolic function. The
lack of an observed effect of exercise training on LV mass is likely due to the duration of
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the exercise stimulus (8 weeks). Indeed, an intervention consisting of several months of
aerobic training was found to be sufficient to exert physiological LV remodeling [19],
reduce LV wall thickness, and reduced LV wall thickness-to-radius ratio [20]. To what
extent exercise training can improve LV diastolic function by improving the compliance
of the heart remains controversial. Two recent studies examining a full year of exercise
training, in MetS patients without T2DM or CVD [21] and healthy senior individuals [19],
found no significant improvements in resting LV diastolic function. Advancing age and
the development of CVD induce structural and functional alterations to the heart that is
reflected by a reduction in the number of cardiomyocytes, an increase in connective
tissue volume, and an increase in the formation of advanced glycation end products,
which collectively result in impairment of LV diastolic function [22]. Data would suggest
that once these cross-linked collagen proteins are formed they are pathologically
irreversible. Thus, any potential improvements in LV diastolic function to be gained from
exercise training may be limited by cross-linked collagen [19].
The coupling between the heart and arterial system is an important and largely
underappreciated determinant of cardiac performance and energetics [6]. At rest, the
coupling ratio is well maintained around 0.7-1.0 to optimize CV efficiency. This ratio is
preserved with advancing age and in patients with heart failure [8, 23]. Indeed, we have
also recently shown that resting Ea/Ees is around 0.9 in MetS patients [5]. In this study,
exercise training in MetS did not alter resting Ea/Ees, or its components. While resting
Ea/Ees is fairly well conserved, the ability of the CV system to respond to stress, in
particular exercise, is blunted with age, and in heart failure patients [8, 24]. We have
previously shown that the Ea/Ees response to exercise is significantly impaired in MetS
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patients [5], which is, in part, due to impaired LV contractility and a blunted peripheral
vasodilatory response to exercise [5]. Importantly, this study indicates that 8 weeks of
exercise training is sufficient to increase the peak LV contractile response and improve
peak exercise Ea/Ees in MetS patients, as direct result of improved peak Ees.
Although we have shown that arterial-ventricular coupling is improved after
exercise training in middle-aged individuals with MetS, it is also important to identify
whether older individuals with MetS would have the same beneficial effects of exercise
training. In older (age >60 years) healthy individuals, peak exercise cardiac function is
typically improved, at least up to the 7th decade, after exercise training depicted by
increases in Ci, SV, EF, LV contractility, and VO2peak [25-28]. Future research should
establish to what extent older individuals with MetS demonstrate improvements in
arterial and cardiac function after exercise training. This is especially important given
that the presence of MetS with older age is often accompanied by CVD (i.e., T2DM,
coronary artery disease, etc.), and with increased formation of cross-linked advanced
glycation end products in the LV and arterial walls, which may limit the physiological
responses to exercise training [29].
A blunted Ea/Ees response during exercise has been shown to correspond with
a decrease in VO2peak in MetS [5] and heart failure [24] patients. An inverse relationship
has also been reported between VO2peak and Ea/Ees during exercise [30], which was
confirmed in our study. In addition, acute infusion of verapamil improved arterialventricular coupling and resulted in a corresponding improvement in exercise capacity
[31]. These data suggest a direct link between Ea/Ees and aerobic capacity, in that an
improvement in the coupling likely results in a more effective transfer of blood from the
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heart to periphery thereby increasing functional reserve capacity. Indeed, in the
presence of a stiffer heart there is a greater change in BP for a given change in volume,
which in a closed-system, can amplify the BP response and impair net cardiac ejection
[31]. In the current study, we found an increase in peak SV without a significant change
in BP suggesting a more compliant cardiac response after exercise training. Further, the
improvement in peak Ea/Ees was accompanied by a 20% increase in VO2peak, and that
the change in Ea/Ees seemed to contribute (≈16%) towards the improved VO2peak.
Given that aerobic capacity is determined by both central (HR and SV) and peripheral
factors (skeletal muscle mass, calcium cycling, mitochondria capacity, capillary density,
etc.), it is likely that the improved coupling, along with other physiological adaptations
that were not examined in our study, contributed towards the improved VO2peak in MetS
after exercise training. Indeed, Tjonna et al. [32] observed a 16% and 36% increase in
VO2peak after 16 weeks of either continuous aerobic exercise or high intensity aerobic
interval training in MetS, respectively. It was suggested that enhanced skeletal muscle
capacity (improved calcium cycling and mitochondria capacity) contributed to the
exercise-induced improvement in VO2peak [32]. Although, we did not directly measure
skeletal muscle oxidative capacity or oxygen extraction, these responses to exercise
training have been reported elsewhere [32, 33]. In contrast to these findings, we did not
observe an improvement in peak arteriovenous oxygen difference (estimated from the
Fick equation) after 8 weeks of exercise training in MetS, suggesting that muscle
adaptation played a minor role in the reported improvements in aerobic exercise
capacity in our patients. The effects of exercise training on improving peak
arteriovenous oxygen difference in other populations are mixed with some reporting no
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changes [19, 28] and others showing an increase [26, 34]. This lack of change may be
related to the intensity of exercise training, whereby an increase arteriovenous oxygen
difference was reported after high-intensity exercise training, but not after low-intensity
training [26]. An increase in exercise intensity and duration may be required to increase
peripheral oxygen extraction in individuals with MetS. Further, research is needed to
clarify the relationship between Ea/Ees, and VO2peak.
The improvement in LV contractility during exercise may have been due, in part,
to an increased stroke volume, a decreased afterload, and improved arterial-ventricular
coupling. Indeed, improvements in peak exercise SVi and ESVi were reported in MetS
after exercise training. Similar improvements in cardiac volumes have been reported
after exercise training in older sedentary individuals [10, 19]. Improved peak LV
performance post exercise training is unlikely to be due to enhanced myocardial βadrenergic responses, as chronic exercise training has not been reported to alter βadrenergic function [35]. However, exercise training has been shown to improve calcium
handling in experimental animal models, thereby improving cardiomyocyte function [36].
Accordingly, improvements in calcium handling may have contributed to the
improvement in LV contractility noted in MetS. The enhanced ability of the LV to empty
as fitness increases may relate to a reduction in arterial stiffness/afterload in the
conditioned state [37]. However, following 8 weeks of exercise training, no
improvements in Ea during exercise were reported in MetS. In contrast, a significant
reduction in peak vascular resistance was established in the exercise trained MetS
patients. Ea is an integrative index that incorporates the principal elements of arterial
load, including systemic vascular resistance, total arterial compliance, characteristic
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impedance, and systolic and diastolic time intervals. Ea is therefore regarded a
measure of the net arterial load that is imposed on the LV [6]. Thus, the lack of change
in Ea does not necessarily indicate that specific components of arterial load where not
improved at peak exercise after training. This was clearly evident with the improvement
in peak SVRi. Further, the improvement in SVRi or the lack of change in Ea, were not
attributed to the slight changes in peak HR noted in the control group, as evident by
similar findings after adjusting for HR as a time-vary covariate in a mixed effects model.
Whether the improvement in SVRi at peak exercise is due to release of vasodilators
causing vascular relaxation remains to be elucidated. Improvements have also been
noted in resting endothelium-dependent vasodilatation in obese and MetS patients after
exercise training [32]. Accordingly, despite the lack of change in Ea, peak arterial
function may have been improved in MetS, thus contributing to an improved aerobic
capacity.
The beneficial CV effects at peak exercise attributed to exercise training were not
a reflection of a change in body fat or lean mass. However, numerous studies have
reported that regular moderate intensity exercise can result in reductions in weight and
fat mass [38, 39]. Thus, the lack of change in body composition in our study is likely due
to the short duration of exercise training (8 weeks). Further, clinical metabolic
biomarkers (HDL, triglycerides, glucose, etc.) remained unchanged. Although we did not
find improvements in body composition or clinical blood biomarkers after training in
MetS, we believe that improvements in peak CV function and aerobic capacity reflect a
reduction in CV risk in MetS patients. A strong association exists between aerobic
capacity and mortality with a positive correlation between improvements in aerobic
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capacity and an improved prognosis [40]. A relationship that seems to be more robust
than the relationship between weight loss and mortality [41]. For example, for each MET
(3.5 ml/kg/min) increase in exercise capacity confers a 12% improvement in survival [9].
The average increase in peak VO2 (ml/kg/min) in the MetS-ExT group was 3.2
ml/kg/min, suggesting an improvement in survival. Further, the Lifetime Risk Score in
MetS-ExT was significantly reduced by 4%, and the Lifetime Risk Score was inversely
correlated with peak VO2. However, to fully prevent the progression to overt CVD and/or
diabetes, and the pathophysiological changes to the CV system that accompanies this
transition, persistent physical activity in combination with a nutritional dietary regimen
(that includes optimal vitamin/mineral consumption) is required.

Study Limitations
There are several limitations. First, the sample size for our training and nontraining group is modest (n=10 in each). Although we find significant differences in peak
Ea/Ees, this was due principally to a significant change in peak Ees (p<0.05 with
statistical power >0.75), but we were underpowered in our statistical power for Ea
(power=0.10). While it is evident that we have sufficient power in those CV variables
where significance was observed, we cannot exclude the possibility of a type II
statistical error (i.e. that we have falsely accepted the null hypothesis) in the CV
variables that we not-significantly different where power was low. Therefore, these data
should be regarded as preliminary until we, or others can obtain data on a larger
population sample. In the current study, we examined the effects of exercise training on
Ea (net arterial load) as our arterial function parameter. Although it is important to study
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the interaction between the heart and arterial system in the same domain (i.e.,
elastance), measuring specific aspects of arterial function such as characteristic
impedance, arterial stiffness (via pulse wave velocity), and intima medial thickness
would provide additional insights into the beneficial effects of exercise training in MetS.
Further, sex differences in the effects of exercise training on LV stiffness may have
gone undetected given the small number of male vs. female subjects. Future research
should examine whether there are sex-related differences in the coupling response, at
rest and during exercise, after exercise training.
Second, pressure and flow were not directly measured, but rather estimated from
non-invasive surrogates. However, the methods we used have been previously
validated against invasive hemodynamic measurements [14]. Our peak cardiac data
may be underestimated due to a systematic underestimation of LV volumes from 2-D
echocardiography [42, 43] and the challenge of acquiring echocardiograhic images
during exercise. However, the technique we used has been successfully used by others
[24, 44], and similar values have been observed suggesting fidelity in our data.
Third, we were limited in our ability to comprehensively characterize the extent of
diastolic function during exercise because the focus of this study was to examine the
impact of exercise training on peak exercise Ea/Ees and LV systolic function, and
therefore echocardiographic views were optimized to examine systolic function. Further,
the acquisition of LV diastolic parameters during exercise is challenging. Thus, we
cannot rule out that exercise training in MetS also improved peak exercise LV diastolic
function.
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Fourth, peak arteriovenous oxygen difference was not measured but rather it was
estimated using the Fick equation (VO2 divided by cardiac output). The Fick technique
has been used to calculate arteriovenous oxygen difference in number of recent
physiologic studies investigating mechanisms of exercise intolerance [45, 46]. Our peak
arteriovenous oxygen difference values were somewhat higher than reported by others
[45], possibly due to underestimation of cardiac output. Most importantly, because key
variables were measured at all testing times using identical methods in both groups,
and because we assessed changes in reserve capacity (peak values – resting values)
within individuals, comparisons of cardiac output and estimated arteriovenous oxygen
difference between groups are valid.
Lastly, the short duration of exercise training (8 weeks) may have been
insufficient to alter cardiac structure, body composition, and metabolic blood
biomarkers. Thus, longer exercise training programs that incorporate different exercise
modalities (interval, aerobic, and resistance training) are important to fully understand
the role that exercise training has on improving CV structure/function in patients with
MetS.

Conclusion
In conclusion, 8 weeks of aerobic exercise training of moderate-to-high intensity
significantly improved peak exercise arterial-ventricular coupling, LV contractility,
peripheral vascular resistance, and aerobic capacity in MetS individuals without overt
CVD and Type 2 Diabetes. However, no improvements were evident in resting LV
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structure and diastolic function, metabolic profile or body composition after exercise
training.
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Table 1. Effects of exercise training on body composition and metabolic biomarkers in
MetS

Age, years
Sex, female %
Height, cm
Weight, kg
Lean Mass, kg
Body fat, %
BSA, m2
kg/m2

BMI,
Waist
circumference, cm
Triglycerides, mg/dL
HDL, mg/dL
Glucose, mg/dL
HbA1c, %
Insulin, µIU/mL

MetS non-trained (n=10)
Pre
Post
43 ± 3
60
171 ± 3
99
± 7
99
± 7
64
± 4
64
± 4
35
± 2
35
± 3

MetS trained (n=10)
Pre
Post
48 ± 3
70
168 ± 3
105 ± 6
105
59
± 5
59
43
± 3†
43

± 6
± 2
± 2†

2.10

± 0.08

2.10

± 0.09

2.13

± 0.07

2.12

± 0.07

34

± 2

34

± 2

37

± 2

37

± 2

104

± 3

103

± 5

124

± 10

122

± 10

149
41
98
5.7
10.4

±
±
±
±
±

169
40
97
5.5
10.7

±
±
±
±
±

116
47
99
5.7
9.0

±
±
±
±
±

140
45
97
5.6
9.0

±
±
±
±
±

21
4
2
0.1
2.4

20
2
3
0.1
2.2

17
5
3
0.1
1.5

24
4
3
0.1
1.8

1.34 ± 0.30 1.27 ± 0.30 1.23 ± 0.19 1.45 ± 0.34
HOMA-IR
Hypertensive
70
60
(>140/90) %
Diabetes Mellitus % 0
0
Medications, %
Hypertension
20
30
Cholesterol
0
10
Values are mean ± sem; BSA: body surface area; BMI: body mass index; HDL: high
density lipoprotein; HbA1c: hemoglobin A1c; HOMA-IR: homeostatic model assessment
of insulin resistance.
†p<0.05 vs, MetS non-trained group at specific visit (i.e., Pre or Post)
Of note no significant differences were found compare pre and post values within a
group
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Table 2: Effects of exercise training on supine left ventricular geometry and diastolic
function in MetS

MetS non-trained (n=10)
Pre
Post

MetS trained (n=10)
Pre
Post

LV geometry
Septal wall
0.95 ± 0.05 0.96 ± 0.06 0.92 ± 0.06 0.92 ± 0.05
thickness, cm
Posterior wall
0.87 ± 0.06 0.89 ± 0.06 0.86 ± 0.07 0.93 ± 0.06
thickness, cm
LV internal
4.41 ± 0.13 4.38 ± 0.16 4.73 ± 0.16 4.67 ± 0.12
dimension, cm
161 ± 8
164
± 11
181
± 21
187
± 16
LV Mass, g
77
± 3
78
± 3
84
± 9
88
± 6
LV Mass Index,
2
g/m
Relative Wall
0.40 ± 0.03 0.42 ± 0.04 0.36 ± 0.03 0.40 ± 0.02
Thickness
LV diastolic function
E, m/s
0.75 ± 0.03 0.75 ± 0.04 0.88 ± 0.05 0.92 ± 0.06
A, m/s
0.64 ± 0.03 0.60 ± 0.04 0.77 ± 0.07 0.74 ± 0.07
E/A ratio
1.21 ± 0.07 1.29 ± 0.07 1.24 ± 0.14 1.32 ± 0.13
IVRT, m/s
76
± 5
71
± 5
75
± 8
61
± 5
Dec T, m/s
203 ± 12
204
± 14
193
± 9
175
± 8
e’, m/s
0.12 ± 0.01 0.13 ± 0.01 0.11 ± 0.01 0.11 ± 0.01
E/e’
6.20 ± 0.26 6.21 ± 0.46 9.28 ± 1.05 9.13 ± 1.18
LV EDP, mmHg
16
± 1
16
± 1
18
± 1
17
± 1
Values are mean ± SEM; E: peak velocity of the early diastolic mitral flow; A: peak velocity
of the late diastolic mitral flow; E/A: E divided by A; IVRT: isovolumetric relaxation time; Dec
T: mitral flow deceleration time of early filling velocity; e’: mitral annular early diastolic
velocity; E/e’: E divided by e’; LV EDP: left ventricular end-diastolic pressure. Of note no
significant differences were found compare pre and post values within a group
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Table 3. Effects of exercise training on cardiovascular function in MetS
MetS non-trained (n=10)
Pre
Post
EDVi, ml/m2
Seated
Peak
ESVi, ml/m2
Seated
Peak
SVi, ml/m2
Seated
Peak
HR, bpm
Seated
Peak
CI, L·min/m2
Seated
Peak
EF. %
Seated
Peak≠
SBP, mmHg
Seated
Peak
DBP, mmHg
Seated
Peak
ESP, mmHg
Seated
Peak
SVRi, dyne·m2/s·cm-5
Seated

MetS trained (n=10)
Pre
Post

47

±

2

53

±

3

47

±

2

49

±

2

49

±

2

51

±

2

46

±

2

52

±

3

21

±

1

23

±

2

20

±

1

20

±

1

18

±

1

17

±

1

17

±

2

14

±

2*

26

±

2

30

±

2

26

±

2

29

±

1

31

±

2

35

±

2

29

±

2

38

±

2*

68

±

4

67

±

4

65

±

3

64

±

3

164

±

4

157

±

4*

154

±

6

151

±

6

1.81

±

0.16

2.05

±

0.15

1.70

±

0.11

1.85

±

0.12

4.98

±

0.27

5.39

±

0.32

4.50

±

0.42

5.78

±

0.46*

56

±

2

58

±

2

56

±

2

60

±

1

62

±

2

67

±

3

63

±

3

74

±

2*†

127

±

4

122

±

3

121

±

4

122

±

3

192

±

6

190

±

6

188

±

5

185

±

7

82

±

3

80

±

3

83

±

2

80

±

1

73

±

8

76

±

4

76

±

5

64

±

7

117

±

4

110

±

2

109

±

4

110

±

3

173

±

5

171

±

5

169

±

4

167

±

6

4593

±

381

3848

±

256*

4729

±

360

4245

±

301

1877
± 141
1755
± 115
2243
± 244
1565
± 167*
Peak≠
Values are mean ± SEM; EDVi: end-diastolic volume index; SVi: stroke volume index; ESVi: end-systolic
volume index; Ci: cardiac output index; EF: ejection fraction; SBP: systolic blood pressure; DBP: diastolic
blood pressure; ESP: end systolic blood pressure; SVRi: systemic vascular resistance index.*p<0.05
compared to Pre-values within a group (MetS-NonT or MetS-ExT); ≠significant (p<0.05) group (MetSNonT vs. MetS-ExT) by time (pre to post) interaction. †p<0.05 vs, MetS non-trained group at specific visit
(i.e., Pre or Post)
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Table 4: Effects of exercise training on aerobic capacity in MetS
MetS non-trained (n=10)
MetS trained (n=10)
Pre
Post
Pre
Post
Ventilatory threshold, l/min
1.13 ± 0.14 1.27 ± 0.12 1.20 ± 0.13 1.56 ± 0.21*
Ve/VCO2 slope
34.8 ± 1.49 34.4 ± 1.27 34.4 ± 1.4
35.7 ± 1.2*
Respiratory exchange ratio
1.13 ± 0.03 1.10 ± 0.01 1.10 ± 0.02 1.09 ± 0.02
BORG scale
19
± 0.3
19
± 0.2
19
± 0.5
19
± 0.4
≠
Peak VO2, (L/min)
1.89 ± 0.20 1.84 ± 0.18 1.68 ± 0.16 2.00 ± 0.19*
≠
Peak VO2, (ml/kg/min) LM
29.4 ± 2.2
28.7 ± 1.5
29.4 ± 1.6
35.0 ± 1.7*†
Peak VO2, (ml/kg/min) BW ≠ 19.1 ± 1.6
18.6 ± 1.2
16.2 ± 1.0
19.4 ± 1.0*†
Peak A-VO2 Diff, ml/100ml
18.4 ± 2.0
16.4 ± 1.2
18.5 ± 1.5
16.2 ± 1.0
Values are mean ± SEM; A-VO2 Diff: arteriovenous oxygen difference. *p<0.05 compared to Prevalues within a group (MetS-NonT or MetS-ExT); ≠significant (p<0.05) group (MetS-NonT vs.
MetS-ExT) by time (pre to post) interaction. †p<0.05 vs, MetS non-trained group at specific visit
(i.e., Pre or Post)
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Figure Legends
Figure 1. Change in arterial-ventricular coupling (Ea/Ees), LV end-systolic elastance
(Ees), and arterial elastance (Ea) from rest to peak exercise in Mets who underwent
exercise training (MetS-ExT, diamond) and in MetS who remained inactive (MetS-NonT,
triangles). Post intervention for both MetS group is depicted by a dashed line. Exercise
training significantly reduced peak Ea/Ees, and increased peak Ees in MetS, and there
was a significant time (pre and post intervention) by group (MetS-ExT vs. MetS-NonT)
for Ea/Ees and Ees. *p<0.05 illustrates significant differences pre and post intervention
in MetS Ex-T; +p<0.05 time by group interaction. Data presented as means ± SEM.
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Figure 1.
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Abstract
Background and Aims: Large elastic artery stiffening (AS) is a feature of normative
aging and reflects a process by which degenerative adaptations in large arteries lead to
wall stiffening. Metabolic syndrome (MetS) is associated with pathological vascular
adaptations including AS which may play a role in mediating CVD risk in this population.
Resveratrol (RSV), a naturally occurring polyphenol, has been shown to indirectly
increase bioavailability of nitric oxide through changes in vascular oxidative stress and
inflammation. Thus, RSV may represent an ideal therapy to target AS in MetS. The
objective of this study was to investigate whether single oral doses of RSV can reduce
AS and central aortic blood pressure in large elastic arteries of individuals with MetS.
Methods and Results: 28 subjects (28-70 years): 17 healthy controls and 11 MetS
consumed two doses of RSV (500 and1000 mg) and a placebo at weekly intervals in a
double-blind, randomized fashion. AS and BP were measured before and at 45 and 75
minutes after consumption of the supplement. Plasma samples were obtained at
baseline and at 60 minutes after consumption of the supplement and subsequently
analyzed for RSV concentration. Data were analyzed by a two-way repeated-measures
analysis of variance. No significant effect of RSV was observed, however, detectable
concentration of RSV and its primary metabolites was shown in a small subset of
participants (n=20).
Conclusion: Acute supplementation with 500 or 1000mg of RSV had no observable
effect on AS or blood pressure at 45 or 75 minutes post-consumption. These results
warrant further investigation of the use of supplementation with RSV as a strategy to
target AS in MetS.
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Introduction
Large elastic artery stiffening (AS) occurs as a result of normative biological
aging, and describes a process by which degenerative adaptations in the conduit
arteries lead to wall stiffening. In the presence of AS, the heart must fulfill the increased
force requirements to accommodate the less compliant arteries. Over time, the
additional load placed on the heart leads to LV hypertrophy (LVH) and heart failure.
Importantly, AS has notable functional implications on the large elastic arteries, as it
contributes to a diminishing of the Windkessel effect, or in other words the ability of the
elastic aorta to maintain a continuous and steady blood flow to peripheral vessels [1].
AS is increased in the presence of CVD and results in elevations in pulse pressure at
the site of central and peripheral arteries, which can extend to the microcirculation
contributing to target organ damage [2-5].
The metabolic syndrome (MetS) is defined by the co-occurrence of clinical
criteria and is used to identify patients at high risk for CVD, type II diabetes (T2DM), and
all cause mortality and accordingly, has become an important therapeutic target of
lifestyle modification. MetS is associated with pathological vascular adaptations
including, but not limited to, AS [6, 7]. AS is known to be significantly increased in MetS
compared to age-matched healthy controls [6, 8]. In MetS, AS may have a detrimental
impact on cardiac function; Increases in central systolic blood pressure that accompany
AS, promote cardiac hypertrophy leading to decreases in diastolic pressure, and
impairment of coronary perfusion [9]. Thus, the increased risk of CVD associated with
MetS may be due, in part, to increased AS. Indeed, data from our laboratory
demonstrates that MetS patients have increased AS, arterial wall remodeling, abnormal
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resting cardiac diastolic function, impaired peak exercise cardiac contraction, and
reduced aerobic capacity compared to non-MetS [6]. The increase in AS observed in
MetS is of clinical importance as a 1.0 m/second increase in AS is associated with a 1518 percent increase risk of CV events [10, 11]. Promising evidence from animal [12-14]
and initial human research [15, 16] demonstrate the potential of resveratrol (RSV) for
CV protection. Specifically, the cardioprotective effects of RSV supplementation have
been attributed to the actions of RSV to acutely reduce inflammation and oxidative
stress; two phenomena associated with MetS that are known to alter the arterial wall,
decrease the bioavailability of the vasodilator nitric oxide (NO) and contribute to acute
changes in AS [17-20]. Furthermore, RSV has been demonstrated to exert a
vasorelaxing effect in an ex-vivo preparation of abdominal aortic rings of SpraqueDawley rats [21]. The vasorelaxing effects of RSV in Sprague-Dawley aortic rings were
attributed to endothelial-dependent and endothelial-independent mechanisms, opening
of the K+ channel resulting in hyperpolarization of vascular smooth muscle, and
inhibition of extracellular calcium influx and intracellular calcium release in smooth
muscle cells [21].
While changes in structural components of the arterial wall occur over a longer
duration to negatively increase AS, acute changes may also occur to mediate stiffness.
Notably, changes in vascular smooth muscle cell (VSMC) tone and sympathetic
nervous system activity have been shown to acutely modulate AS [22]. More
specifically, sympathetic stimulation can alter AS through an indirect change in arterial
pressure or through a direct increase in vascular tone, causing vasoconstriction and
decreased arterial diameter [23-25]. Moreover, impaired endothelial dysfunction, as a
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result of low-grade inflammation [26] enhances vasoconstrictor activity, altering large
artery smooth muscle tone [27-29] which may contribute to acute changes in AS.
Accordingly, nutritional supplementation with RSV may represent a promising
therapy for reducing AS, and subsequently alleviating CVD risk in individuals with MetS.
Therefore, the objective of the current randomized, double-blind, placebo-controlled
study was to investigate whether single oral doses of RSV can reduce AS and central
aortic blood pressure (cSBP) in large elastic arteries of individuals with MetS. We
hypothesized that treatment with single doses of RSV would result in acute reductions
in AS and cSBP in individuals afflicted with MetS.
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Materials
Study Population
The study population consisted of 28 subjects (28-70 years): 17 healthy controls
(44 ± 3; 83% Female) and 11 MetS (51 ± 3; 64% Female). Healthy controls were free
from clinically manifest CVD as determined by a detailed medical history, physical
examination, and evidence of normal resting and exercise electrocardiograms. MetS
subjects were free from clinically manifest CVD and diabetes mellitus. None of the
participants were current or former smokers or were currently receiving treatment for
peripheral artery disease. Exclusion criteria included T2DM (HbA1c ≥ 6.5% or use of
diabetic medications), pulmonary disease, angina, atrial fibrillation, aortic stenosis,
anemia, myocardial infarction, stroke, or coronary revascularization as assessed by a
detailed medical history, physical examination, and a resting and exercise
electrocardiogram. Subjects who participated in regular exercise, defined as >30 min, 3
times/week were excluded. All participants signed a written informed consent form that
was approved by the Institutional Review Board of West Virginia University.

Definition of the Metabolic Syndrome
MetS was defined according to the Third Report of the National Cholesterol
Education Program Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (NCEP ATPIII) [30] which requires three or more of the
following five components: abdominal obesity (waist men >102 cm, women 95 >88 cm),
low HDL cholesterol (men <40 mg/dl; women <50 mg/dl), hypertriglyceridemia (≥150
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mg/dl), elevated fasting glucose (≥100 mg/dl and <126 mg/dl) and elevated blood
pressure (≥130/≥85 mmHg or use of hypertensive medications).

Study Design
All assessments were performed between 7:00 and 10:00AM in a quiet,
temperature-controlled room following a 12-hour fast and abstinence from alcohol,
caffeine, and vitamins. Participants were asked to withhold all cardiovascular
medications for at least 24 hours prior to assessments. All participants were asked to
maintain current dietary habits and to limit excessive polyphenol intake (including
consumption of peanuts, red wine, green tea, etc.) for the duration of the study.
Participants attended the laboratory on 4 separate occasions. The first occasion
was for the completion of a screening visit to acquire patient consent and to perform
anthropometric measures. On each of the 3 remaining visits, participants consumed 2
identical capsules containing the following: inert placebo or 500mg trans-resveratrol.
The capsules were combined to achieve combinations of placebo, 500mg of transresveratrol, or 1000mg of trans-resveratrol. Each treatment was assigned an A, B, or C
by an independent staff member. Each treatment was consumed ad libitum with water
at weekly intervals in a double blind randomized fashion. No member of the
investigational team was aware of the contents of the capsules until a blind-data review
was completed.
On completion of anthropometric measurements and a minimum of 15 minutes of
quiet supine rest supine measures of baseline arterial structure and function were
performed followed by a baseline venous blood draw. Based on pharmacokinetic
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results, peak RSV concentrations occur between 0.8-1.5 hours following administration
of RSV [31]. Thus, measures of arterial structure and function were repeated at 45 and
75 minutes post-capsule consumption. An additional venous blood draw was collected
at 60 minutes post-capsule consumption.

Anthropometric Measurements
At screening visit, height, weight, and waist and hip circumferences were
determined

using

standard

laboratory

procedures

for

all

participants.

Waist

circumference was assessed at the site of the smallest circumference between the rib
cage and the iliac crest with subjects in a standing position. Hip circumference was
assessed at the site of the largest circumference between the waist and thighs. Lean
body mass and fat mass were measured using air displacement plethysmography
(BodPod®; Life measurement, Concord, CA, USA). During the assessment of body
composition subjects were dressed in close-fitting bathing suits and a swim cap. Body
mass index (BMI) was calculated as weight (kg) / height (m)2.

Arterial Function
Brachial systolic (SBP) and diastolic (DBP) blood pressures were measured
using an automated, oscillometric sphygmomanometer (Critikon Dinamap Compact BP
monitor, GE Medical, Tampa, Fla, USA) and pulse pressure (PP) was calculated from
SBP-DBP. Pulse wave analysis was performed noninvasively on the radial artery
(SphygmoCor system, AtCor Medical, Sydney, Australia). All measurements were made
in triplicate, and the mean values used for subsequent analysis. The SphygmoCor
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system synthesizes a central (ascending aortic) pressure waveform from the radial
pressure waveform that does not differ from that of an intra-arterially recorded wave [32]
using a validated generalized transfer function [33]. These waveforms were calibrated
against brachial mean arterial and diastolic pressure to estimate aortic pressures. The
characteristics of the aortic pulse wave (Figure 1) were determined as previously
described [34] using established guidelines [35].
Carotid to femoral pulse wave velocity (cfPWV; central arterial stiffness) and
carotid to radial pulse wave velocity (crPWV: peripheral arterial stiffness) were
measured by applanation tonometry (AtCor Medical, Sydney, Australia). ECG-gated
waveforms were sequentially recorded. Aortic distance (D) was calculated as the
difference in the distances from the carotid to the suprasternal notch and from the
suprasternal notch to the femoral artery or radial artery. Time delay was calculated
using a foot-of-the-wave method.

Blood Collection and Analysis
Venous blood sampling was performed between 7:00 and 10:00AM following an
overnight 12-hour fast at baseline and again at 60 minutes following capsule
consumption. Patient plasma acquired from venous blood samples was sent to West
Virginia University Hospital’s central laboratory in Morgantown, WV for lipid profile
analysis. Total cholesterol, HDL cholesterol, triglycerides, and fasting blood glucose
were determined in plasma (lithium heparin, Becton Dickenson plasma separator tubes)
using Beckman Coulter (Brea, CA) DxC automated chemistry analyzers. Total
cholesterol was measured using a cholesterol esterase/cholesterol oxidase-or
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peroxidase-driven, timed endpoint method (coefficient of variation, <7%). Triglycerides
were measured using a lipase/glycerol kinase/glycerophosphate oxidase/horseradish
peroxidase-driven, timed endpoint method (coefficient of variation, 5%-7%). Glucose
was measured electrochemically using a glucose oxidase-/catalase-/molybdate-driven
oxygen rate method (coefficient of variation, <5%). Glycated hemoglobin (A1c fraction)
was measured in whole blood (K2-EDTA; Becton Dickenson) using a Bio-Rad (Hercules,
CA) Variant II Turbo high-performance liquid chromatography system (coefficient of
variation, <2%). Insulin was measured in serum (untreated/red top tube; Becton
Dickenson) on an Immulite 2000 immunochemistry system (Siemens) (coefficient of
variation, <10%).

Plasma Concentration of Resveratrol and its Metabolites
Select plasma samples (n=20) were delivered to Protea Biosciences, Inc.
(protea®, Morgantown, WV) for determination of resveratrol and its primary metabolites.
Plasma concentrations of resveratrol (3,5,4'-trihydroxy-trans- stilbene) and its primary
metabolites, including trans-resveratrol-3-O-sulfate, trans-resveratrol-3-O-glucuronide,
and trans-resveratrol-4-O-glucuronide were determined using liquid chromatography
tandem mass spectrometry (HPLC: Shimadzu LC-20AD HPLC, Tokyo, Japan); MS:
Triple-Quad 4000, ABSciex Toronto, Canada). Briefly, fasting venous blood samples
(15-20ml) were drawn at baseline and at 60 minutes post-capsule ingestion of 500mg of
trans-resveratrol, 1000mg of trans-resveratrol or placebo in a small sample of
participants (n=20) in EDTA coated tubes. Blood samples were processed into plasma
and stored at -80°C before extraction. Plasma samples were delivered to Protea
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Biosciences, Inc. (protea®, Morgantown, WV) for the determination of concentrations of
resveratrol and its metabolites.
Calibration and quality control solutions were prepared by spiking human plasma
with solutions of varying concentrations of resveratrol and metabolites in 50:50
methanol:water. Blank solutions were prepared by spiking human plasma with 50:50
methanol:water. All standards, controls, and blanks were then aliquotted into 1.5μl
microcentrifuge tubes using a 50μl sample volume.
All plasma samples were thawed on the bench top at room temperature,
vortexed for 1 minute and aliquoted into 1.5μl microcentrifuge tubes using a 50μl
sample volume. Acetonitrile was added to all internal standards. Next, 200μl of Working
Internal Standard Solution (50ng/ml resveratrol-

13C
6

in acetonitrile) was added to all

other samples using a repeater pipet to precipitate the proteins. All tubes were capped
and vortexed for 1 minute. The samples were then centrifuged for 5 minutes at 10,000
RMP. 100μl of water was added to each sample well of a Nunc (U96 PP 2ml) 96-well
plate. The plate was then sealed with a pre-slit capmat, vortexed for 1 minute, and
stored at 4°C.

Statistical Analysis
Normality was evaluated by the Kolmogorov-Smirnov test. Categorical variables
were compared by the chi-square test, whereas baseline comparisons between groups
were analyzed by an independent t-test or Mann–Whitney test. The changes from
baseline to 45 and 75 minutes post capsule consumption in arterial parameters were
examined by a time (baseline to 45 or 75 minutes post capsule consumption) by group
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(MetS vs. Controls) by treatment (placebo, 500mg RSV, or 1000mg RSV) interaction
evaluated using a two-way repeated-measures analysis of variance with Tukey’s post
hoc test. Additionally, the changes from baseline to 45 and 75 minutes post capsule
consumption in arterial parameters were examined by a time (baseline to 45 or 75
minutes post capsule consumption) by treatment (placebo, 500mg RSV, or 1000mg
RSV) interaction evaluated using a two-way repeated-measures analysis of variance
with Tukey’s post hoc test. Multiple linear regression analysis was used to determine
whether age, risk score, and baseline measurements could predict changes in arterial
and central blood pressure parameters following supplementation with RSV. Data are
presented as means ± s.e.m. and P<0.05 was required for significance. All analyses
were performed using SPSS version 22 (SPSS Inc., Chicago, IL, USA).
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Results
Subject Characteristics
Baseline characteristics of the study cohort are presented in Table 1. Twentyeight participants were recruited from the surrounding Morgantown area and were
separated into two groups, healthy controls and MetS, based on the NCEP ATPIII
guidelines for the definition of MetS. Age and sex were similar between groups despite
an overall majority of female participants. As expected, Mets participants had
significantly elevated baseline CVD risk factors.

Baseline Arterial Measurements
Baseline arterial measurements for MetS and controls are represented in Table
2. Mets and controls exhibited similar baseline values in arterial parameters with the
exception of brachial and central systolic blood pressure, SEVR, and AS as measured
using cfPWV. In aggreement with previous findings from our laboratory [6, 34, 36] MetS
were characterized by general increases in bSBP and cSBP and increased AS
compared to healthy controls.

Resveratrol Plasma Concentrations
Mean plasma concentrations of trans-resveratrol and its conjugates at baseline
and 60 minutes post-capsule consumption in a small sub sample of participants (n=20)
are shown in Figure 2. Due to rapid and extensive metabolism and formation of
metabolites including resveratrol glucuronides and resveratrol sulfates. Unmetabolized
trans-resveratrol reached small but detectable concentrations in plasma following oral
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doses of 500 mg and 1000 mg. These results demonstrate that, irrespective of the
presence or absence of MetS, plasma RSV and three of its primary metabolites were
detectable at 60 minutes post-oral supplementation of 500mg or 1000mg of RSV. Our
resolution to examine RSV at doses of 500mg/day and 1000mg/day was primarily
based on the understanding that RSV when administered orally is well absorbed but
exhibits a very low bioavailability, and has been shown to be well tolerated in humans
with no marked toxicity reported at much higher dosages as compared to our selected
dosage. Evidence indicates that a range of dosages from 30mg to 5000mg produce
various physiological effects in humans [37-40]. These results demonstrate the
feasibility of administering RSV at levels detectable in plasma.

Relationship between Resveratrol Supplementation on AS and Blood Pressure
Graphical representation of the change in arterial stiffness and central blood
pressure parameters at 45 and 75 minutes post oral supplementation with placebo,
500mg RSV, and 1000 mg RSV is shown in Figures 3-5. Using a two-way we evaluated
the effect of RSV to elicit changes in Arterial and central blood pressure parameters at
45 and 75 minutes post capsule consumption by a time (baseline to 45 or 75 minutes
post capsule consumption) by group (MetS vs. Controls) by treatment (placebo, 500mg
RSV, or 1000mg RSV) interaction evaluated using a two-way repeated-measures
analysis of variance. Interestingly, no significant effect of resveratrol on arterial and
central blood pressure parameters was identified between MetS and healthy controls.
Next, we repeated this statistical analysis without separation of participants into MetS
and control groups. Similarly, no time (baseline to 45 or 75 minutes post capsule
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consumption) by treatment (placebo, 500mg RSV, or 1000mg RSV) effects were
observed.
Moving forward, we wanted to understand whether changes in AS and blood
pressure following supplementation with RSV can be predicted based on age,
riskpoints, and baseline values of AS and blood pressure. Using multiple regression
analysis we report that baseline bPP and cPP significantly predict changes in bPP and
cPP 75 respectively, 75 minutes following oral ingestion of 500mg of RSV. Additionally,
basline values of bSBP, bPP, and cPP significantly predict changes in bSBP, bPP, and
cPP, respectively, 45 minutes following oral ingestion of 1000mg of RSV. Importantly
the these relationships were inverse, meaning that higher baseline values of select
brachial and central blood pressure measurements predict decreases in delta values
(baseline – 45 or 75 minutes) following treatment with RSV. Results from multiple
regression analysis are depicted in Table 3.
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Discussion
AS occurs with advancing age and is further elevated in MetS compared to agematched healthy controls [6, 8]. Complications of AS include the development of LVH,
reductions in coronary perfusion [9]. Thus, the increased risk of CVD associated with
MetS may be due, in part, to increased AS. Indeed, data from our laboratory
demonstrates that MetS patients have increased AS, arterial wall remodeling, abnormal
resting cardiac diastolic function, impaired peak exercise cardiac contraction, and
reduced aerobic capacity compared to non-MetS [6]. Importantly, changes in vascular
smooth muscle cell (VSMC) tone and sympathetic nervous system activity have been
shown to acutely modulate AS [22] and may represent effective therapeutic targets for
affecting improvements in AS and likely CVD in MetS.
Resveratrol, is a polyphenolic compound found in dietary sources including, but
not limited to, grape skins, peanuts, and red wine.

In the last decade RSV has

generated substantial interest among the scientific community and within popular culture
for its CV protective potential. Namely, RSV has been shown to reduce inflammation and
oxidative stress, as well as to promote smooth muscle vasorelaxation through both
chronic and acute mechanisms that remain unclear. For these reasons, we sought to
investigate the effects of two single doses of RSV on arterial and blood pressure
parameters in MetS and healthy controls.
A comparison between MetS and controls to determine the whether RSV was
able to improve AS and blood pressure showed no significant interactions. These
findings precluded our original hypothesis that 500mg or 1000mg of RSV would affect
acute improvements in AS and blood pressure, and further, that we would be able to
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capture these acute improvements at 45 and 75 minutes following capsule ingestion in
MetS.

Further investigation revealed the ability of some baseline blood pressure

parameters to predict how they would change in response to treatment with RSV. While
the literature regarding RSV treatment in clinical research is still in its infancy and is
largely controversial, the results from this study are in contrast to recent evidence that
RSV at higher doses (≥150 mg/day) significantly decreases SBP [41]. Further, single
doses of RSV have recently been demonstrated to acutely improve flow-mediated
dilation (FMD) in a dose-dependent manner [39].
Although the data presented here do not find a significant short-term effect of 500
and 1000mg of RSV on AS and central blood pressure, it must be emphasized that our
results should neither discourage nor slight the actions of RSV as a therapeutic
approach to human disease. It is true that we are unable to draw a significant positive
conclusion for our investigation of whether 500mg and 1000mg can acutely alter AS and
blood pressure in MetS; however, by the same token we are unable to demonstrate that
RSV exerts any negative effects that may exacerbate AS, or contribute to elevated blood
pressure in MetS. Moreover, addressing the many limitations and caveats of this study
may shed light on the inconclusive nature of our current findings.

Limitations
First, due to the small sample size of our MetS and control groups our study is
underpowered for the comparisons required to determine a time by treatment by group
effect on AS. For this reason these data should be regarded as preliminary until we can
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obtain data on a larger population sample. While we reported non-significant results
from multivariate modeling, we can speculate that in MetS significant elevations in
baseline parameters of AS and blood pressure, may indicate a greater potential for
improvement in these parameters and warrants further investigation. Second, although
age and sex were similar between groups in our study, we included a wide range of aged
individuals, a majority of which were women, begging the question as to whether there
may be divergent mechanisms by which RSV can exert its effects in men and women
and whether or not these differences have the potential to mask improvements in AS
conferred by RSV require further investigation in a cohort with more equal numbers of
both men and women. Third, we did not provide a measure of autonomic function in this
study. The potential affects of RSV on autonomic function [42], which has been shown
to modulate acute changes in AS [22], was not assessed, but future studies should
consider this mechanism which can be easily accomplished in the short-term by
recording beat-to-beat changes in BP and HR. Additional concerns that may limit the
interpretation of this study include patient selection. While comparisons of group
demographics and baseline parameters of AS and blood pressure were indicative of our
ability to successfully screen for MetS, the elevations in this small group were only
moderate, especially with respect to age and elevations in blood lipid profile, blood
pressure, and AS. As MetS can be considered to exist as a spectrum in terms of
disease severity, the pariticpants recruited in this study may represent less severe
MetS. It is possible that the determination of the therapeutic potential of RSV to reduce
AS may require the use of participants with more severe disease. Of equal importance
is our resolution to examine two single doses of RSV. Future studies to evaluate the
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therapeutic potential of RSV may be more clinically relevant if they are designed with
the goal of demonstrating long-term disease prevention and maintenance of CV health
via chronic supplementation with RSV. With that in mind, the acute nature of our study
may be too short to show the benefits of RSV for lowering CVD risk in MetS. Finally, our
resolution to examine two time points based on pharmacokinetic data in the existing
literature may have inherently limited our resolution for detecting improvements in AS
and blood pressure. Data from plasma concentrations of RSV and its primary
metabolites suggest that delivery of RSV is not a limiting factor in this study, however, it
is possible that changes elicited by RSV to alter AS or BP may occur before or after our
selected time points and future studies would be better to perform a dose-response
study in a separate cohort to more accurately select the best time points for
investigation into the short-term affects of RSV.

Conclusion
In conclusion, this study demonstrates that acute supplementation with 500 mg
and 1000 mg of RSV failed to modulate improvements in AS and blood pressure at 45
and 75 minutes post-supplementation. Taken together, these findings suggest future
investigation of the short-term and chronic benefits of RSV for improving AS and blood
pressure, with particular attention to patient selection, dose selection, and study
duration.
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Table 1. Patient Demographics and Characteristics

Control
(n=17)

MetS
(n=11)

44 ± 3

51 ± 3

83

64

Height, cm

163.12 ± 2.71

166.75 ± 2.16

Weight, lbs

*147.45 ± 6.4

219.69 ± 8.25

*2.40 ± 0.05

2.90 ± 0.06

*25.49 ± 1.45

35.83 ± 1.14

Waist Circumference, cm

*82.33 ± 2.90

110.32 ± 3.84

Triglycerides, mg/dL

*79.33 ± 7.67

151.29 ± 21.63

HDL Cholesterol, mg/dL

*57.00 ± 2.75

42.21 ± 1.34

Glucose, mg/dL

*91.50 ± 2.03

118.71 ± 8.16

HbA1c, %

*5.15 ± 0.07

5.88 ± 0.28

Insulin, μIU/mL

*5.76 ± 0.69

17.36 ± 1.81

Riskpoints

*14.89 ± 1.89

39.07 ± 2.45

Avg HR, bpm

69.40 ± 1.93

73.00 ± 2.48

Avg. bSBP, mmHg

*114.38± 2.81

124.33 ± 2.87

Avg. bDBP, mmHg

77.15 ± 1.92

82.01 ± 2.21

Avg. bPP, mmHg

37.23 ± 2.39

42.32 ± 3.81

Avg. cSBP, mmHg

*105.52 ± 3.07

113.40 ± 2.23

Avg. cDBP, mmHg

75.02 ± 2.28

78.52 ± 2.62

Avg. cPP, mmHg

30.51 ± 2.05

34.88 ± 3.60

Age, years
Sex, % Female

BSA, m

2

BMI, kg/m

2

Values expressed as mean ± SEM. Abbreviations: MetS, metabolic syndrome;
BSA, body surface area; BMI, body mass index; HDL, high-density lipoprotein;
HR, heart rate; bSBP, brachial systolic blood pressure; bDBP, brachial diastolic
blood pressure; bPP, brachial pulse pressure; cSBP, central systolic blood
pressure; cDBP, central diastolic blood pressure.
*p<0.05 vs. MetS
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Table 2. Baseline Parameters in MetS and Controls
Control
(n=17)

MetS
(n=11)

66.21 ± 2.06

71.11 ± 2.59

*110.29 ± 2.60

123.08 ± 3.43

bpDBP, mmHg

73.29 ± 2.03

76.69 ± 2.24

bPP, mmHg

37.00 ± 1.82

46.38 ± 4.67

cSBP, mmHg

*102.01 ± 2.95

111.26 ± 2.37

cDBP, mmHg

74.13 ± 2.05

77.73 ± 2.25

cPP, mmHg

27.82 ± 1.82

34.41 ± 3.63

AP, mmHg

7.11 ± 1.19

6.94 ± 1.05

AGI

23.42 ± 3.23

19.86 ± 2.41

AGI@HR75, %

19.25 ± 13.53

18.11 ± 2.41

SEVR, %

*158.69 ± 5.20

136.97 ± 8.58

*6.54 ± 0.24

7.73 ± 0.41

HR, bpm
bSBP, mmHg

cfPWV, m/s

Values expressed as mean ± SEM. Abbreviations: MetS, metabolic syndrome;
HR, heart rate; pSBP, brachial systolic blood pressure; bDBP, brachial diastolic
blood pressure; bPP, brachial pulse pressure; cSBP, central systolic blood
pressure; cDBP, central diastolic blood pressure; cPP, central pulse pressure;
AP, augmentation pressure; AGI, augmentation index; AGI@HR75,
augmentation index corrected for a HR of 75; SEVR, sub-endocardial viability
ratio; cfPWV, carotid to femoral pulse wave velocity
*p<0.05 vs. MetS
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Table 3. Multiple linear regression models
B

SE B

β

p

Riskpoints

0.072

0.107

0.129

0.512

Age

0.207

0.100

0.433

0.050

bSBP

-0.269

0.114

-0.470

0.027

Riskpoints

-0.071

0.107

-0.127

0.511

Age

0.190

0.091

0.393

0.048

bPP

-0.305

0.108

-0.519

0.009

Riskpoints

0.064

0.093

0.149

0.496

Age

0.120

0.071

0.323

0.104

cPP

-0.285

0.108

-0.542

0.015

Riskpoints

0.150

0.089

0.378

0.107

Age

-0.057

0.064

-0.173

0.382

cPP

-.0199

0.097

-0.442

0.051

Riskpoints

0.072

0.097

0.147

0.465

Age

-0.051

0.079

-0.124

0.529

bPP

-0.211

0.094

-0.431

0.033

Delta bSBP at 45 min post 500mg RSV

Delta bPP at 45 min post 500mg RSV

Delta cPP at 45 min post 500mg RSV

Delta cPP at 75 min post 1000mg RSV

Delta bPP at 75 min post 1000mg RSV

B denotes the variable estimate; SE B denotes the standard error of the variable estimate; β
denotes the standardized estimate
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Figure Legends
Figure 1. Example of central pressure waveform. The systolic and diastolic pressures
are the peak and trough of the pressure waveform. Augmentation pressure (AP) is the
pressure added to the forward wave by the reflected wave (P1-P2), whereas
augmentation index is the ratio between AP and central pulse pressure (PP = systolic diastolic pressure).

Figure 2. Mean (±SEM) plasma concentrations of trans-resveratrol (A) and its
glucuronidated and sulfated conjugates (B) at baseline and 60 minutes-post ingestion of
500mg or 1000mg of RSV in a small sub cohort of participants (n=20) as determined by
HPLC.

Figure 3. Mean (±SEM) changes (45 or 75 minutes – baseline) in cSBP (A) and cPP
(B) at 45 and 75 minutes post-supplementation with placebo, 500mg RSV, and 1000mg
RSV in MetS and healthy controls. Positive bars represent increases relative to baseline
values and negative bars represent reductions relative to baseline values.

Figure 4. Mean (±SEM) changes (45 or 75 minutes – baseline) in AP (A) and SEVR (B)
at 45 and 75 minutes post-supplementation with placebo, 500mg RSV, and 1000mg
RSV in MetS and healthy controls. Positive bars represent increases relative to baseline
values and negative bars represent reductions relative to baseline values.
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Figure 5. Mean (±SEM) changes (45 or 75 minutes – baseline) in AGI (A) and
AGI@HR75 (B) at 45 and 75 minutes post-supplementation with placebo, 500mg RSV,
and 1000mg RSV in MetS and healthy controls. Positive bars represent increases
relative to baseline values and negative bars represent reductions relative to baseline
values.
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Chapter 6
General Discussion

212

General Discussion
The overall purpose of the investigations presented within this dissertation was to
define CV dysfunction in the metabolic syndrome and to identify practical therapeutic
strategies to improve CV function. Specifically, our goals were to (1) comprehensively
evaluate CV function at rest and during maximal exercise and to validate the presence
of CV dysfunction in a cohort of human subjects with MetS; (2) to evaluate the
therapeutic value of aerobic exercise training for improving large elastic artery stiffening
and arterial-ventricular coupling; and (3) to determine the effect of single-dose
supplementation with RSV on AS and central systolic blood pressure in MetS and
healthy controls. The central hypothesis of this collective work was that subclinical CV
dysfunction develops as a result of co-occurring risk factors associated with MetS, and
can be improved by the implementation of therapeutic lifestyle interventions including
aerobic exercise training and nutritional supplementation with RSV. The rationale for the
work presented within this document is based on the importance of reversing CV
dysfunction associated with MetS for CVD risk reduction as well as to advance our
understanding of the link between CVD and MetS.
MetS is defined by the co-occurrence of clinical risk factors and has become a
principal health concern in the U.S. due to its association with CVD [1]. A systematic
review of data from existing observational studies has determined that MetS is
associated with a 2-fold increased risk in CV outcomes and a 1.5-fold increase in allcause mortality [2]. Numerous studies have demonstrated LV dysfunction at rest in
MetS [3-6], but not all [7, 8], suggesting that LV dysfunction may mediate, in part, the
link between CV risk and MetS. Accordingly, the purpose of our initial efforts was to
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complete a comprehensive assessment of LV and arterial structure and function at rest
and during exercise in MetS vs. age- and sex-matched healthy controls. This study,
presented in Chapter 2, was the first to provide a comparison of LV and arterial function
responses at rest and during dynamic exercise in individuals with MetS but without
T2DM and/or overt CVD and healthy controls. Exclusion of subjects with T2DM and
symptomatic or clinical CVD was an important strength of this study and permitted the
interpretation of our results to be a reflection of MetS rather than a consequence of
conditions that may exacerbate LV dysfunction. Use of load-independent measures to
assess LV contractility at rest eliminated a general shortcoming of many existing
studies. Indeed, altered loading conditions, including abnormal resting HR and
pathological LV chamber remodeling are key features of MetS and may influence loaddependent measures of systolic function. Under resting conditions we observed
elevations in arterial parameters including cIMT and cfPWV (arterial stiffness; AS), and
LVmass, which have been previously described in earlier investigations of MetS [8-10].
Literature suggests that changes in the mechanical and elastic properties of the
large elastic arteries play a role in the underlying mechanism contributing to AS
associated with MetS [11]. Stability and compliance of the large elastic arteries are
dependent on the relative content of two important scaffolding proteins: collagen and
elastin. An imbalance in the production and degradation of these two proteins
contributes to large artery stiffness and may occur in response to inflammation and
endothelial dysfunction [11].
Furthermore, load-independent assessments of LV contractility described in
Chapter 2 revealed no evidence of contractile dysfunction in MetS. Exercise testing is a
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well-established method to generate physiological stress in order to reveal pathological
alterations not present at rest. During maximal exercise MetS demonstrated impaired
LV systolic function, blunted systemic vasodilation, and reduced cardiac pump
performance [12]. Collectively, LV contractile deficits contributed to a blunted arterialventricular coupling reserve and impaired peak aerobic capacity in MetS [12]. Taken
together,

these

data

demonstrate

the

capacity

for

the

development

of

pathophysiological adaptations to CV structure and function in the presence of cooccurring CV risk factors prior to the development of chronic disease. Notably, these
findings underscore the value of MetS as a prognostic tool for the identification of
individuals at high risk for CVD but without evidence of clinical disease including T2DM
and/or overt CVD. Importantly, these data formed the foundational work for
investigations into the use of exercise training for the treatment of arterial stiffness in
MetS without T2DM and/or overt CVD.
As detailed by assessment of arterial structure and function in Chapter 2, this
work and others [12, 13], have demonstrated arterial dysfunction in MetS that is
characterized by elevations in cfPWV, cIMT, carotid cross-sectional area, and carotid
wall stress and tension. Notably, large elastic artery stiffening has been shown to
modulate LV loading conditions through elevations in central systolic pressure [14]. Left
ventricular hypertrophy (LVH) occurs as a maladaptive response to chronic elevations in
central arterial pressure. Complications of LVH include diastolic heart failure, systolic
heart failure, and impaired coronary flow reserve [4]. In Chapter 2 we describe evidence
of early diastolic dysfunction during supine rest in MetS. Consequently, early recognition
and identification of effective strategies for reducing AS may have important clinical
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implications for individuals with MetS.
Aerobic exercise training has been shown by others to be an effective
intervention to reduce AS in young and healthy and middle-aged and older individuals
[15, 16]. Building on our previous findings detailed in Chapter 2, we investigated
whether 8 weeks of aerobic exercise training is an effective strategy to reduce AS in
MetS without T2DM and/or overt CVD. These investigations are detailed in Chapter 3
wherein we demonstrate a reduction in cfPWV in MetS after 8 weeks of aerobic
exercise training. Importantly, improvements in AS occurred in the absence of
significant reductions in weight, BMI, and metabolic profile (Table 3.3) suggesting that
improvements in AS associated with aerobic exercise training are independent of other
established benefits of exercise training. A lack of training effect on established
outcomes of aerobic exercise training begs the question of whether or not a longer
duration or combination diet and exercise is required to elicit improvements in these
parameters; However, an investigation of the effects of altering the intensity or number
of treatment strategies to target AS in MetS warrants consideration.
Central systolic blood pressure, rather than traditional brachial blood pressure, is
known to provide a more accurate index of afterload; reflecting the pressure that the LV
must generate in order to eject blood from the heart to the periphery. Using PWA for the
non-invasive estimation of central pressure we demonstrated significant reductions in
cSBP in MetS. This finding is of clinical importance, as it is known that cSBP is superior
to brachial BP for the prediction of CV outcomes [17]. Furthermore, PWA revealed an
increase in the sub-endocardial viability ratio (SEVR), an index of myocardial oxygen
supply and demand. In the absence of a direct measurement of CV function by Doppler
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echocardiography, changes in the SEVR indicate potential improvements in cardiac
function after 8 weeks of aerobic exercise training in MetS. Whether or not these
improvements in AS elicited by short-term exercise training in MetS will be maintained
over a longer duration of time remains unknown. Recent evidence from existing
literature suggests that in persons with MetS and T2DM, aerobic exercise training elicits
initial improvements in AS, and these benefits are subsequently lost when training is
continued for a longer duration [18]. Consequently, the capacity of aerobic exercise
training to reduce AS may have a more lasting benefit for MetS without chronic disease;
however, this proposal is merely speculative and cannot be supported by data
presented within this document.
Understanding the mechanisms underlying the changes in arterial function
associated with MetS is essential in the prevention or treatment of individuals with cooccurring risk factors for CVD. AS is determined by the composition of the extracellular
matrix (elastin-collagen network) and vascular smooth muscle cell function [11, 19, 20].
Changes that occur in the expression and/or bioactivity of structural proteins in the
arterial wall (and heart) lead to AS. Vascular remodeling of the large elastic arteries,
including fibrosis and elastic fiber degradation results in decreased arterial compliance
[21-23]. It is possible that changes in large artery structure may play a role in the
pathophysiology of AS in MetS. Structural changes to the extracellular matrix of large
arteries in MetS have been attributed to the activation of matrix metalloproteinases
(MMPs), key regulators of arterial and cardiac remodeling [20, 24]. Activation of various
MMPs in the carotid intima-media is associated with characteristics of large artery
stiffening including increased fragmentation of elastin [25], overproduction of abnormal
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collagen [20], increased vascular smooth muscle cell migration and proliferation in the
carotid intima-media layer [26, 27]. In animal models, increased MMP9 activity,
responsible for the degradation of elastin and collagen [25], was directly linked with AS
[28] and cardiac stiffness [29]. MMP activation in MetS may be further exacerbated by
decreased activity of endogenous tissue inhibitor of metalloproteinases (TIMPs). In
hypertensive patients, plasma concentrations of MMP9 and TIMP1 were elevated vs.
controls and are implicated in AS and associated with an increased risk of CV events
[30-32]. Notably, TIMP1 inhibits MMP1 activity that increases type 1 collagen (high
tensile strength and rigidity) formation. MMP/TIMP activity is altered in MetS, with higher
concentrations of MMP2, 8, 9 and TIMP1 vs. controls [33-35]. The ratio of MMP/TIMP
activity plays a central role in remodeling of the extracellular matrix and thus, may
mediate structural changes of the large arteries in the presence of a chronic proinflammatory environment as observed in MetS. As detailed in Chapter 3 we measured
plasma markers of tissue remodeling (MMPs and TIMPs) and found that exercise
training was able to produce favorable reductions in circulating MMP1 and MMP7, both
of which were found to have positive associations with cfPWV [36].
Expanding on structural changes that occur to the extracellular matrix in MetS
that may contribute to AS, additional material properties of the vasculature can play a
role in arterial stiffening, as well. Among these properties the most important
contributors to large artery stiffness include increased synthesis of collagen, nonenzymatic glycation of collagen to form crosslinks, and vascular smooth muscle cell
hypertrophy [20]. Under hyperglycemic conditions, proteins and lipids in the vasculature
may undergo non-enzymatic glycation and oxidation steps that trigger molecular
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transformations resulting in the formation of advanced glycation end products (AGEs).
Elevated levels of oxidative stress and the hyperglycemic environment associated with
MetS promotes the formation and accumulation of advanced glycation end products
(AGEs) which may play a causative role in large artery stiffening [37]. Indeed, animal
models of T2DM and MetS have demonstrated significant associations between arterial
stiffness and enhanced AGE accumulation in conduit arteries [38]. AGE accumulation in
the vasculature contributes to alterations in extracellular and intracellular structure and
function through a variety of mechanisms, including crosslink formation between
proteins in the basement membrane of the extracellular matrix, and through the
modification of cellular function through the activation of AGEs with the cell surface
receptor for AGEs [39]. Crosslink formation of proteins in the extracellular matrix can
alter properties of large structural matrix proteins including type I collagen and elastin
which fosters reduced arterial elasticity and vascular stiffening. In the endothelium,
AGEs reduce the bioavailability and activity of endothelium-derived NO and prostacyclin
and may enhance expression of the vasoconstrictor, endothelin-1 [40]. The fundamental
determinants of AGE formation include the rate of turnover of proteins for glycoxidation,
the degree of hyperglycemia, and the level of oxidant stress [41] and thus, AGE
formation and accumulation is accelerated in MetS and T2DM and likely contributes to
the pathophysiology of arterial stiffening observed in MetS. While we did not quantify
AGE deposition in the studies presented within this dissertation, this measurement
would provide an enhanced understanding of the underlying mechanisms contributing to
AS associated with MetS. Taken together, the results detailed in Chapter 3 suggest that
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aerobic exercise training holds promise as an effective treatment approach for targeting
AS in MetS without chronic disease.
Next, we built upon our previous work by broadening our investigation of the
therapeutic potential of aerobic exercise training for reducing CVD risk in MetS.
Evidence from Chapter 2 demonstrated that individuals afflicted with MetS display not
only deleterious adaptations to arterial structure and function at rest, but also
demonstrate deficiencies during exercise. Specifically, MetS exhibited impaired coupling
between the heart and the arterial system, an interaction termed arterial ventricular
coupling (Ea/Ees). Additionally, a blunted decrease in Ea/Ees during exercise in MetS
was shown to coincide with a significantly reduced exercise capacity. Collectively, these
results suggest an impaired CV response to physiological stress produced during
aerobic exercise in MetS. In Chapter 4 we determine the effects of 8 weeks of aerobic
exercise training on Ea/Ees during peak exercise in MetS without T2DM or clinical
indications of CVD. In this investigation we demonstrate that 8 weeks of aerobic
exercise training was not only able to improve, but to restore peak arterial-ventricular
coupling, peak LV contractility, and aerobic capacity in MetS to levels observed in
healthy untrained controls. The key finding of this study was that improvements in peak
exercise arterial-ventricular coupling in MetS, which was due directly to improvements in
peak LV end-systolic elastance (Ees), a load-independent index of the contractility and
systolic stiffness of the LV. Not surprisingly, 8 weeks of aerobic exercise training failed
to improve resting LV structure, diastolic dysfunction, metabolic profile, or body
composition. The lack of an observed effect is most likely due to the short exercise
training duration. Indeed, others have shown that several months of aerobic training
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alter deleterious LV remodeling [42, 43]. Improvements in arterial-ventricular coupling
were accompanied also by a modest increase in exercise capacity as measured by
VO2peak. It was determined that improvements in Ea/Ees during exercise contributed, to
a small degree, to improvements in exercise capacity, however, it is likely that this
improvement can also be explained by other exercise-induced adaptations not
considered by this study. Nevertheless, improvements in aerobic capacity likely reflect a
reduced CVD risk in MetS. Our initial investigations in Chapter 2 determined that the
blunted decrease of arterial-ventricular coupling in MetS is due not only to impaired LV
contractility but also to a blunted peripheral vasodilation in response to exercise. In
Chapter 4, we proposed that improvements in LV contractility were mediated, in part, by
improvements in SV, afterload, and Ea/Ees. In support of this hypothesis, we
demonstrated improvements in SV but observed no change in the Ea component of
arterial-ventricular coupling, which was in contrast to observed reductions in peak
vascular resistance after exercise training in MetS. Importantly, Ea represents an index
of the net arterial load imposed on the LV that integrates individual elements of arterial
load including, but not limited to, peripheral vascular resistance. For this reason, a lack
of change in Ea does not rule out the potential for improvements in other principal
components of arterial load. As a final point, we reported a lack of effect of exercise
training on body composition or clinical blood biomarkers, which was in agreement with
our findings described in Chapter 3. Taken together, this study demonstrated that 8
weeks of aerobic exercise training of moderate-to-high intensity was sufficient to
improve peak exercise arterial-ventricular coupling, LV contractility, reduce peripheral
vascular resistance, and increase aerobic capacity in MetS without T2DM and/or overt
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CVD.
In Chapters 3 and 4, aerobic exercise training was reported to have beneficial
effects on AS and the interaction between the arteries and the heart in individuals with
MetS [36, 44]. Favorable effects of exercise training on modulating CV function in MetS
may be a result of underlying improvements in inflammation and autonomic nervous
system activity. MetS is characterized by elevated glucose levels and chronic, lowgrade inflammation [45]. Hyperglycemia and excess cytokine secretion increase
oxidative stress [46], which reduces NO bioavailability [47] and may exert an acute
and chronic influence on AS [48]. Increased large artery stiffness is associated with
normative aging and is an independent predictor for an increased risk for stroke,
coronary artery disease, and heart failure [10]. In individuals with metabolic disease,
such as MetS, the interaction of AS with other CV risk factors (i.e. hypertension, obesity,
and dyslipidemia) accelerates the vascular aging process [49] that results in large artery
stiffening. Recent literature has shed light on the importance of inflammation in the
pathogenesis of AS.
The activation of MMPs and TIMPs, regulators of tissue remodeling, is mediated,
in part, by the renin-angiotensin system, oxidative stress, endothelial dysfunction, and
increased expression of pro-inflammatory cytokines and cellular adhesion molecules
[50, 51]. MetS is associated with a pro-inflammatory state, which favors endothelial
dysfunction and impaired vasodilation [21-23]. Impaired relaxation of the smooth muscle
is associated with diminished production or availability of vasodilator substances,
particularly NO, due to a decline in the production of NO by the endothelium,
inactivation of NO by reactive oxygen species (ROS), or a decline in the availability of
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co-factors required for the synthesis of NO. In the presence of cardiovascular risk
factors (e.g. hypertension, T2DM, hyperglycemia, etc.) the normal production of NO by
eNOS is altered such that eNOS favors the generation of ROS including superoxide,
and hydrogen peroxide. Generation of ROS stimulates the continued production of ROS
creating a positive feedback loop leading to chronic elevations in oxidative stress and a
reduction in NO bioavailability [39]. Moreover, inflammation may directly diminish NO
bioavailability through the production of ROS, which effectively augments oxidative
stress and promotes the upregulation of inflammation [39].
In addition, the local production of hormones that play a role in the structural
modification of the arteries has been implicated in the development of AS. Specifically,
AS has been linked to increased activity of ANG II, which is responsible for vascular
smooth muscle cell hypertrophy, increased production of collagen, activation of MMPs
and increased production of ROS and other inflammatory cytokines [39]. The release of
inflammatory cytokines stimulates the production of C-reactive protein (CRP) by
vascular smooth muscle cells. CRP plays an indirect role in the pathology of arterial
stiffness through its direct promotion of endothelial dysfunction [52]. Taken together,
these findings suggest an association between the role of inflammation, oxidative
stress, and endothelial dysfunction in the pathology of impaired arterial elasticity in
MetS.
Structural changes that may play a role in arterial dysfunction associated with
MetS may take several months to develop, however AS may also be altered acutely
through changes in VSMC tone, which is regulated by sympathetic nervous system
(SNS) activity and endothelial cell function [53]. The SNS is known to play a key role in
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the short-term regulation of vasomotor tone and blood pressure in order to maintain
cardiovascular homeostasis [54]. Recent evidence suggests that sympathetic activity
and vascular function may be linked and more specifically demonstrate that the activity
of the SNS may modulate functional properties of large arteries [54]. In terms of large
artery stiffness, sympathetic activity may alter AS through an indirect change in arterial
pressure or through an active increase in vascular tone, peripheral vasoconstriction and
decreased arterial diameter [54]. Data from human-based research has demonstrated
associations between increased sympathetic discharge and large artery stiffness[54]. It
is notable that the association between sympathetic activity and large artery stiffness
may be bidirectional. Large artery stiffness may impair carotid baroreflex sensitivity
while conversely, increased sympathetic discharge may play a role in the modulation of
arterial stiffness. Although we did not use a direct measure of SNS activity in the studies
included in this document, exercise training has previously been reported to improve
autonomic control in obese women [55] which may represent a potential mechanism by
which aerobic exercise training can illicit improvements in AS in MetS.
Current guidelines for the treatment of MetS suggest therapeutic lifestyle
changes including both diet and physical activity. Chapters 2-4 demonstrate the
capacity for improvements in CV function in MetS following short-term exercise training.
This would suggest that preservation of CV improvements over time requires
maintenance of lifestyle changes specifically, regular physical activity. Other strategies
for the treatment of MetS include pharmacological or dietary interventions that focus on
improving NO bioavailability, oxidant stress, inhibit the renin-angiotensin system, and
target AGE cross-links. Nutritional supplementation represents an attractive therapeutic
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intervention for alleviating CV dysfunction in MetS as it is effortless to integrate and
maintain. Chapter 5 demonstrates a divergence from the use of exercise-training to
induce improvements in MetS and describes the initial efforts by our laboratory to
investigate the therapeutic potential for RSV, a naturally occurring nutritional
supplement, to induce acute changes in AS and BP in MetS. In addition to changes in
the structural components of the arterial wall that manifest over a period of time, shortterm changes may occur to mediate vascular stiffness. Specifically, changes in VSMC
tone and SNS activity have been demonstrated to modulate AS in an acute fashion [5659]. Evidence from human [60, 61] and animal [62-64] research demonstrate the
potential of RSV for CV protection based on the ability of RSV to acutely reduce
inflammation and oxidative stress, two mechanisms mediating large artery stiffness
associated with MetS [56-59].
Building on evidence from studies examining the effects of dietary supplements
on arterial compliance we hypothesized that a single dose of RSV would elicit acute
improvements in AS and central blood pressure in MetS. For example, high dietary
intake of isoflavones is associated with a reduced PWV in healthy individuals [20].
Further, supplementation with curcumin, the active ingredient in turmeric, a spice that is
used frequently in Indian cuisine has been shown to improved AS in young rodent
models [11]. Similarly, in aged animals, 4 weeks of supplementation with curcumin was
associated with reduced superoxide bioavailability and whole artery AGE expression.
Taken together, these findings provide support for the use of dietary supplementation as
an effective intervention for improving AS in individuals in MetS.
Results from Chapter 5 led us to fail to reject the null hypothesis that an acute
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dose of 500mg or 1000mg of RSV does not alter AS or central BP at 45 or 75 minutes
post-supplementation in MetS and we are unable to accept the alternative hypothesis
that single-dose RSV supplementation can improve AS and central BP at 45 and 75
minutes post-supplementation in MetS. In an effort to reconcile these findings we
suggest several limitations that may have contributed to our results. These limitations
are reviewed in detail in Chapter 5. While we were unable to provide evidence in
support of the therapeutic potential of RSV to improve CVD risk through AS and BP,
improvements in study design and recruitment are encouraged for building upon this
preliminary data and are reviewed in Chapter 7.
In conclusion, our data provides a comprehensive examination of the
consequences to CV function in MetS prior to evidence of T2DM and/or chronic CVD.
Further, we perform initial evaluations of both physical and nutritional changes in
lifestyle as strategies for improving CV dysfunction and subsequent risk for CVD in
MetS. The findings of this dissertation are in agreement with the central hypothesis that
subclinical CV dysfunction at rest and during exercise occurs in the presence of MetS
without T2DM and/or over CVD, and that this dysfunction can be improved by
implementation of therapeutic lifestyle interventions, including aerobic exercise training.
While we cannot apply this conclusion to evidence presented within this document for
the therapeutic potential of chronic nutritional supplementation with RSV, we believe
future studies may provide the evidence-based support necessary to extend these
conclusions to supplementation with RSV in MetS. The results of the studies contained
within this dissertation underscore the importance of establishing targeted strategies for
reversing CV function at rest and during exercise in MetS.
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Future Directions
Metabolic syndrome is a multifaceted disease state characterized by multiple cooccurring risk factors. Clinical manifestation of MetS carries a profound risk for CVD that
surpasses the sum of the individual CVD risk carried by each component [1]. Mets can
lead to deleterious alterations to CV structure and function even in the absence of
T2DM and overt CVD [2-4]. Current recommendations from the NIH for the treatment of
MetS include adoption of healthy lifestyle changes including, but not limited to, regular
physical activity and a heart healthy diet [5]. Preventing or slowing the progression and
onset of T2DM is one of the primary goals of treating MetS, second only to CVD risk
reduction [5], however, the ideal treatment or treatment combination for long-term
improvements in CVD risk and prevention of T2DM in MetS without chronic CVD is
largely unknown. Future studies in animals and humans examining the long-term effects
of lifestyle changes in MetS would provide a greater understanding of the underlying
pathological mechanisms of MetS.
Investigations outlined in Chapter 3-4 of this dissertation provide initial evidence
for the promise of short-term aerobic exercise training for improving AS, LV contractility,
and coupling of the heart and arteries in MetS without T2DM and/or CVD. Future
studies should focus on addressing the important limitations reported in these chapters
as well as build upon the foundation that this work provides. In particular, future studies
to address the effects of exercise training on AS in MetS should focus on uncovering
the mechanisms responsible for reported improvements. Specifically, a non-invasive
assessment of autonomic function using Finapres technology could provide a way to
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determine the role of sympathetic activity in reductions in cfPWV that accompany shortterm aerobic exercise. Due to the lack of an observed effect on metabolic plasma
markers, future studies should consider a longer exercise training duration or higher
intensity training to identify whether longer duration or higher intensity can exert
additional benefits to individuals afflicted with MetS. Studies of longer duration would
have the added advantage of determining whether the benefits associated with shortterm aerobic exercise can be maintained over time. Most importantly, future longitudinal
studies, which have the benefit of being able to establish a sequence of events, should
be conducted to examine the ability of long term exercise training to prevent or delay
the progression to T2DM and CVD.
Furthermore, due to a lack of observed effect of exercise training on arterial load
(as indicated by no pre to post change in Ea in Chapter 3) in MetS, the use of other
assessments of arterial function including characteristic impedance and cIMT may
provide evidence for a more conclusive effect of exercise training on arterial
structure/function.
One common challenge in human-based subject research is achieving large and
equal numbers of both male and female participants, as is evidenced by data presented
within this document. Unequal representation in gender within current literature should
be a key consideration for the planning of future studies. Potential investigations into the
consequence of sex differences on the effects of exercise training and nutritional
supplementation may have an important impact on the interpretation of conclusions
from existing literature, and for the development of target treatment strategies for MetS.
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A further complication of research surrounding MetS is the inherent complexity of
co-occurring risk factors. For example, by considering MetS to be a single co-morbid
condition as the studies presented in this document do, one may overlook the
importance of different combinations of the individual components of MetS, and how
these combinations respond to treatment strategies. Future studies using MetS should
attempt to examine how different clusters of MetS components impact CV function and
progression to T2DM and overt CVD in MetS. Additionally, the use of a continuous
scale to classify MetS may allow insight to how metabolic disease severity affects CV
function and also response to treatment.
For a more mechanistic understanding of the CV dysfunction underlying MetS,
future research may be best conducted in animal models of MetS, such as the obese
Zucker fatty. Animal models of Mets may allow for a more detailed study of the
contribution of changes in inflammatory status and oxidant stress to treatment for MetS.
Furthermore, animal models of disease represent a more controlled and cost-effective
starting point for determining efficacy of various treatment options for MetS, especially
future investigations of nutritional supplementation.
The overall obejective of this dissertation was to define CV dysfunction in the
metabolic syndrome and to identify practical therapeutic strategies to improve CV
dysfunction, specifically to target large artery stiffness and coupling between the arteries
and heart; therefore, future directions should focus on achieving a more thorough
understanding of the CV risk associated with MetS and whether long-term therapeutic
lifestyle change (physical and nutritional) can prevent the progression of MetS to T2DM
and clinical CVD.
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